METHODS FOR THE USE OF GALECTIN 3 BINDING PROTEIN DETECTED IN THE URINE FOR MONITORING THE SEVERITY AND PROGRESSION OF LUPUS NEPHRITIS

Abstract

Embodiments of the present invention describe compositions and methods incorporating the measurement of LGALS3BP in the urine of patients diagnosed with lupus nephritis (LN) in order to monitor the severity and progression of said LN.

Description

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is, hereby, incorporated by reference in its entirety. Said ASCII copy, created on Dec. 15, 2017, is named P16-214WO_SL.txt and is 433,834 bytes in size.

FIELD OF THE INVENTION

The invention relates generally to the detection of LGALS3BP in urine within methodologies for detecting and monitoring the progression of lupus nephritis (LN).

BACKGROUND OF THE INVENTION

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by the formation of autoantibody-containing immune complexes (ICs) that trigger inflammation, tissue damage, and premature mortality (Tsokos G C, N Engl J Med (2011); 365:2110-2121). SLE ICs often contain nucleic acids that are recognized by numerous innate immune receptors that can initiate pathological mechanisms leading to production of cytokines, and ultimately to immune responses leading to organ damage. Due to the great clinical diversity and idiopathic nature of SLE, management of SLE depends on its specific manifestations and severity. Therefore, medications suggested to treat SLE are not necessarily effective for the treatment of all manifestations and complications such as lupus nephritis (LN). The pathogenesis of LN is believed to derive from deposition of immune complexes in the kidney glomeruli that initiates an inflammatory response causing kidney damage (Davidson A2016, Nature Reviews Rheumatology 12:143-153). An estimated 30-60% of patients with SLE develop nephritis over the course of their disease that requires medical evaluation and treatment. LN is a progressive disease, running a course of clinical exacerbations and remissions. Late stage LN is characterized by irreversible scarring in the kidney, which cannot be treated with current SLE drugs, necessitating a kidney transplant (Lionaki S et al., World Journal of Transplantation, 2014, 4(3): 176-182).

General indications of lupus nephritis are foamy or bloody urine due to compromised kidney filtering function leading to high urinary protein concentration. Lupus nephritis is diagnosed by kidney biopsy (Schwartz N et al., Curr Opin Rheumatol. 2014). Renal function can be measured by blood urea nitrogen (BUN) testing, serum creatinine assessment, urinalysis (total protein, red blood cells and cellular casts), spot urine test for creatinine and protein concentration, or 24-hour urine test for creatinine clearance and protein excretion. Proper monitoring of kidney disease in LN is currently not possible as biopsies are invasive and usually only performed for initial diagnosis. Although kidney function can be approximated using current tests, they all fail to estimate the level of causal inflammation (Zickert A, et al., Lupus Sci Med 2014, 1:e000018; Alvarado et al. Lupus 2014, 23: 840). Without the ability to assess the inflammatory state of the kidney, physicians cannot accurately assess the effectiveness of their treatments, as these treatments are directed to resolve the ongoing inflammation. Accurate monitoring of the causal inflammation in the kidney could help physicians with aggressive treatment decisions and a treat-to-target approach, thereby slowing disease progression, improving patient's lives, and lowering health care costs by preventing the need for expensive kidney transplants.

SLE is treated with antimalarials, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants and biologics such as Belimumab (BAFF neutralization) and Rituximab (B cell depletion). While many patients fail to respond or respond only partially to the standard of care medications listed above, the long-term use of high doses of corticosteroids and cytotoxic therapies may have profound side effects such as bone marrow suppression, increased infections with opportunistic organisms, irreversible ovarian failure, alopecia, and increased risk of malignancy. Infectious complications coincident with active SLE and its treatment with immunosuppressive medications are the most common cause of death in patients with SLE. Therefore, there is a need for alternative diagnostics, which can better provide a definitive diagnosis of SLE/LN and monitor disease activity to allow more targeted aggressive treatment with fewer side effects.

Galectin-3 binding protein [other aliases include: LGALS3BP (and all related polymorphisms), uG3BP, G3BP, Mac2-BP, p90, Lectin Galactoside-Binding Soluble 3 Binding Protein, BTBD17B, CyCAP, gp90, L3 antigen, M2BP, Mac-2-binding protein, MAC-2-BP and TANGO10B] is the gene product of a ubiquitously expressed gene that belongs to the scavenger receptor family (Koths, K. et al. 1993 J. Biol. Chem. 268:14245). The 585 amino acid (aa) human protein contains an 18 aa signal sequence and four domains (Hohenester, E. et al. 1999 Nat. Struct. Biol. 6:228; Muller, S. A. et al. 1999 J. Mol. Biol. 291:801; Hellstern, S. et al. 2002 J. Biol. Chem. 277:15690). Domain 1 is a group A scavenger receptor domain, domain 2 is a BTB/POZ domain that strongly mediates dimerization, and domain 3 is an IVR domain, that is also found following the POZ domain in Drosophila Kelch protein. Although little is known about domain 4, recombinant domains 3 and 4 reproduce the solid-phase adhesion profile of full-length Galectin-3BP. Glycosylation at seven N-linked sites, generates a molecular size of 85-97 kDa (Ullrich, A. et al. (1994) J. Biol. Chem. 269:18401). Galectin-3BP dimers form linear and ring-shaped oligomers, most commonly decamers and dodecamers. LGALS3BP is a protein secreted by certain types of tumor cells wherein expression levels correlate with tumor progression (Grassadonia, A. et al. 2004 Glycoconj. J. 19:551). Apart from its direct effect on tumor cell proliferation/survival, LGALS3BP can also upregulate expression of vascular endothelial growth factor and promote angiogenesis. Its levels are augmented during HIV-1 infection and its activity is believed to reduce infectivity of HIV-1 through interference with the maturation and incorporation of envelope proteins into virions (Lodermeyer V et al. Retrovirology. 2013 24; 10:111). Serum levels of LGALS3BP are increased in patients with Behcet's disease and correlate with disease activity (Lee Y J et al. Clin Exp Rheumatol. 2007 25(4 Suppl 45):541-5). Increased levels of plasma LGALS3BP are also observed in certain cohorts of SLE patients (Nielsen C T et al. Lupus Sci Med. 2014 19; 1(1)). LGALS3BP has an IRF7 regulatory element in its promoter (Heinig M et al. Nature. 2010 23; 467(7314):460-4) indicating regulation by type I IFN and explaining its link to viral infections and inflammation.

There is an urgent, yet still unmet, need for use in clinical medicine and biomedical research for improved non-invasive tools to: i) identify if SLE is about to manifest as LN, ii) evaluating changes in renal pathophysiology in LN in subjects already diagnosed with LN and iii) evaluating disease progression/regression in subject already diagnosed with LN.

SUMMARY OF THE INVENTION

The present invention provides compositions and methods of assessing the present and ongoing renal inflammation status in a mammalian subject with or at a risk of developing LN, by detecting the quantity (e.g., determining the level) of Galectin-3 binding protein (LGALS3BP) in a body fluid sample. The present invention also provides a method of monitoring the effectiveness of a treatment for renal pathophysiology in LN by determining the level of LGALS3BP in the body fluid before and in particular after treatments designed to treat flares associated with LN. The properties and characteristics of LGALS3BP as a predictive marker allow for its use in this manner for the early detection of renal pathophysiology in LN or changes in renal pathophysiology in LN status in the context of LN.

In one embodiment, the present invention provides a method for the early detection of a renal pathophysiology in LN in a mammal, comprising the steps of: i) obtaining or providing a sample of a body fluid from a mammal that is not experiencing an acute renal disease in LN, the body fluid selected from the group consisting of urine, plasma, and serum; ii) detecting (e.g., determining) the level of LGALS3BP in the sample (e.g., using an antibody against LGALS3BP); and iii) evaluating the renal pathophysiology in LN status of the subject, based on the level of LGALS3BP in the sample. The evaluation of the renal pathophysiology in LN status can be used to determine whether the renal pathophysiology in LN is sub-clinical, stable, or progressing (i.e., progressive renal disease). The method also provides an evaluation of the renal status as a progressive or worsening renal pathophysiology in LN with only a single sampling and assay.

In one embodiment the present invention provides a method for the detection of any change in a renal pathophysiology in LN status of a mammal, comprising the steps of: i) obtaining a first sample of a body fluid from a mammal exhibiting at least one symptom of SLE, the body fluid selected from the group consisting of urine, plasma, and serum (in a preferred embodiment said body fluid is urine); ii) detecting (e.g., determining) the level of LGALS3BP in the first sample (e.g., using an antibody against LGALS3BP); iii) obtaining at least one subsequent sample of the body fluid from the mammal after a period of time after obtaining the first sample; iv) detecting (e.g., determining) the level of LGALS3BP in at least one subsequent sample (e.g., using an antibody against LGALS3BP); and v) evaluating the renal pathophysiology in LN status of the mammal, based on comparing the level of LGALS3BP in the at least one subsequent sample to the level of LGALS3BP in the first sample. Generally, a higher level of LGALS3BP in the subsequent sample is an indication of the worsening renal pathophysiology in LN status in the subject demonstrating at least one symptom of SLE which indicates the imminent progression of SLE into LN, while a similar or reduced level of LGALS3BP in the subsequent sample is an indication of an improvement in the renal pathophysiology in LN status and an indicator SLE of said subject is not about to progress into LN.

In one embodiment the present invention provides a method of monitoring the effectiveness of a treatment for renal pathophysiology in LN in a mammal, comprising the steps of: i) providing or obtaining a baseline sample of a body fluid from a mammal experiencing at least one symptom of LN, the body fluid selected from the group consisting of urine, plasma, and serum (in a preferred embodiment said body fluid is urine); ii) detecting (e.g., determining) the level of LGALS3BP in the baseline sample (e.g., using an antibody against LGALS3BP); iii) providing at least one treatment for the renal pathophysiology in LN to the mammal; iv) providing or obtaining at least one post-treatment sample of the body fluid from the mammal; v) detecting (e.g., determining) the level of LGALS3BP in the post-treatment sample (e.g., using an antibody against LGALS3BP); and vi) evaluating the effectiveness of the treatment, based on comparing the level of LGALS3BP in the post-treatment sample to the level of LGALS3BP in the baseline sample.

One embodiment of the present invention provides a method of identifying the extent of renal pathophysiology in LN in a mammal over time, comprising the steps of: i) obtaining at least one first sample of a body fluid at a first time from a mammal that is experiencing at least one symptom of LN, the body fluid selected from the group consisting of urine, plasma, and serum (in a preferred embodiment said body fluid is urine); ii) detecting (e.g., determining) the level of LGALS3BP in the first sample (e.g., using an antibody against LGALS3BP); iii) obtaining at least one subsequent sample of the body fluid at a time subsequent to the first time, from the mammal; iv) detecting (e.g., determining) the level of LGALS3BP in at least one subsequent sample (e.g., using an antibody against LGALS3BP); and v) determining the extent of the renal pathophysiology in LN in the mammal over time, based on comparing the level of LGALS3BP in at least one subsequent sample to the level of LGALS3BP in the first sample. Typically, the mammalian subject is a human. Where more than one subsequent sample is drawn, they are typically obtained and provided intermittently from the subject, and at predetermined times, ranging from one or more days, to one or more weeks, to one or more months, to one or more years. Other sampling regimens also may be employed. In one embodiment, the mammalian subject is also evaluated to determine if the subject is experiencing another condition that may contribute to the level of LGALS3BP in the sample, such condition including, but limited to, an acute bacterial or viral infection, acute inflammation, an acute or chronic injury to another organ or cancer. Such another condition may not effect or cause an injury to the kidney. However, such condition on its own can contribute the amount of LGALS3BP detected in the urine, making it difficult to distinguish such LGALS3BP from LGALS3BP that is expressed as a direct result of a renal pathophysiology in LN. Some types of other conditions can effect high levels of LGALS3BP that can overwhelm the concentration of LGALS3BP resulting from the renal injury.

A variety of protein detection formats are contemplated, including, but not limited to, ELISA (enzyme linked immunosorbent assay), SMC immunoassay technology (Single Molecule Counting) and Western Blot.

In some embodiments assay devices, in particular ELISA devices, comprise coated microtiter plates. In some embodiments, a capture reagent (i.e., LGALS3BP antibody) is applied in the wells of a microtiter plate. In this assay, a test sample (e.g., blood or urine) potentially containing an analyte of interest (e.g., LGALS3BP) is placed in the wells of a microtiter plate that contain the immobilized capture reagent. The analyte specifically binds the immobilized antibody; then, unbound materials are washed away leaving primarily the analyte-antibody complex bound to the plate. This complex can be detected in a variety of manners, such as by use of a labelled detector reagent, e.g., labeled LGALS3BP antibody. One advantage of the microtiter plate format is that multiple samples can be tested simultaneously (together with controls) each in one or more different wells of the same plate; thus, permitting high-throughput analysis of numerous samples.

In some embodiments, a competitive ELISA assay is utilized (see e.g., U.S. Pat. Nos. 5,958,715, and 5,484,707, each of which is herein incorporated by reference). The competitive ELISA may be quantitative or non-quantitative. In a competitive ELISA, the wells of a microtiter plate are first coated with a fusion protein comprising all or a fragment of LGALS3BP. The sample to be tested is added to the plate along with an antibody that is specific for LGALS3BP. The LGALS3BP in the sample competes for binding to the antibody with the immobilized peptide. The plate is washed and the antibody bound to the immobilized LGALS3BP polypeptide is then detected using any suitable method (e.g., a secondary antibody comprising a label or a group reactive with an enzymatic detection system). The amount of signal is inversely proportional to the amount of LGALS3BP present in the sample (e.g., a high signal is indicative of low amounts of LGALS3BP being present in the sample).

In some embodiments, the immunoassay devices of the present invention permit the performance of relatively inexpensive, disposable, membrane-based assays for the visual identification of the presence (or absence) of an analyte in a liquid sample. Such devices are usually formatted as freestanding dipsticks (e.g., test strips) or as devices having some sort of housing. Typically, an immunoassay device of the present invention can be used with as little as about 200 microliters of liquid sample, and detection of an analyte in the sample can (but need not) be complete within 2-5 minutes. In preferred embodiments, no ancillary instrumentation is required to perform such tests, and such devices easily can be used in clinics, laboratories and field locations.

In some embodiments, the ELISA is an immunochromatographic “sandwich” assay. In general, sandwich immunochromatographic procedures call for mixing the sample that may contain the analyte to be assayed for example, LGALS3BP, with an antibody specific for LGALS3BP. The antibody, i.e., detector reagent, is mobile and typically is linked to a label or another signaling reagent, such as dyed latex, a colloidal metal sol, or a radioisotope. This mixture is then applied to a chromatographic medium containing a band or zone of immobilized antibodies that recognize LGALS3BP (i.e., the capture antibody or reagent). The chromatographic medium often is in the form of a strip that resembles a dipstick. When the complex of LGALS3BP and the detector reagent reaches the zone of the immobilized capture antibody on the chromatographic medium, binding occurs and the detector reagent complex is localized at the zone. This indicates the presence of the molecule to be assayed. This technique can be used to obtain quantitative or semi-quantitative results. Examples of sandwich immunoassays performed on test strips are described in U.S. Pat. Nos. 4,168,146 and 4,366,241, each of which is incorporated herein by reference.

In some embodiments a “Western blot” format is used to detect proteins of interest. Western Blot refers to the analysis of protein(s) (or polypeptides) immobilized onto a support such as nitrocellulose or a membrane. The proteins are run on acrylamide gels to separate the proteins, followed by transfer of the protein from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized proteins are then exposed to antibodies with reactivity against an antigen of interest. The binding of the antibodies may be detected by various methods, including the use of radiolabeled antibodies.

In another embodiment of the present invention, there is provided a method for generating a result useful in diagnosing and non-invasively monitoring renal pathology using samples obtained from a mammalian subject. The method includes: obtaining a dataset associated with the samples, wherein the dataset comprises protein expression levels for markers selected from the group consisting of: urinary creatinine and proteinuria expressed as a ratio of urine protein: creatinine (uPCR); and inputting the dataset into an analytical process that uses the data to generate a result useful in diagnosing and monitoring the renal pathology.

In some embodiments, the definition of lupus nephritis comprises one or more of: lupus nephritis, idiopathic immune-complex glomerulonephritis, glomerular nephritis, tubulo-interstitial nephritis.

In some embodiments, the diagnostic aspects of the present invention can better inform when invasive kidney biopsies and/or changes in therapeutic regimes should be considered. A diagnostic kidney biopsy should be done to guide therapy when a lupus patient presents with clinical evidence of new kidney inflammation such as the detection of increased levels of LGALS3BP as provided by the diagnostic embodiments of the present invention.

In some embodiments renal classification of lupus nephritis comprises one or more of:

Class I disease (minimal mesangial glomerulonephritis) in its histology has a normal appearance under a light microscope, but mesangsial deposits are visible under an electron microscope. At this stage urinalysis is normal.

Class II disease (mesangial proliferative glomerulonephritis) is noted by mesangial hypercellularity and matrix expansion. Microscopic hematuria with or without proteinuria may be seen. Hypertension, nephrotic syndrome, and acute kidney insufficiency are very rare at this stage.

Class III disease (focal glomerulonephritis) is indicated by sclerotic lesions involving less than 50% of the glomeruli, which can be segmental or global, and active or chronic, with endocapillary or extracapillary proliferative lesions. Under the electron microscopy, subendothelial deposits are noted, and some mesangial changes may be present. Immunofluorescence reveals positively for IgG, IgA, IgM, C3, and C1q (indicative of immune complex deposits). Clinically, hematuria and proteinuria are present, with or without nephrotic syndrome, hypertension, and elevated serum creatinine. Diffuse proliferative lupus nephritis as seen in a pathology specimen.

Class IV disease (diffuse proliferative nephritis) is both the most severe, and the most common subtype. More than 50% of glomeruli are involved. Lesions can be segmental or global, and active or chronic, with endocapillary or extracapillary proliferative lesions. Under electron microscopy, subendothelial deposits are noted, and some mesangial changes may be present. Clinically, hematuria and proteinuria are present, frequently with nephrotic syndrome, hypertension, hypocomplementemia, elevated anti-dsDNA titers and elevated serum creatinine.

Class V disease (membranous glomerulonephritis) is characterized by diffuse thickening of the glomerular capillary wall (segmentally or globally), with diffuse membrane thickening, and subepithelial deposits seen under the electron microscope. Clinically, stage V presents with signs of nephrotic syndrome. Microscopic hematuria and hypertension may also been seen. Stage V also can also lead to thrombotic complications such as renal vein thromboses or pulmonary emboli.

Class VI, or advanced sclerosing lupus nephritis. It is represented by global sclerosis involving more than 90% of glomeruli, and represents healing of prior inflammatory injury. Active glomerulonephritis is not usually present. This stage is characterized by slowly progressive kidney dysfunction, with relatively bland urine sediment. Response to immunotherapy is usually poor. A tubuloreticular inclusion within capillary endothelial cells is also characteristic of lupus nephritis, and can be seen under an electron microscope in all stages. It is not diagnostic however, as it exists in other conditions such as HIV infection. It is thought to be due to the chronic interferon exposure.

As reported in the data presented in the instant application, unless otherwise stated, LGALS3BP is measured in ng/ml. LGALS3BP/creatinine ratios are ng LGALS3BP/mg creatinine per ml of urine.

In some embodiments, the renal pathophysiology in LN of lupus nephritis comprises one or more of: presence of mesangial immune deposits, presence of sub-endothelial immune deposits, presence of sub-epithelial immune deposits, tubulo-interstitial inflammation, tubulo-interstitial fibrosis, tubulo-interstitial sclerosis, sclerosis, crescentic glomerulonephritis (presence of crescentic lesions or extracapillary proliferation), extracapillary proliferation, endocapillary proliferation, proliferative glomerulonephritis, focal glomerulopathy (or focal glomerulonephritis), focal segmental glomerulopathy (or focal segmental glomerulonephritis), segmental glomerulopathy (or segmental glomerulonephritis), membranous glomerulopathy, glomerular basement membrane abnormalities (such as thickening), glomerulosclerosis (or glomerular sclerosis), mesangial hypercellularity (or mesangial proliferation), mesangial matrix expansion, mesangial fibrosis.

In some embodiments, the analytical process is a Linear Discriminant Analysis model. Further, in some embodiments, the analytical process can include use of a predictive model. In some embodiments, the analytical process comprises comparing the obtained dataset with a reference dataset.

In some embodiments, the reference dataset comprises protein expression levels obtained from one or more healthy control subjects. In other embodiments, the method further comprises obtaining a statistical measure of a similarity of the obtained dataset to the reference dataset.

In some embodiments, the method further comprises using the classification for diagnosis, staging, prognosis, kidney inflammation levels, assessing extent of progression, monitoring a therapeutic response, predicting a renal-interstitial inflammation (INF) episode, or distinguishing stable from unstable manifestations of renal-interstitial inflammation (INF) in subjects presenting at least one symptom of LN.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows LGALS3BP mRNA expression levels in PBMCs isolated from HC and LN patients with low or high IFN-a signature.

FIG. 2A presents data showing that LGALS3BP is induced by inflammatory stimuli including but not limited to IFN-a with LGALS3BP expression by QPCR using RNA extracted from in vitro differentiated primary human macrophages activated with indicated stimuli for 6 h. Expression between samples was normalized using HPRT1 as a housekeeping gene.

FIG. 2B presents additional data showing that LGALS3BP is induced by inflammatory stimuli including but not limited to IFN-a with LGALS3BP measured by ELISA in supernatants of in vitro differentiated primary human macrophages activated with indicated stimuli for 20 h.

FIG. 3 shows LGALS3BP protein levels in serum, urine and plasma. LGALS3BP plasma and urine levels were measured in healthy control donors, SLE and LN patients by ELISA. Urinary LGALS3BP protein levels were significantly higher (P<0.0001, 1-way Anova with Tukey post test) in LN patients vs SLE patients or healthy controls. This difference is not noted in serum obtained from the same subjects. No linear correlation exist between plasma and urine levels.

FIG. 4A shows gene expression levels of LGALS3BP in the glomeruli and tubulointerstitium of kidney tissue sections from HC and LN patients. A total of 46 samples (n=14 HC and 32 LN) from the European Renal cDNA Bank were processed and used for microarray analysis as described (Berthier et al., JI 2012). Biopsy sections were manually micro dissected into glomerular and tubulointerstitial compartments and gene expression profiling was performed using the Human Genome U133A Affymetrix GeneChip arrays, wherein, gene expression levels for LGALS3BP were significantly higher in both the glomeruli (p=9.221e-12) and the tubulointerstitium (p=1.511e-4) as compared to HC.

FIG. 4B shows gene expression levels of CCL2 (MCP-1) in the glomeruli and tubulointerstitium of kidney biopsies from HC and LN patients. A total of 46 samples (n=14 HC and 32 LN) from the European Renal cDNA Bank were processed and used for microarray analysis as described (Berthier et al., JI 2012). Biopsy sections were manually microdissected into glomerulus and tubulointerstitial compartments and gene expression profiling was performed using the Human Genome U133A Affymetrix GeneChip arrays, wherein, gene expression levels for CCL2 (MCP-1) were not equivalent between HC and LN samples in both the glomeruli and tubulointerstitium.

FIG. 4C shows gene expression levels of TNFSF12 in the glomeruli and tubulointerstitium of kidney biopsies from HC and LN patients. A total of 46 samples (n=14 HC and 32 LN) from the European Renal cDNA Bank were processed and used for microarray analysis as described (Berthier et al., JI 2012). Biopsy sections were manually microdissected into glomerular and tubulointerstitial compartments and gene expression profiling was performed using the Human Genome U133A Affymetrix GeneChip arrays, wherein, TNFSF12 gene expression levels were significantly higher in LN glomeruli (p=0.017) but significantly lower in tubuolointerstitium (p=9.08e-5).

FIG. 4D shows galectin 3 binding protein expression in kidney biopsies from healthy volunteers (HC), LN patients with and without tubulointerstitial nephritis (TIN), diabetes mellitus (DM) and IgA nephropathy (IgAN) patients. Galectin 3 binding protein (light areas), was stained with antibodies analyzed by fluorescence microscopy.

FIG. 5 shows LGALS3BP mRNA expression in the BXSB-Yaa LN mouse model. Diseased mice were euthanized at 20 weeks of age and kidney LGALS3BP expression analyzed by NanoString and normalized to hprt1 expression. Control mice are young (9 weeks) BXSX-Yaa mice before onset of disease. Kidney damage was assessed by histology.

FIG. 6A shows total LGALS3BP normalized to urinary creatinine ratios in the urine of healthy controls (HC), lupus nephritis (LN), and systemic lupus erythematosus (SLE) donors.

FIG. 6B shows total protein to creatinine ratios in the urine of healthy controls (HC), lupus nephritis (LN), and systemic lupus erythematosus (SLE) donors.

FIG. 6C shows urinary albumin to creatinine ratios in the urine of healthy controls (HC), lupus nephritis (LN), and systemic lupus erythematosus (SLE) donors.

FIG. 7A shows correlations of urinalysis measurements, wherein, albumin to creatinine ratios and total protein to creatinine ratios correlated well to one another with a correlation coefficient of 0.95.

FIG. 7B shows correlations of urinalysis measurements, wherein, LGALS3BP to creatinine ratios positively correlate with total protein to creatinine ratios (R=0.494).

FIG. 7C shows correlations of urinalysis measurements, wherein, LGALS3BP to creatinine ratios positively correlate with albumin to creatinine ratios (R=0.484).

FIG. 8A shows changes in urinary protein measurements in patients across multiple visits. All values are presented as normalized to creatinine levels. Each dot represents a sample and each line represents a donor. The color of the line represents the disease group with LN samples colored purple, SLE samples colored cyan, and HC samples colored dark gray.

FIG. 8B shows changes in albumin measurements in patients across multiple visits. All values are presented as normalized to creatinine levels. Each dot represents a sample and each line represents a donor. The color of the line represents the disease group with LN samples colored purple, SLE samples colored cyan, and HC samples colored dark gray.

FIG. 8C shows changes in LGALS3BP measurements in patients across multiple visits. All values are presented as normalized to creatinine levels. Each dot represents a sample and each line represents a donor. The color of the line represents the disease group with LN samples colored purple, SLE samples colored cyan, and HC samples colored dark gray.

FIG. 9 shows binding curves of selected anti-LGALS3BP monoclonal antibodies. Serial dilutions of monoclonal antibodies identified in antibody phage library screens were tested for binding in an ELISA using microtiter plates coated with full length recombinant human LGALS3BP. Monoclonal antibody binding to plate-bound LGALS3BP was detected with a secondary anti-Ig antibody conjugated to horseradish peroxidase (HRP). Binding was revealed using HRP substrate and optical density was measured at 450 nm.

FIG. 10A and FIG. 10B show anti-LGALS3BP monoclonal antibody pairing for sandwich ELISA. 100 ng/mL recombinant LGALS3BP (FIG. 10B) was used as analyte and compared to buffer only control (FIG. 10A). Antibodies were conjugated to beads and tested in a multiplex Luminex assay to determine best pairs. Each antibody was detected in a different channel allowing the evaluation of the pairs in the same environment. Values are arbitrary units from the Luminex reader. Columns are capture antibodies, rows are detection antibodies.

FIG. 11A shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb1-mAb9). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 11B shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb3-mAb11). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 11C shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb3-mAb22). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 11D shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb114-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 12A shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb103-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 12B shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb109-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 12C shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb110-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 12D shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb112-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 13A shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb105-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 13B shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb29-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 13C shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb113-mAb116). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 13D shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb102-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 14A shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb103-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 14B shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb109-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 14C shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb114-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 14D shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb110-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients. (SLE) patients.

FIG. 15A shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb116-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 15B shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb112-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 15C shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb105-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 15D shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb25-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 16A shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb26-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 16B shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb29-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 16C shows a monoclonal antibody pair evaluated for use in a sandwich ELISA to capture and detect LGALS3BP in human urine samples. Graphs are derived from Luminex pairing experiments. Shown is ‘capture mAb-detection mAb’ (i.e., mAb113-mAb103). LGALS3BP concentrations are in ng/ml for urine samples from healthy controls (healthy), lupus nephritis patients (LN) and extrarenal systemic lupus erythematosus (SLE) patients.

FIG. 17 presents data which shows LGALS3BP is stable in urine under various storage conditions. Urine samples from 3 LN patients (stored at −80 C) were thawed and stored under different conditions: repeated freeze-thaws, room temperature for 1 h or 18 h, 37 C or 4 C or −20 C overnight. LGALS3BP levels in urine samples were measured by sandwich ELISA. Shown are mean+SEM of technical duplicates from 3 LN patients.

FIG. 18 shows urinary LGALS3BP concentrations (ng/ml) are significantly elevated in LN patients from different patient cohorts. LGALS3BP was measured with our prototype kit in urine samples from indicated controls and patients. LN patients were obtained from two different cohorts, from two different locations in the US. LGALS3BP levels are significantly higher in both LN cohorts compared to all other groups (P<0.0001, one-way ANOVA with Tukey's multiple comparisons test). Grey area depicts range of healthy control samples.

FIG. 19 presents LGALS3BP to creatinine ratios in urine samples from HC, SLE, LN and IgAN.

FIG. 20 presents the same data of FIG. 19 reformatted so that urinary protein to creatinine ratio (UPCR) is the metric presented in the y-axis.

FIG. 21A LGALS3BP shows better separation of LN patients from extrarenal SLE patients and healthy controls than CCL2 (MCP-1). Urinary LGALS3BP was measured in samples from indicated groups and normalized to urine creatinine levels. **P<0.01, ****P<0.00001, one-way ANOVA with Tukey's multiple comparisons test.

FIG. 21B LGALS3BP shows better separation of LN patients from extrarenal SLE patients and healthy controls than CCL2 (MCP-1). Urinary CCL2 (MCP-1) was measured in samples from indicated groups and normalized to urine creatinine levels. **P<0.01, ****P<0.00001, one-way ANOVA with Tukey's multiple comparisons test.

FIG. 22A and FIG. 22B described data confirming that detection of urinary LGALS3BP gives better sensitivity and specificity for detecting LN than CCL2 (MCP-1). Receiver operating characteristics (ROC) curves of urinary LGALS3BP/creatinine (Cr) and CCL2 (MCP-1)/creatinine ratios for distinguishing LN from healthy controls (HC) or extrarenal SLE (SLE).

FIG. 23A shows correlations of urinalysis measurements, wherein, albumin to creatinine ratios and total protein to creatinine ratios closely correlated to one another with a correlation coefficient of 0.965.

FIG. 23B shows correlations of urinalysis measurements (using the reagents associated the diagnostic kit presented in the Experimental section of the instant application), wherein, LGALS3BP to creatinine ratios show weak positive correlation with total protein to creatinine ratios

(r=0.494).

FIG. 24 shows correlations of urinalysis measurements (using the reagents associated the diagnostic kit presented in the Experimental section of the instant application), wherein, LGALS3BP to creatinine ratios show weak positive correlation with albumin to creatinine ratios (r=0.484).

FIG. 25 describes data showing urinary LGALS3BP/creatinine ratios in different kidney disease groups. The graph shows increased levels of LGALS3BP preferentially in LN when active (flaring). This shows a disease-specific pattern in uG3BP expression and a trend that is driven by active inflammation in the context of LN.

FIG. 26A shows means for urinary LGALS3BP/creatinine ratios in different kidney disease groups. Urinary LGALS3BP concentrations (ng/ml) were normalized to creatinine concentration (mg/ml), natural log transformed and outliers were excluded for data analysis. JMP pro v12 is used including ANOVA and Wilcoxon non parametric multiple comparison.

FIG. 26B shows significant p values between comparison groups. Urinary LGALS3BP data were normalized to creatinine concentration, natural log transformed and outliers were excluded for data analysis. JMP pro v12 is used including ANOVA and Wilcoxon non parametric multiple comparison.

FIG. 27A, FIG. 27B and FIG. 27C show weak positive correlation between urinary LGALS3BP/creatinine and urinary protein/creatinine ratios in LN irrespective of disease status (all, active or in remission)

FIG. 28A shows urinary protein to creatinine ratios (UPCR) in International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of LN in active disease versus patients in remission. UPCR is associated with kidney damage and always higher in active disease regardless of ISN/RPS class.

FIG. 28B shows urinary LGALS3BP/creatinine ratios International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of LN in active disease versus patients in remission. Urinary LGALS3BP/creatinine levels are elevated in active disease compared to remission in class II to IV but not V. Class II to IV are inflammatory forms of LN while class V is less inflammatory, further support for urinary LGALS3BP being a readout of active inflammation in the kidney.

FIG. 29 shows the fluctuation, over time, of urinary LGALS3BP/creatinine levels in LN patients. LN patient urine was monitored monthly.

FIG. 30 shows how the initiation of LN-specific treatments reduces urinary LGALS3BP levels over time. Specifically, newly diagnosed LN patients were put on Eurolupus treatment (specific) and urinary LGALS3BP levels tracked over time.

DETAILED DESCRIPTION

Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or groups of compositions of matter. Thus, as used herein, the singular forms “a”, “an” and “the” include plural aspects unless the context clearly dictates otherwise. For embodiment, reference to “a” includes a single as well as two or more; reference to “an” includes a single as well as two or more; reference to “the” includes a single as well as two or more and so forth.

Each embodiment of the present disclosure described herein is to be applied mutatis mutandis to each and every other embodiment unless specifically stated otherwise.

Those skilled in the art will appreciate that the disclosure herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the disclosure includes all such variations and modifications. The disclosure also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the disclosure, as described herein.

The present disclosure is performed without undue experimentation using, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA technology, peptide synthesis in solution, solid phase peptide synthesis, and immunology. Such procedures are described, for embodiment, in Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, New York, Second Edition (1989), whole of Vols I, II, and III; Benny K. C. Lo, Antibody Engineering: Methods and Protocols, (2004) Humana Press, Vol. 248; DNA Cloning: A Practical Approach, Vols. I and II (D. N. Glover, ed., 1985), IRL Press, Oxford, whole of text; Oligonucleotide Synthesis: A Practical Approach (M. J. Gait, ed, 1984) IRL Press, Oxford, whole of text, and particularly the papers therein by Gait, pp 1-22; Atkinson et al., pp 35-81; Sproat et al., pp 83-115; and Wu et al., pp 135-151; Nucleic Acid Hybridization: A Practical Approach (B. D. Hames & S. J. Higgins, eds., 1985) IRL Press, Oxford, whole of text; Immobilized Cells and Enzymes: A Practical Approach (1986) IRL Press, Oxford, whole of text; Perbal, B., A Practical Guide to Molecular Cloning (1984); Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.), whole of series; J. F. Ramalho Ortigao, “The Chemistry of Peptide Synthesis” In: Knowledge database of Access to Virtual Laboratory website (Interactiva, Germany); Sakakibara Biochem. Biophys. Res. Commun 73: 336-342, 1976; Merrifield J. Am. Chem. Soc. 85: 2149-2154, 1963; Barany and Merrifield (1979) in The Peptides (Gross, E. and Meienhofer, J. eds.), vol. 2, pp. 1-284, Academic Press, New York. 12. Wunsch, E., ed. (1974) Synthese von Peptiden in Houben-Weyls Metoden der Organischen Chemie (Muller, E., ed.), vol. 15, 4th edn., Parts 1 and 2, Thieme, Stuttgart; Bodanszky, M. (1984) Principles of Peptide Synthesis, Springer-Verlag, Heidelberg; Bodanszky, M. & Bodanszky, A. (1984) The Practice of Peptide Synthesis, Springer-Verlag, Heidelberg; Bodanszky Int. J. Peptide Protein Res. 25: 449-474, 1985; Handbook of Experimental Immunology, Vols. I-IV (D. M. Weir and C. C. Blackwell, eds., 1986, Blackwell Scientific Publications); and Animal Cell Culture: Practical Approach, 3rd edn (John R. W. Masters, ed., 2000), ISBN 0199637970, whole of text.

Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Preferred embodiments of the present invention are based on the role that LGALS3BP plays as a predictive marker in quantitating levels of kidney inflammation in LN.

An exemplary full length human LGALS3BP polypeptide sequence (SEQ ID NO: 1) is as follows:

MTPPRLFWVWLLVAGTQGVNDGDMRLADGGATNQGRVEIFYRGQWGTVCD
NLWDLTDASVVCRALGFENATQALGRAAFGQGSGPIMLDEVQCTGTEASL
ADCKSLGWLKSNCRHERDAGVVCTNETRSTHTLDLSRELSEALGQIFDSQ
RGCDLSISVNVQGEDALGFCGHTVILTANLEAQALWKEPGSNVTMSVDAE
CVPMVRDLLRYFYSRRIDITLSSVKCFHKLASAYGARQLQGYCASLFAIL
LPQDPSFQMPLDLYAYAVATGDALLEKLCLQFLAWNFEALTQAEAWPSVP
TDLLQLLLPRSDLAVPSELALLKAVDTWSWGERASHEEVEGLVEKIRFPM
MLPEELFELQFNLSLYWSHEALFQKKTLQALEFHTVPFQLLARYKGLNLT
EDTYKPRIYTSPTWSAFVTDSSWSARKSQLVYQSRRGPLVKYSSDYFQAP
SDYRYYPYQSFQTPQHPSFLFQDKRVSWSLVYLPTIQSCWNYGFSCSSDE
LPVLGLTKSGGSDRTIAYENKALMLCEGLFVADVTDFEGWKAAIPSALDT
NSSKSTSSFPCPAGHFNGFRTVIRPFYLTNSSGVD

DEFINITIONS

“Inflammation” is used herein in the general medical sense of the word and may be an acute or chronic; simple or suppurative; localized or disseminated; cellular and tissue response initiated or sustained by any number of chemical, physical or biological agents or combination of agents.

“Inflammatory state” is used to indicate the relative biological condition of a subject resulting from inflammation, or characterizing the degree of inflammation.

The terms “patient” and “subject” are used in this disclosure to refer to a mammal being treated or in need of treatment for a condition such as LN. The terms include human patients and volunteers, non-human mammals such as a non-human primates, large animal models and rodents.

A “sample” from a subject may include a single cell or multiple cells or fragments of cells or an aliquot of body fluid, taken from the subject, by means including venipuncture, excretion, ejaculation, massage, biopsy, needle aspirate, lavage sample, scraping, surgical incision or intervention or other means known in the art. The sample is blood, urine, spinal fluid, lymph, mucosal secretions, prostatic fluid, semen, haemolymph or any other body fluid known in the art for a subject. The sample is also a tissue sample.

“Therapy” includes all interventions whether biological, chemical, physical, or combination of the foregoing, intended to sustain or alter the monitored biological condition of a subject.

The term “isolated protein” is intended to mean a protein or polypeptide that by virtue of its origin or source of derivation is not associated with naturally-associated components that accompany it in its native state; is substantially free of other proteins from the same source. A protein may be rendered substantially free of naturally associated components or substantially purified by isolation, using protein purification techniques known in the art. By “substantially purified” is meant the protein is substantially free of contaminating agents, for embodiment, at least about 70% or 75% or 80% or 85% or 90% or 95% or 96% or 97% or 98% or 99% free of contaminating agents.

The term “recombinant” shall be understood to mean the product of artificial genetic recombination. Accordingly, in the context of a recombinant protein comprising an antigen binding domain, this term does not encompass an antibody naturally-occurring within a subject's body that is the product of natural recombination that occurs during B cell maturation. However, if such an antibody is isolated, it is to be considered an isolated protein comprising an antigen binding domain. Similarly, if nucleic acid encoding the protein is isolated and expressed using recombinant means, the resulting protein is a recombinant protein comprising an antigen binding domain A recombinant protein also encompasses a protein expressed by artificial recombinant means when it is within a cell, tissue or subject, for embodiment, in which it is expressed.

The term “Ig fusion protein which specifically binds to LGALS3BP” shall be taken to include an Ig fusion protein (including, but not limited to, an anti-LGALS3BP antibody) capable of binding to LGALS3BP in the manner described and/or claimed herein.

The term “polypeptide” or “polypeptide chain” will be understood to mean a series of contiguous amino acids linked by peptide bonds.

As used herein, the term “antigen binding domain” shall be taken to mean a region of an antibody that is capable of specifically binding to an antigen, that is, a V_H or a V_L or an Fv comprising both a V_H and a V_L. The antigen binding domain need not be in the context of an entire antibody, for embodiment, it can be in isolation (e.g., a domain antibody) or in another form (e.g., scFv).

For the purposes for the present disclosure, the term “antibody” includes a protein capable of specifically binding to one or a few closely related antigens (e.g., LGALS3BP) by virtue of an antigen binding domain contained within a Fv. This term includes four chain antibodies (e.g., two light (L) chains and two heavy (H) chains), recombinant or modified antibodies (e.g., chimeric antibodies, humanized antibodies, human antibodies, CDR-grafted antibodies, primatized antibodies, de-immunized antibodies, synhumanized antibodies, half-antibodies, bispecific antibodies). An antibody generally comprises constant domains, which can be arranged into a constant region or constant fragment or fragment crystallizable (Fc). Exemplary forms of antibodies comprise a four-chain structure as their basic unit. Full-length antibodies comprise two heavy chains (^˜50 to 70 kDa each) covalently linked and two light chains (¹⁸ 23 kDa each). A light chain generally comprises a variable region (if present) and a constant domain and in mammals is either a κ light chain or a λ light chain. A heavy chain generally comprises a variable region and one or two constant domain(s) linked by a hinge region to additional constant domain(s) Heavy chains of mammals are of one of the following types α, δ, ε, γ, or μ. Each light chain is also covalently linked to one of the heavy chains For embodiment, the two heavy chains and the heavy and light chains are held together by inter-chain disulfide bonds and by non-covalent interactions. The number of inter-chain disulfide bonds can vary among different types of antibodies. Each chain has an N-terminal variable region (V_H or V_L wherein each are approximately 110 amino acids in length) and one or more constant domains at the C-terminus. The constant domain of the light chain (CL which is approximately 110 amino acids in length) is aligned with and disulfide bonded to the first constant domain of the heavy chain (C_H1 which is 330 to 440 amino acids in length). The light chain variable region is aligned with the variable region of the heavy chain The antibody heavy chain can comprise 2 or more additional C_H domains (such as, C_H2, C_H3 and the like) and can comprise a hinge region between the C_H1 and C_H2 constant domains Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

As used herein, “variable region” refers to the portions of the light and/or heavy chains of an antibody as defined herein that is capable of specifically binding to an antigen and, includes amino acid sequences of complementarity determining regions (CDRs), that is, CDR1, CDR2, and CDR3, and framework regions (FRs). For embodiment, the variable region comprises three or four FRs (e.g., FR1, FR2, FR3 and optionally FR4) together with three CDRs. V_H refers to the variable region of the heavy chain V_L refers to the variable region of the light chain.

As used herein, the term “complementarity determining regions” (syn. CDRs, i.e., CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable region the presence of which are major contributors to specific antigen binding. Each variable region domain (V_H or V_L) typically has three CDR regions identified as CDR1, CDR2 and CDR3. In one embodiment, the amino acid positions assigned to CDRs and FRs are defined according to Kabat Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., 1987 and 1991 (also referred to herein as “the Kabat numbering system”). In another embodiment, the amino acid positions assigned to CDRs and FRs are defined according to the Enhanced Chothia Numbering Scheme. According to the numbering system of Kabat, V_HFRs and CDRs are positioned as follows: residues 1 to 30 (FR1), 31 to 35 (CDR1), 36 to 49 (FR2), 50 to 65 (CDR2), 66 to 94 (FR3), 95 to 102 (CDR3) and 103 to 113 (FR4). According to the numbering system of Kabat, V_LFRs and CDRs are positioned as follows: residues 1 to 23 (FR1), 24 to 34 (CDR1), 35 to 49 (FR2), 50 to 56 (CDR2), 57 to 88 (FR3), 89 to 97 (CDR3) and 98 to 107 (FR4). The present disclosure is not limited to FRs and CDRs as defined by the Kabat numbering system, but includes all numbering systems, including the canonical numbering system or of Chothia and Lesk J. Mol. Biol. 196: 901-917, 1987; Chothia et al., Nature 342: 877-883, 1989; and/or Al-Lazikani et al., J. Mol. Biol. 273: 927-948, 1997; the numbering system of Honnegher and Pliikthun J. Mol. Biol. 309: 657-670, 2001; or the IMGT system discussed in Giudicelli et al., Nucleic Acids Res. 25: 206-211 1997. In one embodiment, the CDRs are defined according to the Kabat numbering system.

As used herein, the term “Fv” shall be taken to mean any protein, whether comprised of multiple polypeptides or a single polypeptide, in which a V_L and a V_H associate and form a complex having an antigen binding domain that is capable of specifically binding to an antigen. The V_H and the V_L which form the antigen binding domain can be in a single polypeptide chain or in different polypeptide chains. Furthermore, a Fv of the disclosure (as well as any protein of the disclosure) may have multiple antigen binding domains which may or may not bind the same antigen. This term shall be understood to encompass fragments directly derived from an antibody as well as proteins corresponding to such a fragment produced using recombinant means. In some embodiments, the V_H is not linked to a heavy chain constant domain (C_H) 1 and/or the V_L is not linked to a light chain constant domain (CL). Exemplary Fv containing polypeptides or proteins include a Fab fragment, a Fab′ fragment, a F(ab′) fragment, a scFv, a diabody, a triabody, a tetrabody or higher order complex, or any of the foregoing linked to a constant region or domain thereof, for embodiment, C_H2 or C_H3 domain, for embodiment, a minibody.

A “Fab fragment” consists of a monovalent antigen-binding fragment of an immunoglobulin, and can be produced by digestion of a whole antibody with the enzyme papain, to yield a fragment consisting of an intact light chain and a portion of a heavy chain or can be produced using recombinant means.

A “Fab′ fragment” of an antibody can be obtained by treating a whole antibody with pepsin, followed by reduction, to yield a molecule consisting of an intact light chain and a portion of a heavy chain comprising a V_H and a single constant domain. Two Fab′ fragments are obtained per antibody treated in this manner A Fab′ fragment can also be produced by recombinant means.

A “single chain Fv” or “scFv” is a recombinant molecule containing the variable region fragment (Fv) of an antibody in which the variable region of the light chain and the variable region of the heavy chain are covalently linked by a suitable, flexible polypeptide linker.

As used herein, the term “binds” in reference to the interaction of a Ig fusion protein which specifically binds to LGALS3BP or an antigen binding domain thereof with an antigen means that the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the antigen. For embodiment, an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody binds to epitope “A”, the presence of a molecule containing epitope “A” (or free, unlabeled “A”), in a reaction containing labeled “A” and the antibody, will reduce the amount of labeled “A” bound to the antibody.

As used herein, the term “specifically binds” shall be taken to mean that a protein of the disclosure (e.g., an anti-LGALS3BP antibody) reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular antigen or cell expressing same than it does with alternative antigens or cells. For embodiment, a protein that specifically binds to an antigen binds that antigen with greater affinity, avidity, more readily, and/or with greater duration than it binds to other antigens. For embodiment, a protein binds to LGALS3BP with materially greater affinity than it does to other immunoglobulin superfamily ligands or to antigens commonly recognized by polyreactive natural antibodies (i.e., by naturally occurring antibodies known to bind a variety of antigens naturally found in humans) It is also understood by reading this definition that, for embodiment, a protein that specifically binds to a first antigen may or may not specifically bind to a second antigen. As such, “specific binding” does not necessarily require exclusive binding or non-detectable binding of another antigen, this is meant by the term “selective binding”.

As used herein, the term “epitope” (syn. “antigenic determinant”) shall be understood to mean a region of LGALS3BP to which a protein comprising an antigen binding domain of an antibody binds. This term is not necessarily limited to the specific residues or structure to which the protein makes contact. For embodiment, this term includes the region spanning amino acids contacted by the protein and/or at least 5 to 10 or 2 to 5 or 1 to 3 amino acids outside of this region. In some embodiments, the epitope is a linear series amino acids. An epitope may also comprise a series of discontinuous amino acids that are positioned close to one another when LGALS3BP is folded, that is, a “conformational epitope”. The skilled artisan will also be aware that the term “epitope” is not limited to peptides or polypeptides. For embodiment, the term “epitope” includes chemically active surface groupings of molecules such as sugar side chains, phosphoryl side chains, or sulfonyl side chains, and, in certain embodiments, may have specific three dimensional structural characteristics, and/or specific charge characteristics. An epitope or peptide or polypeptide comprising same can be administered to an animal to generate antibodies against the epitope.

As used herein, the term “diagnosis”, and variants thereof such as, but not limited to, “diagnose”, “diagnosed” or “diagnosing” includes any primary diagnosis of a clinical state or diagnosis of recurrent disease.

METHODS

The following methods were used to source and prepare materials (including, but not limited to, human and non-human tissues, cells and proteins) used in the following Experimental Examples section in the instant patent application.

In Vitro Stimulation of Human Macrophages

Human PBMCs were isolated from buffy coat preparations of healthy donors (New York Blood Center) using Ficoll Paque Plus (GE Health Sciences) according to the manufacturer's instructions. Monocytes were purified by adherence to plastic for 90 minutes and subsequently differentiated to macrophages by culture with 100 ng/ml GM-CSF (Sargramostim, Sanofi) in RPMI 1640 (Gibco) containing Pen/Strep and 10% heat inactivated fetal bovine serum (Corning). On day 7 inflammatory stimuli (recombinant IFNα, CpG for TLR9, LPS for TLR4, small molecule agonist for TLR7/8 and IFNα) were added and LGALS3BP mRNA measured by qCPR after 6 h and LGALS3BP protein by ELISA after 20 h. mRNA was measured with Taqman technology (Applied Biosystems) and HPRT1 used as a housekeeping gene for normalization. Samples were run on an Applied Biosystems QuantStudio instrument. LGALS3BP protein was measured with a commercially available ELISA kit (Abnova).

LGALS3BP Expression in Blood

Patient whole blood was collected and PBMCs were isolated by Ficoll density centrifugation. PBMCs were frozen at −80° C. in 90% fetal calf serum containing 10% DMSO. When ready for further analysis, cells were rapidly thawed, lysed with Buffer RLT (Qiagen) containing 1% (3-mercaptoethanol, and RNA was extracted using the RNeasy mini kit (Qiagen). This was followed by DNAse1 treatment and additional cleanup using SPRI beads (Life Technologies). RNA-seq was subsequently performed using the Smartseq2 protocol. Data are presented as FPKM values.

LGALS3BP Expression in Kidneys from LN Patients and Healthy Controls

Human renal biopsies were collected after obtaining informed consent, processed, and used for microarray analysis. Detailed method information can be found in the original reference (Berthier C C et al., JI 2012). This data was accessed from the GEO database under GSE32591. The linear expression data are shown.

LGALS3BP Expression in BXSB-Yaa Model

All procedures using animals were performed in accordance with all local and national laws and regulations regarding animal care. Male BXSB-Yaa mice were purchased from Jackson. At 20 weeks of age mice were euthanized via CO2 asphyxiation and blood was collected via the vena cava. At the conclusion of studies kidneys were collected, fixed in formalin and shipped to HistoTox Labs where they were processed for hematoxylin and eosin staining and scored for histological evidence of damage by a trained pathologist. The scoring system used was modified from a previously published system (Chan, O., Madaio, M. P., and Shlomchik, M. J. 1997. The roles of B cells in MRL/lpr murine lupus. Ann N Y Acad Sci 815:75-87) and evaluates kidney sections based on glomerular crescents, protein casts, interstitial inflammation, and vasculitis and a total histology score is obtained based on a composite score of these parameters.

Plasma and Urine Collection

Whole blood and freshly voided urine was obtained from healthy patients or SLE and LN patients. Whole blood was collected in heparin tubes and shipped at ambient temperature. Plasma was collected by spinning whole blood at 720×g for 10 minutes. Plasma was collected and centrifuged again for 15 mins at 2000×g to remove platelets. All samples were stored at −80 C.

Antibodies/Library Based Methods

The present disclosure also encompasses screening of libraries of antibodies or proteins comprising antigen binding domains thereof (e.g., comprising variable regions thereof) to identify a Ig fusion protein which specifically binds to LGALS3BP of the disclosure. For embodiment, a library comprising a V_H of the disclosure and a plurality of V_L regions can be screened to identify a Ig fusion protein which specifically binds to LGALS3BP of the disclosure.

Embodiments of libraries contemplated by this disclosure include naïve libraries (from unchallenged subjects), immunized libraries (from subjects immunized with an antigen) or synthetic libraries. Nucleic acid encoding antibodies or regions thereof (e.g., variable regions) are cloned by conventional techniques (e.g., as disclosed in Sambrook and Russell, eds, Molecular Cloning: A Laboratory Manual, 3rd Ed, vols. 1-3, Cold Spring Harbor Laboratory Press, 2001) and used to encode and display proteins using a method known in the art. Other techniques for producing libraries of proteins are described in, for embodiment in U.S. Pat. No. 6,300,064 (e.g., a HuCAL library of Morphosys AG), U.S. Pat. Nos. 5,885,793, 6,204,023, 6,291,158, or 6,248,516.

The Ig fusion protein which specifically binds to LGALS3BPs according to the disclosure may be soluble secreted proteins or may be presented as a fusion protein on the surface of a cell, or particle (e.g., a phage or other virus, a ribosome or a spore). Various display library formats are known in the art. For embodiment, the library is an in vitro display library (e.g., a ribosome display library, a covalent display library or a mRNA display library, e.g., as described in U.S. Pat. No. 7,270,969). In yet another embodiment, the display library is a phage display library wherein proteins comprising antigen binding domains of antibodies are expressed on phage, for embodiment, as described in U.S. Pat. Nos. 6,300,064, 5,885,793, 6,204,023, 6,291,158, or 6,248,516. Other phage display methods are known in the art and are contemplated by the present disclosure. Similarly, methods of cell display are contemplated by the disclosure, for embodiment, bacterial display libraries, for embodiment, as described in U.S. Pat. No. 5,516,637; yeast display libraries, for embodiment, as described in U.S. Pat. No. 6,423,538; or a mammalian display library.

Methods for screening display libraries are known in the art. In one embodiment, a display library of the present disclosure is screened using affinity purification, for embodiment, as described in Scopes (In: Protein purification: principles and practice, Third Edition, Springer Verlag, 1994). Methods of affinity purification typically involve contacting proteins comprising antigen binding domains displayed by the library with a target antigen (e.g., LGALS3BP) and, following washing, eluting those domains that remain bound to the antigen.

Any variable regions or scFvs identified by screening are readily modified into a complete antibody, if desired. Exemplary methods for modifying or reformatting variable regions or scFvs into a complete antibody are described, for embodiment, in Jones et al., J. Immunol. Methods 354: 85-90, 2010; or Jostock et al., J. Immunol. Methods, 289: 65-80, 2004. Alternatively, or additionally, standard cloning methods are used, e.g., as described in Ausubel et al., (In: Current Protocols in Molecular Biology. Wiley Interscience, ISBN 047 150338, 1987), and/or (Sambrook et al., (In: Molecular Cloning: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, New York, Third Edition 2001).

In one embodiment, the present disclosure provides a method of producing or isolating a Ig fusion protein which specifically binds to LGALS3BP of the disclosure by screening a display library, for embodiment, a phage display library, for embodiment, as described in U.S. Pat. Nos. 6,300,064 and/or 5,885,793. For embodiment, the present inventors have isolated scFvs by biopanning a human scFv immunoglobulin gene library by rounds of selection against full length recombinant human LGALS3BP. Once isolated, a Ig fusion protein which specifically binds to LGALS3BP of the invention can be cloned and expressed and optionally reformatted as, for embodiment, an IgG1 antibody using known methods in the art.

In one embodiment, the present disclosure provides a method of producing a Ig fusion protein which specifically binds to LGALS3BP, the method comprising:

• • (i) screening a Ig fusion protein which specifically binds to LGALS3BP preparation or library for a binding protein that binds to the extracellular domain of LGALS3BP, for embodiment, the extracellular domain of recombinant human LGALS3BP; and
  • (ii) isolating a Ig fusion protein which specifically binds to LGALS3BP having a desired binding affinity for the extracellular domain of LGALS3BP.

In one embodiment, a Ig fusion protein which specifically binds to LGALS3BP preparation is screened. A LGALS3BP preparation may be made by, for embodiment, immunizing an animal with a LGALS3BP antigen so as to produce antibodies that react with the extracellular domain of LGALS3BP.

In another embodiment, a Ig fusion protein which specifically binds to LGALS3BP library is screened. The library may be a phage library, for embodiment, a scFv phage library or a Fab phage library.

In one embodiment, the method comprises producing a population of phage particles displaying at their surface a population of binding molecules having a range of binding specificities for a target LGALS3BP epitope or antigen. Such phage particles comprise a phagemid genome comprising a nucleic acid encoding the binding protein. This nucleic acid can be isolated, cloned and expressed in a recombinant system to produce the Ig fusion protein which specifically binds to LGALS3BP of the invention.

Exemplary cells used for expressing a Ig fusion protein which specifically binds to LGALS3BP of the disclosure are CHO cells, myeloma cells or HEK cells. The cell may further comprise one or more genetic mutations and/or deletions that facilitate expression of a modified antibody. One non-limiting embodiment is a deletion of a gene encoding an enzyme required for fucosylation of an expressed immunoglobulin or antibody.

Protein Purification

Following production/expression, a Ig fusion protein which specifically binds to LGALS3BP of the disclosure is purified using a method known in the art. Such purification provides the protein of the disclosure substantially free of nonspecific protein, acids, lipids, carbohydrates, and the like. In one embodiment, the protein will be in a preparation wherein more than about 90% (e.g., 95%, 98% or 99%) of the protein in the preparation is a Ig fusion protein which specifically binds to LGALS3BP of the disclosure.

Standard methods of peptide purification are employed to obtain an isolated Ig fusion protein which specifically binds to LGALS3BP of the disclosure, including but not limited to various high-pressure (or performance) liquid chromatography (HPLC) and non-HPLC polypeptide isolation protocols, such as size exclusion chromatography, ion exchange chromatography, hydrophobic interaction chromatography, mixed mode chromatography, phase separation methods, electrophoretic separations, precipitation methods, salting in/out methods, immunochromatography, and/or other methods.

Ig Fusion Protein which Specifically Binds to LGALS3BPs/Anti-LGALS3BP Antibodies

Selected embodiments of the present invention are based on the inventors' production of human antibodies that bind specifically to LGALS3BP. These human anti-LGALS3BP antibodies derived from a phage display library of human scFv sequences; the obtained scFv phage clone reformatted as an IgG1 mAb.

The present disclosure is broadly directed to a Ig fusion protein which specifically binds to LGALS3BP comprising an antigen binding domain which specifically binds to LGALS3BP.

Qqq

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 32, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 33 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 34 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 35, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 36 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 37. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 2.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 38, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 39 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 40 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 41, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 42 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 43. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 3.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 44, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 45 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 46 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 47, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 48 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 49. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 4.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 50, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 51 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 52 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 53, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 54 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 55. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 5

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 56, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 57 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 58 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 59, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 60 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 61. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 6.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 62, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 63 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 64 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 65, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 66 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 67. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 7.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 68, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 69 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 70 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 71, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 72 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 73. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 8.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 74, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 75 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 76 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 77, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 78 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 79. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 9.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 80, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 81 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 82 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 83, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 84 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 85. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 10.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 86, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 87 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 88 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 89, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 90 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 91. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 11.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 92, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 93 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 94 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 95, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 96 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 97. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 12.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 98, the V_HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 99 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 100 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 101, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 102 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 103. A condensation of the three V_HCDRs and the three V_LCDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 13.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 104, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 105 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 106 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 107, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 108 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 109. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 14.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 110, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 111 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 112 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 113, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 114 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 115. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 15.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 116, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 117 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 118 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 119, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 120 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 121. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 16.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 122, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 123 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 124 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 125, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 126 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 127. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 17.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 128, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 129 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 130 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 131, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 132 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 133. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 18.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 134, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 135 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 136 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 137, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 138 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 139. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 19.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 140, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 141 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 142 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 143, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 144 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 145. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 20.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 146, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 147 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 148 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 149, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 150 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 151. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 21.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 152, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 153 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 154 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 155, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 156 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 157. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 22.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 158, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 159 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 160 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 161, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 162 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 163. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 23.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 164, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 165 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 166 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 167, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 168 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 169. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 24.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 170, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 171 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 172 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 173, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 174 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 175. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 25.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 176, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 177 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 178 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 179, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 180 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 181. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 26.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 182, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 183 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 184 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 185, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 186 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 187. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 27.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 188, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 189 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 190 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 191, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 192 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 193. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 28.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 194, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 195 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 196 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 197, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 198 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 199. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 29.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 200, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 201 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 202 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 203, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 204 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 205. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 30.

In one embodiment, the present invention discloses a LGALS3BP Ig fusion protein which specifically binds to LGALS3BP, wherein, the Ig fusion protein comprises a heavy chain variable region (V_H) which comprises three complementarity determining regions (CDRs), wherein, V_HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 206, the V_H CDR2 comprises the amino acid sequence shown in SEQ ID NO: 207 and the V_HCDR3 the amino acid sequence shown in amino acids of SEQ ID NO: 208 and a light chain variable region (V_L) which comprises three complementarity determining regions (CDRs), wherein, V_LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 209, the V_LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 210 and the V_LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 211. A condensation of the three V_HCDRs and the three V_L CDRs of the LGALS3BP Ig fusion protein recited in the aforementioned paragraph is shown in the amino acids of SEQ ID NO: 31.

In one embodiment, the V_H and the V_L are in a single polypeptide chain. For embodiment, the Ig fusion protein which specifically binds to LGALS3BP is:

• • (i) a single chain Fv fragment (scFv); or
  • (ii) a dimeric scFv (di-scFv); or
  • (iii) (i) or (ii) linked to a Fc or a heavy chain constant domain (C_H) 2 and/or C_H3; or
  • (iv) (i) or (ii) linked to a protein that binds to an immune effector cell.

In selected embodiments of the present invention, it is contemplated that the V_L and V_H are in separate polypeptide chains For example, the Ig fusion protein which specifically binds to LGALS3BP is:

• • (i) a diabody; or
  • (ii) a triabody; or
  • (iii) a tetrabody; or
  • (iv) a Fab; or
  • (v) a F(ab′)2; or
  • (vi) a Fv; or
  • (vii) one of (i) to (vi) linked to a Fc or a C_H2 and/or C_H3

In preferred embodiments of the present invention the Ig fusion protein which specifically binds to LGALS3BPs of the present invention are full length antibodies.

Tables 1-7 present different amino acid sequences descriptive of the Ig fusion proteins which specifically binds to LGALS3BPs described by various embodiment of the present invention.

TABLE 1
VH & VL CDR SEQUENCES COMBINED
mAb ID	HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3	Seq ID No:
mAb1	GlyPheThrPheSerSerTyrGlyIleSerTyrAspGlySerAsnLysAlaLysGlySerSerProTyrTyrTyrT	2
	yrGlyMetAspValGlnSerValSerThrAsnGlyAlaSerGlnGlnTyrAsnThrTrpProProValArg
mAb2	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspThrAlaSerGlyGlyMetAsp	3
	ValGlnSerValSerSerAsnGlyAlaSerGlnGlnTyrGlyTyrSerGlnIleThr
mAb3	GlyPheThrPheSerSerTyrGlyIleSerGlySerGlyGlySerThrAlaLysAlaThrGlyTyrSerSerGlyTr	4
	pTyrGlyAlaTyrPheAspTyrGlnSerValSerSerSerTyrGlyAlaSerGlnGlnTyrGlySerSerProLeu
	Thr
mAb4	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluPheGlnAsp	5
	SerSerSerTrpTyrGluGlyArgAlaPheAspIleSerSerAspValGlyGlyTyrAsnTyrAspValSerSerS
	erTyrAlaGlySerSerValVal
mAb5	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGlyGlyValGlyA	6
	laThrTrpTyrTyrGlyMetAspValLysLeuGlyAspLysTyrGlnAspSerGlnThrTrpAspSerSerThr
	ValVal
mAb6	GlyPheThrPheSerSerTyrSerIleTrpTyrAspGlySerAsnLysAlaArgLeuGlySerGlyTrpSerLeu	7
	AspTyrSerSerAspValGlyGlyTyrAsnTyrAspValAsnSerSerTyrThrSerSerAsnThrLeuValVal
mAb7	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrP	8
	roAspTyrSerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValV
	al
mAb8	GlyPheThrPheSerAsnAlaTrpIleLysSerLysAsnAspGlyGlyThrThrThrThrAlaProSerLeuMe	9
	tAspValSerSerTyrIleAlaThrAsnSerSerAspSerAlaAlaTrpAspAspSerLeuAsnAlaTyrVal
mAb9	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrP	10
	roAspTyrSerSerAspIleGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuValVal
mAb10	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrP	11
	roAspTyrSerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuValV
	al
mAb11	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrP	12
	roAspTyrSerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValV
	al
mAb12	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspLeuHisSerAlaAlaGlyPheA	13
	spTyrGlyAsnAsnTyrGluAsnAsnGlyThrTrpAspSerSerLeuAsnValGlyVal
mAb13	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspPheGluGlySerGlyAlaLeu	14
	AspValAsnIleGlyAspLysArgTyrAspThrGlnValTrpAspThrAspThrAsnHisAlaVal
mAb14	GlyPheThrPheSerAsnAlaTrplIeLysSerLysAsnAspGlyGlyThrThrThrThrAlaProSerLeuMe	15
	tAspValIleLeuGlyHisTyrHisGlyLysAspAsnAsnSerArgAspArgSerGlyThrGlnValLeu
mAb15	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspLeuSerTyrSerAspAlaPhe	16
	AspIleSerSerAsnIleGlyAsnAsnTyrAspAsnAspGlyThrTrpAspAsnSerLeuSerAlaValVal
mAb16	GlyPheThrPheSerSerTyrGlyIleTrpTyrAspGlyAsnAsnLysAlaArgAspAsnSerGlySerTyrAs	17
	nTrpPheAsnProSerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrSerGlySerAsnAsnL
	euValVal
mAb22	GlyPheThrPheSerSerTyrProIleSerTyrAspGlyGlyAsnLysAlaArgValGlySerGlyGlyTrpThrP	18
	roAspTyrSerSerAspValGlyGlyTyrAsnTyrGluValThrSerSerTyrThrSerSerSerThrPheValV
	al
mAb101	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysAlaArgAspArgGlyValGluGlyAla	19
	TyrGlyMetAspValGlnArgValArgSerSerTyrGlyAlaSerGlnGlnTyrGlySerSerProProArgIleIl
	e
mAb102	GlyTyrThrPheThrGlyTyrTyrIleAsnProAsnSerGlyGlyThrAlaArgGlyGlyAspCysSerSerThr	20
	SerCysTyrAspProAspTyrGlyGlySerIleAlaSerAsnTyrLysAspAsnGlnSerTyrGlySerGlyAsn
	ValVal
mAb103	GlyTyrThrPheThrSerTyrTyrIleAsnProSerGlyGlySerThrAlaArgGluAspHisAspTyrSerAsn	21
	GlnGlyGlyPheAspTyrGlnSerValThrSerAsnTyrGlyAlaSerGlnGlnTyrGlySerSerProThr
mAb104	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluLysIleAlaV	22
	alAlaGlyTyrTyrTyrGlyMetAspValLysLeuGlyAspLysTyrGlnAsnAsnGlnAlaTrpAspSerSer
	AlaValVal
mAb105	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrSerSerLysTrpTyrAsnAlaArgGlyGlySerSerG	23
	luPheTyrTyrTyrGlyMetAspValLysLeuGlyAsnLysTyrGluAsnAsnGlnAlaTrpAspSerSerThr
	AlaVal
mAb106	GlyPheThrPheAspAspTyrAlaIleSerTrpAsnSerGlySerIleAlaLysAspIleAlaAlaGlyGlyLeuAs	24
	pSerGlnSerlIeSerSerTyrAlaAlaSerGlnGlnSerTyrSerThrSerTrpThr
mAb107	GlyTyrThrPheThrSerTyrGlyIleSerAlaTyrAsnGlyAsnThrAlaArgGlyLeuGlyAspSerSerSerS	25
	erTyrThrSerAsnIleGlyAlaAsnHisThrLysAsnAlaAlaTrpAspAspSerLeuArgGlyTrpThr
mAb108	GlyTyrSerPheThrSerTyrTrpIleTyrProGlyAspSerAspThrAlaSerGlyAlaSerProTyrTyrPheA	26
	spTyrSerLeuArgSerTyrTyrGlyLysAsnAsnSerArgAspSerSerGlyAsnHisTrpVal
mAb109	GlyTyrThrPheThrSerTyrGlyIleSerAlaTyrAsnGlyAsnThrAlaArgAspProValTyrSerSerSerT	27
	rpGlyGlyTyrAlaPheAspIleGlnGlyValAsnSerAspGlyAlaSerGlnGlnTyrAsnAsnTrpProTrpT
	hr
mAb110	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysThrArgValGlySerGlyGlyTrpThr	28
	ProAspTyrSerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuVal
	Val
mAb111	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspThrAlaSerGlyGlyMetAsp	29
	ValGlnSerValSerSerAsnGlyAlaSerGlnGlnTyrGlyTyrSerGlnIleThr
mAb112	GlyPheThrPheSerSerTyrGlyIleTrpTyrAspGlySerAsnLysAlaArgGluValValGlySerTyrTyrL	30
	euAspTyrSerSerAspIleGlyGlyTyrLysTyrAspValThrGlySerTyrSerSerSerSerSerHisTyrVal
mAb113	GlyPheThrPheSerSerTyrTrplIeLysGlnAspGlySerGluLysAlaArgAspLeuHisCysGlySerSer	31
	CysGlyProGluAlaGlnThrlIeSerSerTyrGlyAlaSerGlnGlnSerTyrSerThrProGlnThr

TABLE 2
VH AND VL ELISA REACTIVITY
			huEGFR
			ELISA
mAb	Seq ID	huLGALS3BP	reactivity
ID	No:	ELISA reactivity (OD)	(OD)
mAb1		1.5794	0.0948
mAb2		2.559	0.0944
mAb3		2.5552	0.0936
mAb4		2.5288	0.0898
mAb5		0.8091	0.0856
mAb6		2.5542	0.0797
mAb7		1.6491	0.1006
mAb8		0.128	0.0899
mAb9		2.5658	0.0984
mAb10		2.4879	0.096
mAb11		2.5157	0.0978
mAb12		2.5803	0.0939
mAb13		2.5866	0.084
mAb14		0.203	0.0901
mAb15		0.8852	0.0785
mAb16		2.549	0.0844
mAb22		2.47	0.0925
mAb101		Full dose response in graph
mAb102		Full dose response in graph
mAb103		Full dose response in graph
mAb104		Full dose response in graph
mAb105		Full dose response in graph
mAb106		Full dose response in graph
mAb107		Full dose response in graph
mAb108		Full dose response in graph
mAb109		Full dose response in graph
mAb110		Full dose response in graph
mAb111		Full dose response in graph
mAb112		Full dose response in graph
mAb113		Full dose response in graph

TABLE 3
DISCRETE CDR5 FOR VH AND VL SEQUENCES
mAb	HCDR1	HCDR2	HCDR3	LCDR1	LCDR2	LCDR3
mAb1	GlyPheT	IleSerTyrAs	AlaLysGlySe	GlnSerValS	GlyAlaSer	GlnGlnTyrAsnThrTrpProProV
	hrPheSer	pGlySerAsn	rSerProTyrT	erThrAsn	(SEQ ID	alArg
	SerTyrGl	Lys (SEQ ID	yrTyrTyrGly	(SEQ ID	NO: 36)	(SEQ ID NO: 37)
	y (SEQ	NO: 33)	MetAspVal	NO: 35)
	ID NO:		(SEQ ID NO:
	32)		34)
mAb2	GlyPheT	IleTyrSerGl	AlaArgAspT	GlnSerValS	GlyAlaSer	GlnGlnTyrGlyTyrSerGlnIleThr
	hrValSer	yGlySerThr	hrAlaSerGly	erSerAsn	(SEQ ID	(SEQ ID NO: 43)
	SerAsnTy	(SEQ ID NO:	GlyMetAsp	(SEQ ID	NO: 42)
	r (SEQ ID	39)	Val (SEQ ID	NO: 41)
	NO: 38)		NO: 40)
mAb3	GlyPheT	IleSerGlySe	AlaLysAlaT	GlnSerValS	GlyAlaSer	GlnGlnTyrGlySerSerProLeuT
	hrPheSer	rGlyGlySerT	hrGlyTyrSer	erSerSerTyr	(SEQ ID	hr
	SerTyrGl	hr	SerGlyTrpT	(SEQ ID	NO: 48)	(SEQ ID NO: 49)
	y	(SEQ ID NO:	yrGlyAlaTyr	NO: 47)
	(SEQ ID	45)	PheAspTyr
	NO: 44)		(SEQ ID NO:
			46)
mAb4	GlyAspSe	ThrTyrTyrA	AlaArgGluP	SerSerAspV	AspValSer	SerSerTyrAlaGlySerSerValVal
	rValSerS	rgSerLysTrp	heGlnAspS	alGlyGlyTyr	(SEQ ID	(SEQ ID NO: 55)
	erAsnSer	TyrAsn	erSerSerTrp	AsnTyr	NO: 54)
	AlaAla	(SEQ ID NO:	TyrGluGlyA	(SEQ ID
	(SEQ ID	51)	rgAlaPheAs	NO: 53)
	NO: 50)		pIle (SEQ ID
			NO: 52)
mAb5	GlyAspSe	ThrTyrTyrA	AlaArgGlyG	LysLeuGlyA	GlnAspSer	GlnThrTrpAspSerSerThrValV
	rValSerS	rgSerLysTrp	lyValGlyAla	spLysTyr	(SEQ ID	al
	erAsnSer	TyrAsn	ThrTrpTyrT	(SEQ ID	NO: 60)	(SEQ ID NO: 61)
	AlaAla	(SEQ ID NO:	yrGlyMetAs	NO: 59)
	(SEQ ID	57)	pVal (SEQ
	NO: 56)		ID NO: 58)
mAb6	GlyPheT	IleTrpTyrAs	AlaArgLeuG	SerSerAspV	AspValAsn	SerSerTyrThrSerSerAsnThrLe
	hrPheSer	pGlySerAsn	lySerGlyTrp	alGlyGlyTyr	(SEQ ID	uValVal (SEQ ID NO: 67)
	SerTyrSe	Lys (SEQ ID	SerLeuAspT	AsnTyr	NO: 66)
	r (SEQ ID	NO: 63)	yr (SEQ ID	(SEQ ID
	NO: 62)		NO: 64)	NO: 65)
mAb7	GlyPheT	IleSerTyrAs	AlaArgValGl	SerSerAspV	AspValSer	SerSerTyrThrSerSerSerThrLe
	hrPheSer	pGlySerAsn	ySerGlyGly	alGlyGlyTyr	(SEQ ID	uValVal (SEQ ID NO: 73)
	SerTyrPr	Lys (SEQ ID	TrpThrProA	AsnTyr	NO: 72)
	o (SEQ ID	NO: 69)	spTyr (SEQ	(SEQ ID
	NO: 68)		ID NO: 70)	NO: 71)
mAb8	GlyPheT	IleLysSerLys	ThrThrAlaP	SerSerTyrIl	SerAspSer	AlaAlaTrpAspAspSerLeuAsnA
	hrPheSer	AsnAspGly	roSerLeuM	eAlaThrAsn	(SEQ ID	laTyrVal (SEQ ID NO: 79)
	AsnAlaTr	GlyThrThr	etAspVal	Ser	NO: 78)
	p (SEQ ID	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID
	NO: 74)	75)	76)	NO: 77)
mAb9	GlyPheT	IleSerTyrAs	AlaArgValGl	SerSerAspIl	GluValSer	SerSerTyrThrSerSerSerThrLe
	hrPheSer	pGlySerAsn	ySerGlyGly	eGlyGlyTyr	(SEQ ID	uValVal (SEQ ID NO: 85)
	SerTyrPr	Lys (SEQ ID	TrpThrProA	AsnTyr	NO: 84)
	o (SEQ ID	NO: 81)	spTyr (SEQ	(SEQ ID
	NO: 80)		ID NO: 82)	NO: 83)
mAb10	GlyPheT	IleSerTyrAs	AlaArgValGl	SerSerAspV	GluValSer	SerSerTyrThrSerSerSerThrLe
	hrPheSer	pGlySerAsn	ySerGlyGly	alGlyGlyTyr	(SEQ ID	uValVal (SEQ ID NO: 91)
	SerTyrPr	Lys (SEQ ID	TrpThrProA	AsnTyr	NO: 90)
	o (SEQ ID	NO: 87)	spTyr (SEQ	(SEQ ID
	NO: 86)		ID NO: 88)	NO: 89)
mAb11	GlyPheT	IleSerTyrAs	AlaArgValGl	SerSerAspV	AspValSer	SerSerTyrThrSerSerSerThrLe
	hrPheSer	pGlySerAsn	ySerGlyGly	alGlyGlyTyr	(SEQ ID	uValVal (SEQ ID NO: 97)
	SerTyrPr	Lys (SEQ ID	TrpThrProA	AsnTyr	NO: 96)
	o (SEQ ID	NO: 93)	spTyr (SEQ	(SEQ ID
	NO: 92)		ID NO: 94)	NO: 95)
mAb12	GlyPheT	IleTyrSerGl	AlaArgAspL	GlyAsnAsnT	GluAsnAsn	GlyThrTrpAspSerSerLeuAsnV
	hrValSer	yGlySerThr	euHisSerAl	yr (SEQ ID	(SEQ ID	alGlyVal (SEQ ID NO: 103)
	SerAsnTy	(SEQ ID NO:	aAlaGlyPhe	NO: 101)	NO: 102)
	r (SEQ ID	99)	AspTyr
	NO: 98)		(SEQ ID NO:
			100)
mAb13	GlyPheT	IleTyrSerGl	AlaArgAspP	AsnIleGlyAs	TyrAspThr	GlnValTrpAspThrAspThrAsn
	hrValSer	yGlySerThr	heGluGlySe	pLysArg	(SEQ ID	HisAlaVal (SEQ ID NO: 109)
	SerAsnTy	(SEQ ID NO:	rGlyAlaLeu	(SEQ ID	NO: 108)
	r (SEQ ID	105)	AspVal	NO: 107)
	NO: 104)		(SEQ ID NO:
			106)
mAb14	GlyPheT	IleLysSerLys	ThrThrAlaP	IleLeuGlyHi	GlyLysAspA	AsnSerArgAspArgSerGlyThrG
	hrPheSer	AsnAspGly	roSerLeuM	sTyrHis	sn	lnValLeu
	AsnAlaTr	GlyThrThr	etAspVal	(SEQ ID	(SEQ ID	(SEQ ID NO: 115)
	p (SEQ ID	(SEQ ID NO:	(SEQ ID NO:	NO: 113)	NO: 114)
	NO: 110)	111)	112)
mAb15	GlyPheT	IleTyrSerGl	AlaArgAspL	SerSerAsnIl	AspAsnAsp	GlyThrTrpAspAsnSerLeuSerA
	hrValSer	yGlySerThr	euSerTyrSe	eGlyAsnAs	(SEQ ID	laValVal (SEQ ID NO: 121)
	SerAsnTy	(SEQ ID NO:	rAspAlaPhe	nTyr	NO: 120)
	r (SEQ ID	117)	AspIle (SEQ	(SEQ ID
	NO: 116)		ID NO: 118)	NO: 119)
mAb16	GlyPheT	IleTrpTyrAs	AlaArgAspA	SerSerAspV	GluValSer	SerSerTyrSerGlySerAsnAsnLe
	hrPheSer	pGlyAsnAs	snSerGlySe	alGlyGlyTyr	(SEQ ID	uValVal (SEQ ID NO: 127)
	SerTyrGl	nLys (SEQ	rTyrAsnTrp	AsnTyr	NO: 126)
	y (SEQ ID	ID NO: 123)	PheAsnPro	(SEQ ID
	NO: 122)		(SEQ ID NO:	NO: 125)
			124)
mAb22	GlyPheT	IleSerTyrAs	AlaArgValGl	SerSerAspV	GluValThr	SerSerTyrThrSerSerSerThrPh
	hrPheSer	pGlyGlyAsn	ySerGlyGly	alGlyGlyTyr	(SEQ ID	eValVal (SEQ ID NO: 133)
	SerTyrPr	Lys (SEQ ID	TrpThrProA	AsnTyr	NO: 132)
	o (SEQ ID	NO: 129)	spTyr (SEQ	(SEQ ID
	NO: 128)		ID NO: 130)	NO: 131)
mAb101	GlyPheT	IleSerTyrAs	AlaArgAspA	GlnArgValA	GlyAlaSer	GlnGlnTyrGlySerSerProProAr
	hrPheSer	pGlySerAsn	rgGlyValGlu	rgSerSerTyr	(SEQ ID	gIleIle
	SerTyrAl	Lys (SEQ ID	GlyAlaTyrGl	(SEQ ID	NO: 138)	(SEQ ID NO: 139)
	a (SEQ ID	NO: 135)	yMetAspVa	NO: 137)
	NO: 134)		l (SEQ ID
			NO: 136)
mAb102	GlyTyrTh	IleAsnProA	AlaArgGlyG	GlyGlySerOl	LysAspAsn	GlnSerTyrGlySerGlyAsnValVa
	rPheThr	snSerGlyGl	IyAspCysSe	eAlaSerAsn	(SEQ ID	l
	GlyTyrTy	yThr (SEQ	rSerThrSer	Tyr (SEQ ID	NO: 144)	(SEQ ID NO: 145)
	r (SEQ ID	ID NO: 141)	CysTyrAspP	NO: 143)
	NO: 140)		roAspTyr
			(SEQ ID NO:
			142)
mAb103	GlyTyrTh	IleAsnProS	AlaArgGluA	GlnSerValT	GlyAlaSer	GlnGlnTyrGlySerSerProThr
	rPheThrS	erGlyGlySer	spHisAspTy	hrSerAsnTy	(SEQ ID	(SEQ ID NO: 151)
	erTyrTyr	Thr (SEQ ID	rSerAsnGln	r (SEQ ID	NO: 150)
	(SEQ ID	NO: 147)	GlyGlyPheA	NO: 149)
	NO: 146)		spTyr (SEQ
			ID NO: 148)
mAb104	GlyAspSe	ThrTyrTyrA	AlaArgGluL	LysLeuGlyA	GlnAsnAsn	GlnAlaTrpAspSerSerAlaValVa
	rValSerS	rgSerLysTrp	ysIleAlaVal	spLysTyr	(SEQ ID	l
	erAsnSer	TyrAsn	AlaGlyTyrT	(SEQ ID	NO: 156)	(SEQ ID NO: 157)
	AlaAla	(SEQ ID NO:	yrTyrGlyMe	NO: 155)
	(SEQ ID	153)	tAspVal
	NO: 152)		(SEQ ID NO:
			154)
mAb105	GlyAspSe	ThrTyrTyrS	AlaArgGlyG	LysLeuGlyA	GluAsnAsn	GlnAlaTrpAspSerSerThrAlaV
	rValSerS	erSerLysTrp	lySerSerGlu	snLysTyr	(SEQ ID	al (SEQ ID NO: 163)
	erAsnSer	TyrAsn	PheTyrTyrT	(SEQ ID	NO: 162)
	AlaAla	(SEQ ID NO:	yrGlyMetAs	NO: 161)
	(SEQ ID	159)	pVal (SEQ
	NO: 158)		ID NO: 160)
mAb106	GlyPheT	IleSerTrpAs	AlaLysAspIl	GlnSerIleSe	AlaAlaSer	GlnGlnSerTyrSerThrSerTrpTh
	hrPheAs	nSerGlySerI	eAlaAlaGly	rSerTyr	(SEQ ID	r
	pAspTyr	le (SEQ ID	GlyLeuAspS	(SEQ ID	NO: 168)	(SEQ ID NO: 169)
	Ala (SEQ	NO: 165)	er (SEQ ID	NO: 167)
	ID NO:		NO: 166)
	164)
mAb107	GlyTyrTh	IleSerAlaTy	AlaArgGlyL	ThrSerAsnIl	ThrLysAsn	AlaAlaTrpAspAspSerLeuArgG
	rPheThrS	rAsnGlyAsn	euGlyAspSe	eGlyAlaAsn	(SEQ ID	lyTrpThr (SEQ ID NO: 175)
	erTyrGly	Thr (SEQ ID	rSerSerSerT	His (SEQ ID	NO: 174)
	(SEQ ID	NO: 171)	yr (SEQ ID	NO: 173)
	NO: 170)		NO: 172)
mAb108	GlyTyrSe	IleTyrProGl	AlaSerGlyAl	SerLeuArgS	GlyLysAsn	AsnSerArgAspSerSerGlyAsnH
	rPheThrS	yAspSerAsp	aSerProTyr	erTyrTyr	(SEQ ID	isTrpVal
	erTyrTrp	Thr (SEQ ID	TyrPheAspT	(SEQ ID	NO: 180)	(SEQ ID NO: 181)
	(SEQ ID	NO: 177)	yr (SEQ ID	NO: 179)
	NO: 176)		NO: 178)
mAb109	GlyTyrTh	IleSerAlaTy	AlaArgAspP	GlnGlyValA	GlyAlaSer	GlnGlnTyrAsnAsnTrpProTrpT
	rPheThrS	rAsnGlyAsn	roValTyrSer	snSerAsp	(SEQ ID	hr (SEQ ID NO: 187)
	erTyrGly	Thr	SerSerTrpG	(SEQ ID	NO: 186)
	(SEQ ID	(SEQ ID NO:	lyGlyTyrAla	NO: 185)
	NO: 182)	183)	PheAspIle
			(SEQ ID NO:
			184)
mAb110	GlyPheT	IleSerTyrAs	ThrArgValG	SerSerAspV	GluValSer	SerSerTyrThrSerSerSerThrLe
	hrPheSer	pGlySerAsn	lySerGlyGly	alGlyGlyTyr	(SEQ ID	uValVal (SEQ ID NO: 193)
	SerTyrPr	Lys (SEQ ID	TrpThrProA	AsnTyr	NO: 192)
	o (SEQ ID	NO: 189)	spTyr (SEQ	(SEQ ID
	NO: 188)		ID NO: 190)	NO: 191)
mAb111	GlyPheT	IleTyrSerGl	AlaArgAspT	GlnSerValS	GlyAlaSer	GlnGlnTyrGlyTyrSerGlnIleThr
	hrValSer	yGlySerThr	hrAlaSerGly	erSerAsn	(SEQ ID	(SEQ ID NO: 199)
	SerAsnTy	(SEQ ID NO:	GlyMetAsp	(SEQ ID	NO: 198)
	r (SEQ ID	195)	Val (SEQ ID	NO: 197)
	NO: 194)		NO: 196)
mAb112	GlyPheT	IleTrpTyrAs	AlaArgGluV	SerSerAspIl	AspValThr	GlySerTyrSerSerSerSerSerHis
	hrPheSer	pGlySerAsn	alValGlySer	eGlyGlyTyr	(SEQ ID	TyrVal
	SerTyrGl	Lys (SEQ ID	TyrTyrLeuA	LysTyr (SEQ	NO: 204)	(SEQ ID NO: 205)
	y (SEQ ID	NO: 201)	spTyr (SEQ	ID NO: 203)
	NO: 200)		ID NO: 202)
mAb113	GlyPheT	IleLysGlnAs	AlaArgAspL	GlnThrIleSe	GlyAlaSer	GlnGlnSerTyrSerThrProGlnT
	hrPheSer	pGlySerGlu	euHisCysGl	rSerTyr	(SEQ ID	hr
	SerTyrTr	Lys (SEQ ID	ySerSerCys	(SEQ ID	NO: 210)	(SEQ ID NO: 211)
	p (SEQ ID	NO: 207)	GlyProGluA	NO: 209)
	NO: 206)		la (SEQ ID
			NO: 208)

TABLE 4
DISCRETE CDR5 FOR LH SEQUENCES
	SEQ		SEQ		SEQ
	ID		ID		ID
VH_ID	NO:	VH_CDR1	NO:	VH_CDR2	NO:	VH_CDR3
VH_1	212	GlyAspSerIleSerSerG	382	IleSerTyrAspGlySerAs	552	AlaArgValGlySerGlyGlyTrpThrPr
		lyTyrTrp		nLys		oAspTyr
VH_2	213	GlyAspSerValSerSer	383	IleAsnProAsnSerGlyGl	553	AlaArgGluValAlaThrIleProAlaHi
		AsnSerAlaAla		yThr		sPheAspTyr
VH_3	214	GlyAspSerValSerSer	384	IleSerAlaTyrAsnGlyAs	554	AlaArgAspTyrAspIleLeuThrGlyL
		AsnSerAlaAla		nThr		euAspTyr
VH_4	215	GlyAspSerValSerSer	385	IleSerGlySerGlyGlyArg	555	AlaLysAspTrpAlaGlyTyrIleAsnGl
		AsnSerAlaAla		Thr		yTrpTyrGlyAsn
VH_5	216	GlyAspSerValSerSer	386	IleSerGlySerGlyGlySer	556	AlaLysAspTrpAlaGlyTyrValAsnG
		AsnSerAlaAla		Thr		lyTrpTyrGlyAsn
VH_6	217	GlyAspSerValSerSer	387	IleSerGlySerGlyGlySer	557	AlaLysAspTrpGlyThrSerLeuLeuT
		AsnSerAlaAla		Thr		yrGlyTyrPheAspTyr
VH_7	218	GlyAspSerValSerSer	388	IleSerTyrAspGlySerAs	558	AlaArgValGlySerGlyGlyTrpThrPr
		AsnSerAlaAla		nLys		oAspTyr
VH_8	219	GlyAspSerValSerSer	389	IleTyrSerGlyGlySerThr	559	AlaArgAspPheGluGlySerGlyAlaL
		AsnSerAlaAla				euAspVal
VH_9	220	GlyAspSerValSerSer	390	ThrTyrTyrSerSerLysTr	560	AlaArgGlyGlySerSerGluPheTyrT
		AsnSerAlaAla		pTyrAsn		yrTyrGlyMetAspVal
VH_10	221	GlyAspSerValSerSer	391	IleSerGlySerGlyGlyIleT	561	AlaLysAspTrpAlaGlyTyrThrAsnG
		AspSerAlaSer		hr		lyTrpTyrGlySer
VH_11	222	GlyGlySerIleSerGlyS	392	IleSerGlySerGlyGlyIleT	562	AlaLysAspTrpAlaGlyTyrThrAsnG
		erAsnTyrTyr		hr		lyTrpTyrGlySer
VH_12	223	GlyGlySerIleSerSerS	393	IleSerGlySerGlyGlySer	563	AlaLysAspArgSerArgArgAlaProT
		erAsnTrp		Thr		yrTyrPheAspTyr
VH_13	224	GlyGlySerIleSerSerS	394	IleSerGlySerGlyGlySer	564	AlaLysValTyrArgGlyTyrAspAlaP
		erAsnTrp		Thr		heAspIle
VH_14	225	GlyGlySerIleSerSerS	395	IleTyrProGlyAspSerAs	565	AlaArgHisAlaGlyAspGlyGlnIleAs
		erAsnTrp		pThr		pTyr
VH_15	226	GlyGlySerIleSerSerS	396	ThrTyrTyrArgSerLysTr	566	AlaArgGluGlySerGlyLeuTyrTyrT
		erAsnTrp		pTyrAsn		yrTyrGlyMetAspVal
VH_16	227	GlyGlySerValSerSer	397	IleSerGlySerGlyGlySer	567	AlaArgGlyGlySerGlyTrpTyrHisTy
		AsnSerAlaAla		Thr		rPheAspTyr
VH_17	228	GlyGlyThrPheSerSer	398	IleSerGlyThrGlyGlyArg	568	AlaLysAspTrpAlaGlyTyrIleAsnGl
		TyrAla		Thr		yTrpTyrGlySer
VH_18	229	GlyGlyThrPheSerSer	399	IleSerTyrAspGlySerAs	569	AlaArgValGlySerGlyGlyTrpThrPr
		TyrAla		nLys		oAspTyr
VH_19	230	GlyGlyThrPheSerSer	400	IleTrpTyrAspGlySerAs	570	AlaArgLeuGlySerGlyTrpSerLeuA
		TyrAla		nLys		spTyr
VH_20	231	GlyPheThrPheAsnTh	401	IleSerGlySerGlyAspArg	571	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrAla		Thr		yTrpPheGlyAsn
VH_21	232	GlyPheThrPheAsnTh	402	IleSerGlySerGlyAspIle	572	AlaLysAspTrpAlaGlyTyrValAsnG
		rTyrAla		Thr		lyTrpTyrGlyAsn
VH_22	233	GlyPheThrPheAsnTh	403	IleSerTyrAspGlySerAs	573	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrAla		nLys		oAspTyr
VH_23	234	GlyPheThrPheAspAs	404	IleAsnAlaGlyAsnGlyAs	574	AlaArgGlyGlyTyrCysSerSerThrS
		pTyrAla		nThr		erCysTyrProAspTyrAsnTrpPheA
						spPro
VH_24	235	GlyPheThrPheAspAs	405	IleSerGlySerGlyAspArg	575	AlaLysAspTrpAlaGlyTyrIleAsnGl
		pTyrAla		Thr		yTrpTyrAlaAsn
VH_25	236	GlyPheThrPheAspAs	406	IleTyrSerGlyGlySerThr	576	AlaArgAspArgArgGlyGlyAsnTrp
		pTyrAla				TyrGluPheAspTyr
VH_26	237	GlyPheThrPheAspAs	407	IleTyrSerGlyGlySerThr	577	AlaArgGluGlyLeuAlaMetAlaGly
		pTyrAla				TyrPheAspTyr
VH_27	238	GlyPheThrPheGlyAs	408	IleLysHisAspGlySerGlu	578	AlaArgValAlaValGlyAlaAsnLeuA
		nHisGly		Gln		laPheAspIle
VH_28	239	GlyPheThrPheSerAr	409	IleSerGlySerGlyAspArg	579	AlaLysAspTrpAlaGlyTyrIleAsnGl
		gTyrGly		Thr		yTrpTyrGlyAsn
VH_29	240	GlyPheThrPheSerAs	410	IleIleProIlePheGlyThrA	580	AlaArgGlyMetAlaGlnSerProAla
		nAlaTrp		la		PheAspTyr
VH_30	241	GlyPheThrPheSerAs	411	IleSerGlySerGlyGlyArg	581	AlaLysAspTrpAlaGlyTyrIleAsnGl
		nAlaTrp		Thr		yTrpTyrGlyAsn
VH_31	242	GlyPheThrPheSerAs	412	ThrTyrTyrAsnSerLysTr	582	AlaArgGluThrGlyGlyPheAspTyr
		nAlaTrp		pTyrAsn
VH_32	243	GlyPheThrPheSerAs	413	IleAsnThrAspGlyGlyAs	583	AlaArgAspProValArgGlyAspGly
		nTyrAla		nThr		TyrAsnPheAspTyr
VH_33	244	GlyPheThrPheSerAs	414	IleSerGlySerGlyAspIle	584	AlaLysAspTrpAlaGlyTyrValAsnG
		nTyrAla		Thr		lyTrpTyrGlyAsn
VH_34	245	GlyPheThrPheSerAs	415	IleSerGlySerGlyGlySer	585	AlaLysAlaThrGlyTyrSerSerGlyTr
		nTyrAla		Thr		pTyrGlyAlaTyrPheAspTyr
VH_35	246	GlyPheThrPheSerAs	416	IleTyrHisSerGlySerThr	586	AlaArgAspArgGlySerMetAspVal
		nTyrAla
VH_36	247	GlyPheThrPheSerAs	417	IleTyrProGlyAspSerAs	587	AlaArgLeuGlyArgThrSerHisGlnS
		nTyrAla		pThr		erTrpAspLeuGlyTyr
VH_37	248	GlyPheThrPheSerAs	418	IleTyrProGlyAspSerAs	588	AlaSerGlyAlaSerProTyrTyrPheA
		nTyrAla		pThr		spTyr
VH_38	249	GlyPheThrPheSerAs	419	IleTyrSerGlyGlySerThr	589	AlaArgGluSerAsnThrAlaAsnThr
		nTyrAla				HisPheAspTyr
VH_39	250	GlyPheThrPheSerAs	420	ThrTyrTyrArgSerLysTr	590	AlaArgGlyGlyValGlyAlaThrTrpT
		nTyrAla		pTyrAsn		yrTyrGlyMetAspVal
VH_40	251	GlyPheThrPheSerAs	421	IleSerTyrAspGlySerAs	591	AlaLysGlnGlnTrpLeuGlyThrTrpT
		nTyrGly		nLys		yrPheAspLeu
VH_41	252	GlyPheThrPheSerAs	422	IleSerTyrAspGlySerAs	592	AlaLysGlyLeuLeuValAlaSerIleTy
		nTyrGly		nLys		rAspAlaPheAspIle
VH_42	253	GlyPheThrPheSerAs	423	IleSerTrpAsnSerGlySer	593	AlaLysAspIleAlaAlaGlyGlyLeuAs
		pTyrAla		Ile		pSer
VH_43	254	GlyPheThrPheSerAs	424	ValSerGlySerGlyThrSe	594	AlaLysAspTrpAlaGlyTyrIleAsnGl
		pTyrTyr		rThr		yTrpTyrGlyAsn
VH_44	255	GlyPheThrPheSerSe	425	IleAsnProAsnSerGlyAs	595	AlaArgGluGlnTrpLeuGlyProAla
		rTyrAla		pThr		HisPheAspTyr
VH_45	256	GlyPheThrPheSerSe	426	IleAsnProAsnSerGlyGl	596	AlaArgGluArgAsnArgAlaGlyGlu
		rTyrAla		yThr		PheSerAlaPheAspIle
VH_46	257	GlyPheThrPheSerSe	427	IleGluProGlyAsnGlyAs	597	AlaArgGlyAlaSerGlyLeuAspPhe
		rTyrAla		pThr
VH_47	258	GlyPheThrPheSerSe	428	IleLysGlnAspGlySerGlu	598	AlaArgAspLeuHisCysGlySerSerC
		rTyrAla		Lys		ysGlyProGluAla
VH_48	259	GlyPheThrPheSerSe	429	IleSerAlaTyrAsnGlyAs	599	AlaArgAspProValTyrSerSerSerT
		rTyrAla		nThr		rpGlyGlyTyrAlaPheAspIle
VH_49	260	GlyPheThrPheSerSe	430	IleSerAlaTyrAsnGlyAs	600	AlaArgAspThrPheGlyGlyGlySer
		rTyrAla		nThr		TyrTyrGlyHisGlyTyr
VH_50	261	GlyPheThrPheSerSe	431	IleSerAsnAspGlyValAs	601	AlaArgGluAsnSerAsnAlaTrpLys
		rTyrAla		nAsn		ValMetAspVal
VH_51	262	GlyPheThrPheSerSe	432	IleSerGlySerGlyAspArg	602	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrAla		Thr		yTrpTyrGlyAsn
VH_52	263	GlyPheThrPheSerSe	433	IleSerGlySerGlyGlyArg	603	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrAla		Thr		yTrpTyrGlyAsn
VH_53	264	GlyPheThrPheSerSe	434	IleSerGlySerGlyGlyArg	604	AlaLysAspTrpAlaGlyTyrIleAspGl
		rTyrAla		Thr		yTrpTyrGlyAsn
VH_54	265	GlyPheThrPheSerSe	435	IleSerGlySerGlyGlyArg	605	AlaLysAspTrpGlyAlaTyrSerSerGl
		rTyrAla		Thr		yTrpTyrGlyAsp
VH_55	266	GlyPheThrPheSerSe	436	IleSerGlySerGlyGlyAsn	606	AlaLysAspTrpAlaGlyTyrSerAsnG
		rTyrAla		Ile		lyTrpTyrGlySer
VH_56	267	GlyPheThrPheSerSe	437	IleSerGlySerGlyGlyIleT	607	AlaLysAspTrpAlaGlyTyrSerAsnG
		rTyrAla		hr		lyTrpPheGlySer
VH_57	268	GlyPheThrPheSerSe	438	IleSerTyrAspGlyGlyAs	608	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrAla		nLys		oAspTyr
VH_58	269	GlyPheThrPheSerSe	439	IleSerTyrAspGlySerAs	609	AlaValGlyValGlyPheIleThrAspGl
		rTyrAla		nGln		yTyrPheGlnHis
VH_59	270	GlyPheThrPheSerSe	440	IleSerTyrAspGlySerAs	610	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrAla		nLys		oAspTyr
VH_60	271	GlyPheThrPheSerSe	441	IleSerTyrAspGlySerAs	611	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrAla		nLys		oAspTyr
VH_61	272	GlyPheThrPheSerSe	442	IleSerTyrAspGlySerAs	612	AlaLysGlnGlnTrpLeuGlyThrTrpT
		rTyrAla		nLys		yrPheAspLeu
VH_62	273	GlyPheThrPheSerSe	443	IleSerTyrAspGlySerAs	613	AlaLysGluTrpGlyGlyGlyAspSerP
		rTyrAla		nLys		roThrAspMetGlyLeuPheAspTyr
VH_63	274	GlyPheThrPheSerSe	444	IleSerTyrAspGlySerAs	614	ThrArgValGlySerGlyGlyTrpThrP
		rTyrAla		nLys		roAspTyr
VH_64	275	GlyPheThrPheSerSe	445	IleTrpTyrAspGlyAsnAs	615	AlaArgAspAsnSerGlySerTyrAsn
		rTyrAla		nLys		TrpPheAsnPro
VH_65	276	GlyPheThrPheSerSe	446	IleTyrProGlyAspSerAs	616	AlaArgSerHisGlyGlySerAsnTrpP
		rTyrAla		pThr		heAspPro
VH_66	277	GlyPheThrPheSerSe	447	IleTyrProGlyAspSerAs	617	AlaThrSerLeuGlyAspAspAlaPhe
		rTyrAla		pThr		AspIle
VH_67	278	GlyPheThrPheSerSe	448	IleTyrProGlyAspSerGl	618	AlaArgLeuGlyHisSerGlySerTrpT
		rTyrAla		uThr		yrPheAspLeu
VH_68	279	GlyPheThrPheSerSe	449	IleTyrSerGlyGlySerThr	619	AlaArgAspLeuSerTyrSerAspAla
		rTyrAla				PheAspIle
VH_69	280	GlyPheThrPheSerSe	450	IleTyrSerGlyGlySerThr	620	AlaArgAspMetThrThrValAspAla
		rTyrAla				PheAspIle
VH_70	281	GlyPheThrPheSerSe	451	IleTyrSerGlyGlySerThr	621	AlaArgAspThrAlaSerGlyGlyMet
		rTyrAla				AspVal
VH_71	282	GlyPheThrPheSerSe	452	PheTyrSerGlyGlySerTh	622	AlaArgGluProTyrProGlyGlyProP
		rTyrAla		r		heAspIle
VH_72	283	GlyPheThrPheSerSe	453	IleSerAlaSerGlyGlySer	623	AlaAsnLeuTyrGlyAspTyrAsnAla
		rTyrGly		Thr		Tyr
VH_73	284	GlyPheThrPheSerSe	454	IleSerGlySerGlyAspArg	624	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrGly		Thr		yTrpTyrGlyAsn
VH_74	285	GlyPheThrPheSerSe	455	IleSerGlySerGlyGlyArg	625	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrGly		Thr		yTrpTyrGlyAsn
VH_75	286	GlyPheThrPheSerSe	456	IleSerGlySerGlyGlyIleT	626	AlaLysAspTrpAlaGlyTyrThrAsnG
		rTyrGly		hr		lyTrpTyrGlySer
VH_76	287	GlyPheThrPheSerSe	457	IleSerGlySerGlyGlySer	627	AlaLysAspLeuValLeuGly
		rTyrGly		Thr
VH_77	288	GlyPheThrPheSerSe	458	IleSerTrpAsnSerGlySer	628	AlaLysAspTrpAspSerSerGlyTyrT
		rTyrGly		Ile		rpProLeuPheAspTyr
VH_78	289	GlyPheThrPheSerSe	459	IleSerTyrAspGlySerAs	629	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrGly		nLys		oAspTyr
VH_79	290	GlyPheThrPheSerSe	460	IleSerTyrAspGlySerAs	630	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrGly		nLys		oAspTyr
VH_80	291	GlyPheThrPheSerSe	461	IleTrpTyrAspGlySerAs	631	AlaArgGluValValGlySerTyrTyrLe
		rTyrGly		nLys		uAspTyr
VH_81	292	GlyPheThrPheSerSe	462	IleAsnProAsnSerGlyGl	632	AlaArgGlyGlyAspCysSerSerThrS
		rTyrPro		yThr		erCysTyrAspProAspTyr
VH_82	293	GlyPheThrPheSerSe	463	IleLysGlnAspGlySerGlu	633	AlaArgIleGlyArgPheGlyArgLysT
		rTyrPro		Lys		yrGlyMetAspVal
VH_83	294	GlyPheThrPheSerSe	464	IleSerAlaTyrAsnGlyAs	634	AlaArgGlyLeuGlyAspSerSerSerS
		rTyrPro		nThr		erTyr
VH_84	295	GlyPheThrPheSerSe	465	IleSerGlySerGlyAspIle	635	AlaLysAspTrpAlaGlyTyrValAsnG
		rTyrPro		Thr		lyTrpTyrGlyAsn
VH_85	296	GlyPheThrPheSerSe	466	IleSerGlySerGlyAspIle	636	AlaLysAspTrpAlaGlyTyrValAsnG
		rTyrPro		Thr		lyTrpTyrGlyAsn
VH_86	297	GlyPheThrPheSerSe	467	IleSerGlySerGlyGlyArg	637	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrPro		Thr		yTrpTyrGlyAsn
VH_87	298	GlyPheThrPheSerSe	468	IleSerGlySerGlyGlyArg	638	AlaLysAspTrpGlyAlaTyrSerSerGl
		rTyrPro		Thr		yTrpTyrGlyAsp
VH_88	299	GlyPheThrPheSerSe	469	IleSerGlySerGlyGlyIleT	639	AlaLysAspTrpAlaGlyTyrThrAsnG
		rTyrPro		hr		lyTrpTyrGlySer
VH_89	300	GlyPheThrPheSerSe	470	IleSerGlyThrGlyGlyArg	640	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrPro		Thr		yTrpTyrGlySer
VH_90	301	GlyPheThrPheSerSe	471	IleSerTyrAspAlaThrAs	641	AlaLysGluArgPheThrGlyGlyTyrT
		rTyrPro		nAsn		yrThrTyrPheAspTyr
VH_91	302	GlyPheThrPheSerSe	472	IleTyrHisSerGlySerThr	642	AlaArgAlaGlyGlyLeuHisLeuAspT
		rTyrPro				yr
VH_92	303	GlyPheThrPheSerSe	473	IleTyrProGlyAspSerAs	643	AlaArgGlyAsnGlyAspGlyGlyPhe
		rTyrPro		pThr		AspTyr
VH_93	304	GlyPheThrPheSerSe	474	IleSerGlySerGlyGlyArg	644	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrSer		Thr		yTrpTyrGlyAsn
VH_94	305	GlyPheThrPheSerSe	475	IleSerGlySerGlyAspIle	645	AlaLysAspTrpAlaGlyTyrValAsnG
		rTyrTrp		Thr		lyTrpTyrGlyAsn
VH_95	306	GlyPheThrPheSerSe	476	IleSerTyrAspGlySerAs	646	AlaArgAspArgGlyValGluGlyAlaT
		rTyrTrp		nLys		yrGlyMetAspVal
VH_96	307	GlyPheThrPheSerSe	477	IleSerTyrAspGlySerAs	647	AlaLysGlyLeuLeuValAlaSerIleTy
		rTyrTrp		nLys		rAspAlaPheAspIle
VH_97	308	GlyPheThrPheSerSe	478	IleTyrHisSerGlySerThr	648	AlaArgGlySerAsnIlePheAspIle
		rTyrTrp
VH_98	309	GlyPheThrPheSerTh	479	IleLysSerLysAsnAspGly	649	ThrThrAlaProSerLeuMetAspVal
		rTyrAla		GlyThrThr
VH_99	310	GlyPheThrPheSerTh	480	IleSerAlaTyrAsnGlyAs	650	AlaArgAspLeuThrPheGlySerGly
		rTyrAla		nThr		ProThrArgAspTyr
VH_100	311	GlyPheThrPheSerTh	481	IleSerGlySerGlyAspIle	651	AlaLysAspTrpAlaGlyTyrThrAsnG
		rTyrAla		Thr		lyTrpTyrGlySer
VH_101	312	GlyPheThrPheSerTh	482	IleSerGlySerGlyAspIle	652	AlaLysAspTrpAlaGlyTyrValAsnG
		rTyrAla		Thr		lyTrpTyrGlyAsn
VH_102	313	GlyPheThrPheSerTh	483	IleSerGlySerGlyGlyArg	653	AlaLysAspTrpGlyAlaTyrSerSerGl
		rTyrAla		Thr		yTrpTyrGlyAsp
VH_103	314	GlyPheThrPheSerTh	484	IleSerGlySerGlyGlySer	654	AlaLysAspTrpAlaGlyTyrIleAsnGl
		rTyrAla		Thr		yTrpTyrGlyAsn
VH_104	315	GlyPheThrPheSerTh	485	IleSerGlySerGlyGlySer	655	AlaLysAspTrpThrAsnGlnTrpLeu
		rTyrAla		Thr		AspAlaTyrPheAspTyr
VH_105	316	GlyPheThrPheSerTh	486	IleSerGlySerGlyGlySer	656	AlaLysGluThrIleLeuTyrAspIleLe
		rTyrAla		Thr		uThrGlyTyrTyrAsnGluGlyAlaPhe
						AspIle
VH_106	317	GlyPheThrPheSerTh	487	IleSerTyrAspGlySerAs	657	AlaLysAspTrpGlyArgPheGlyGluL
		rTyrAla		nLys		euLeuGluGlySerProTyr
VH_107	318	GlyPheThrPheSerTh	488	ThrTyrTyrArgSerLysTr	658	AlaArgGluPheGlnAspSerSerSer
		rTyrAla		pTyrAsn		TrpTyrGluGlyArgAlaPheAspIle
VH_108	319	GlyPheThrValSerSer	489	IleAsnProAsnSerGlyGl	659	AlaArgAspTrpGlyArgGlyValGlyA
		AsnTyr		yThr		spSerGlyPheValAspTyr
VH_109	320	GlyPheThrValSerSer	490	IleAsnProLysSerGlyGly	660	AlaArgAspPheValGlyAlaSerLeu
		AsnTyr		Ala		AspTyr
VH_110	321	GlyPheThrValSerSer	491	IleSerGlySerGlyAspArg	661	AlaLysAspTrpAlaGlyTyrIleAsnGl
		AsnTyr		Thr		yTrpTyrGlyAsn
VH_111	322	GlyPheThrValSerSer	492	IleSerSerSerGlySerThrI	662	AlaArgGlyTyrLeuGlyAlaTrpAsnP
		AsnTyr		le		roAspPheTyrAspTyr
VH_112	323	GlyPheThrValSerSer	493	IleSerTyrAspGlySerAs	663	AlaArgValGlySerGlyGlyTrpThrPr
		AsnTyr		nLys		oAspTyr
VH_113	324	GlyPheThrValSerSer	494	IleThrGlySerGlyGlyThr	664	AlaLysAspTrpAlaGlyTyrIleAsnGl
		AsnTyr				yTrpPheGlySer
VH_114	325	GlyPheThrValSerSer	495	IleTyrProGlyAspSerAs	665	AlaArgLeuGlyAspGlySerAsnPhe
		AsnTyr		pThr		AspTyr
VH_115	326	GlyPheThrValSerSer	496	ThrTyrTyrArgSerLysTr	666	AlaArgGluLysIleAlaValAlaGlyTyr
		AsnTyr		pTyrAsn		TyrTyrGlyMetAspVal
VH_116	327	GlyPheThrValSerSer	497	ThrTyrTyrAsnArgLysTr	667	AlaArgAspGlyGlyTrpSerGlySerA
		AsnTyr		pIleAsn		laLeuAspVal
VH_117	328	GlyTyrArgPheThrSer	498	IleTyrSerGlyGlySerThr	668	AlaArgAspLeuHisSerAlaAlaGlyP
		TyrTrp				heAspTyr
VH_118	329	GlyTyrSerPheThrArg	499	IleLysSerLysAsnAspGly	669	ThrThrAlaProSerLeuMetAspVal
		TyrTrp		GlyThrThr
VH_119	330	GlyTyrSerPheThrSer	500	IleSerGlySerGlyAspArg	670	AlaLysAspTrpAlaGlyTyrIleAsnGl
		TyrTrp		Thr		yTrpTyrGlyAsn
VH_120	331	GlyTyrSerPheThrSer	501	IleSerGlySerGlyAspArg	671	AlaLysAspTrpAlaGlyTyrIleAsnGl
		TyrTrp		Thr		yTrpTyrGlyAsn
VH_121	332	GlyTyrSerPheThrSer	502	IleSerTyrAspGlySerAs	672	AlaLysGlySerSerProTyrTyrTyrTy
		TyrTrp		nLys		rGlyMetAspVal
VH_122	333	GlyTyrSerPheThrSer	503	IleTyrHisSerGlySerThr	673	AlaArgAspGlyGlySerGlyTrpTyrA
		TyrTrp				spTyr
VH_123	334	GlyTyrSerPheThrSer	504	IleTyrSerGlyGlySerThr	674	AlaArgAspThrAlaSerGlyGlyMet
		TyrTrp				AspVal
VH_124	335	GlyTyrSerPheThrSer	505	ThrTyrTyrArgSerLysTr	675	AlaArgGlyValThrValProTyrTyrT
		TyrTrp		pTyrAsn		yrTyrGlyMetAspVal
VH_125	336	GlyTyrSerPheThrSer	506	ThrTyrTyrArgSerLysTr	676	AlaArgSerSerGlySerTyrGlyTyrP
		TyrTrp		pTyrAsn		heGlnHis
VH_126	337	GlyTyrThrPheThrArg	507	ThrTyrTyrArgSerLysTr	677	AlaArgGluGlyThrAspIleTyrTyrTy
		AsnAla		pTyrAsn		rTyrGlyMetAspVal
VH_127	338	GlyTyrThrPheThrGly	508	IleAspTyrSerGlySerThr	678	AlaArgAspGlyTrpIleArgLysGluAl
		TyrTyr				aPheAspPro
VH_128	339	GlyTyrThrPheThrGly	509	IleLysSerLysAsnAspGly	679	ThrThrAlaProSerLeuMetAspVal
		TyrTyr		GlyThrThr
VH_129	340	GlyTyrThrPheThrGly	510	IleSerAlaTyrAsnGlyAs	680	AlaArgAspProGlyGlyTyrTyrTyrT
		TyrTyr		nThr		yrTyrGlyMetAspVal
VH_130	341	GlyTyrThrPheThrGly	511	IleSerTyrAspGlySerAs	681	AlaArgValGlySerGlyGlyTrpThrPr
		TyrTyr		nLys		oAspTyr
VH_131	342	GlyTyrThrPheThrGly	512	IleSerTyrAspGlySerAs	682	AlaLysLeuGlyGlySerTyrSerIleTyr
		TyrTyr		nLys		TyrGlyMetAspVal
VH_132	343	GlyTyrThrPheThrGly	513	IleTyrProGlyAspSerGl	683	AlaArgAspGlyGlyAsnTyrGlnPhe
		TyrTyr		uThr		AspTyr
VH_133	344	GlyTyrThrPheThrSer	514	IleIleProIlePheGlyThrA	684	AlaArgThrGlyArgSerGlySerTyrT
		TyrAla		la		yrSerAspAlaPheAspIle
VH_134	345	GlyTyrThrPheThrSer	515	IleAsnProSerGlyGlySer	685	AlaArgGluAspHisAspTyrSerAsn
		TyrGly		Thr		GlnGlyGlyPheAspTyr
VH_135	346	GlyTyrThrPheThrSer	516	IleIleProIlePheGlyThrA	686	AlaAlaArgAlaProGlyGlySerSerT
		TyrGly		la		yrTyrTyrTyrGlyMetAspVal
VH_136	347	GlyTyrThrPheThrSer	517	IleSerAlaTyrAsnGlyAs	687	AlaArgAspProGlyTyrAspPheTrp
		TyrGly		nThr		SerGlyTyrSerAspVal
VH_137	348	GlyTyrThrPheThrSer	518	IleSerGlySerGlyGlyArg	688	AlaLysAspTrpAlaGlyTyrIleAsnGl
		TyrGly		Thr		yTrpTyrGlyAsn
VH_138	349	GlyTyrThrPheThrSer	519	IleSerTrpAsnSerGlySer	689	AlaLysAspMetTrpGlySerLeuSerl
		TyrGly		Ile		leValGlyAlaThrArgAlaPheAspTy
						r
VH_139	350	GlyTyrThrPheThrSer	520	IleThrGlySerGlyGlyThr	690	AlaLysAspTrpAlaGlyTyrIleAsnGl
		TyrGly				yTrpPheGlySer
VH_140	351	GlyTyrThrPheThrSer	521	IleTyrHisSerGlySerThr	691	AlaArgGlyProLeuLeuIleAlaAlaAl
		TyrGly				aGlyThrAspTyrTyrTyrGlyMetAs
						pVal
VH_141	352	GlyTyrThrPheThrSer	522	IleSerGlySerGlyGlySer	692	AlaSerSerTyrGlyGlyAsnProLeuA
		TyrTyr		Thr		spAlaPheAspIle
VH_142	353	GlyAspSerValSerSer	523	ThrTyrTyrArgSerLysTr	693	AlaArgGluLysIleAlaValAlaGlyTyr
		AsnSerAlaAla		pTyrAsn		TyrTyrGlyMetAspVal
VH_143	354	GlyAspSerValSerSer	524	ThrTyrTyrArgSerLysTr	694	AlaArgGluPheGlnAspSerSerSer
		AsnSerAlaAla		pTyrAsn		TrpTyrGluGlyArgAlaPheAspIle
VH_144	355	GlyAspSerValSerSer	525	ThrTyrTyrArgSerLysTr	695	AlaArgGlyGlyValGlyAlaThrTrpT
		AsnSerAlaAla		pTyrAsn		yrTyrGlyMetAspVal
VH_145	356	GlyPheThrPheAspAs	526	IleSerTrpAsnSerGlySer	696	AlaLysAspIleAlaAlaGlyGlyLeuAs
		pTyrAla		Ile		pSer
VH_146	357	GlyPheThrPheSerAs	527	IleLysSerLysAsnAspGly	697	ThrThrAlaProSerLeuMetAspVal
		nAlaTrp		GlyThrThr
VH_147	358	GlyPheThrPheSerAs	528	IleLysSerLysAsnAspGly	698	ThrThrAlaProSerLeuMetAspVal
		nAlaTrp		GlyThrThr
VH_148	359	GlyPheThrPheSerSe	529	IleSerTyrAspGlySerAs	699	AlaArgAspArgGlyValGluGlyAlaT
		rTyrAla		nLys		yrGlyMetAspVal
VH_149	360	GlyPheThrPheSerSe	530	IleSerGlySerGlyGlySer	700	AlaLysAlaThrGlyTyrSerSerGlyTr
		rTyrGly		Thr		pTyrGlyAlaTyrPheAspTyr
VH_150	361	GlyPheThrPheSerSe	531	IleSerTyrAspGlySerAs	701	AlaLysGlySerSerProTyrTyrTyrTy
		rTyrGly		nLys		rGlyMetAspVal
VH_151	362	GlyPheThrPheSerSe	532	IleTrpTyrAspGlyAsnAs	702	AlaArgAspAsnSerGlySerTyrAsn
		rTyrGly		nLys		TrpPheAsnPro
VH_152	363	GlyPheThrPheSerSe	533	IleTrpTyrAspGlySerAs	703	AlaArgGluValValGlySerTyrTyrLe
		rTyrGly		nLys		uAspTyr
VH_153	364	GlyPheThrPheSerSe	534	IleSerTyrAspGlyGlyAs	704	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrPro		nLys		oAspTyr
VH_154	365	GlyPheThrPheSerSe	535	IleSerTyrAspGlySerAs	705	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrPro		nLys		oAspTyr
VH_155	366	GlyPheThrPheSerSe	536	IleSerTyrAspGlySerAs	706	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrPro		nLys		oAspTyr
VH_156	367	GlyPheThrPheSerSe	537	IleSerTyrAspGlySerAs	707	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrPro		nLys		oAspTyr
VH_157	368	GlyPheThrPheSerSe	538	IleSerTyrAspGlySerAs	708	AlaArgValGlySerGlyGlyTrpThrPr
		rTyrPro		nLys		oAspTyr
VH_158	369	GlyPheThrPheSerSe	539	IleSerTyrAspGlySerAs	709	ThrArgValGlySerGlyGlyTrpThrP
		rTyrPro		nLys		roAspTyr
VH_159	370	GlyPheThrPheSerSe	540	IleTrpTyrAspGlySerAs	710	AlaArgLeuGlySerGlyTrpSerLeuA
		rTyrSer		nLys		spTyr
VH_160	371	GlyPheThrPheSerSe	541	IleLysGlnAspGlySerGlu	711	AlaArgAspLeuHisCysGlySerSerC
		rTyrTrp		Lys		ysGlyProGluAla
VH_161	372	GlyPheThrValSerSer	542	IleTyrSerGlyGlySerThr	712	AlaArgAspLeuHisSerAlaAlaGlyP
		AsnTyr				heAspTyr
VH_162	373	GlyPheThrValSerSer	543	IleTyrSerGlyGlySerThr	713	AlaArgAspLeuSerTyrSerAspAla
		AsnTyr				PheAspIle
VH_163	374	GlyPheThrValSerSer	544	IleTyrSerGlyGlySerThr	714	AlaArgAspPheGluGlySerGlyAlaL
		AsnTyr				euAspVal
VH_164	375	GlyPheThrValSerSer	545	IleTyrSerGlyGlySerThr	715	AlaArgAspThrAlaSerGlyGlyMet
		AsnTyr				AspVal
VH_165	376	GlyPheThrValSerSer	546	IleTyrSerGlyGlySerThr	716	AlaArgAspThrAlaSerGlyGlyMet
		AsnTyr				AspVal
VH_166	377	GlyTyrSerPheThrSer	547	IleTyrProGlyAspSerAs	717	AlaSerGlyAlaSerProTyrTyrPheA
		TyrTrp		pThr		spTyr
VH_167	378	GlyTyrThrPheThrGly	548	IleAsnProAsnSerGlyGl	718	AlaArgGlyGlyAspCysSerSerThrS
		TyrTyr		yThr		erCysTyrAspProAspTyr
VH_168	379	GlyTyrThrPheThrSer	549	IleSerAlaTyrAsnGlyAs	719	AlaArgAspProValTyrSerSerSerT
		TyrGly		nThr		rpGlyGlyTyrAlaPheAspIle
VH_169	380	GlyTyrThrPheThrSer	550	IleSerAlaTyrAsnGlyAs	720	AlaArgGlyLeuGlyAspSerSerSerS
		TyrGly		nThr		erTyr
VH_170	381	GlyTyrThrPheThrSer	551	IleAsnProSerGlyGlySer	721	AlaArgGluAspHisAspTyrSerAsn
		TyrTyr		Thr		GlnGlyGlyPheAspTyr

TABLE 5
VL CDR SEQUENCES COMBINED
mAb ID	VL_CDR1/2/3	SEQ ID NO:
VL_1	ThrSerAsnIleGlyAlaAsnHisThrLysAsnAlaAlaTrpAspAspSerLeuArgGlyTrpThr	722
VL_2	SerSerAspIleGlyGlyTyrLysTyrAspValThrGlySerTyrSerSerSerSerSerHisTyrVal	723
VL_3	GlnSerIleSerSerPheAlaAlaSerGlnGlnSerTyrSerThrProTrpThr	724
VL_4	GlnSerValSerSerAsnGlyAlaSerGlnHisTyrAsnAsnTrpProProGlnIleThr	725
VL_5	GlnSerValSerSerAsnGlyAlaSerGlnGlnTyrGlyTyrSerGlnIleThr	726
VL_6	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	727
VL_7	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	728
VL_8	SerSerAsnIleGlyAlaGlyTyrAspSerSerAsnGlnSerPheAspProSerLeuSerAspSerTrpVal	729
VL_9	SerGlySerIleThrAspAspTyrGluAspHisGlnSerTyrAspAlaGluSerTrpVal	730
VL_10	GlnSerValSerSerAsnGlyAlaSerGlnGlnTyrGlyTyrSerGlnIleThr	731
VL_11	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspLeuLeuTyrVal	732
VL_12	GlnSerValSerSerSerTyrGlyAlaSerGlnGlnTyrGlyArgSerProPheThr	733
VL_13	GlnSerValThrSerAsnTyrGlyAlaSerGlnGlnTyrGlySerSerProThr	734
VL_14	ThrGlyAlaValThrSerGlyPheTyrSerAlaThrLeuLeuTyrTyrGlyGlyAlaGlnProTrpVal	735
VL_15	AsnIleGlySerLysSerAspAspSerGlnLeuTrpAspGlyAlaSerAspLeuValIle	736
VL_16	GlnThrIleSerSerTyrGlyAlaSerGlnGlnSerTyrSerThrProGlnThr	737
VL_17	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	738
VL_18	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	739
VL_19	GlnArgValArgSerSerTyrGlyAlaSerGlnGlnTyrGlySerSerProProArgIleIle	740
VL_20	GlnThrValSerAsnAsnAspAlaSerGlnGlnTyrGlySerSerProLeuThr	741
VL_21	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	742
VL_22	AspIleGluSerLysSerAspAspSerGlnValTrpAspGlyIleIleAsnGlnValVal	743
VL_23	GlnGlyValArgAlaSerSerAlaAlaSerGlnGlnTyrGlyArgSerProThr	744
VL_24	GlnSerIleSerSerTyrAlaAlaSerGlnGlnSerTyrSerThrProProTyrThr	745
VL_25	GlnSerValSerSerSerTyrGlyAlaSerGlnGlnTyrGlySerSerProGlnTyrThr	746
VL_26	AsnIleGlySerLysSerAspAspSerGlnValTrpGlySerSerAsnAspProValVal	747
VL_27	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	748
VL_28	SerSerAsnIleGlyAsnAsnTyrAspAsnAsnGlyThrTrpAspSerSerLeuSerAlaValVal	749
VL_29	AsnIleGlyAlaLysSerAspAspSerGlnValTrpAspAsnThrGlyAspHisProArgValIle	750
VL_30	GlnSerLeuValTyrSerAspGlyAsnThrTyrLysValSerMetGlnGlyLysHisTrpProProThr	751
VL_31	SerLeuArgSerTyrTyrGlyLysAsnAsnSerArgAspSerSerGlyAsnHisTrpVal	752
VL_32	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisSerValVal	753
VL_33	AsnIleGlySerTyrSerAspAspSerGlnValTrpAspSerSerSerAspHisValIle	754
VL_34	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	755
VL_35	AsnLeuGlyGlyArgTyrGlnAspLeuGlnAlaTrpAspThrTyrThrValVal	756
VL_36	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	757
VL_37	SerLeuArgSerTyrTyrGlyLysAsnAsnSerArgAspSerSerGlyAsnHisValVal	758
VL_38	LysLeuGlyAspLysTyrGlnAspThrGlnAlaTrpAspSerSerThrAsnTyrVal	759
VL_39	GlnSerIleAsnSerAsnGlyAlaSerGlnGlnPheGluGlnTrpProLeuThr	760
VL_40	GlnArgIleSerLysTyrGlySerSerGlnGlnSerAspSerValProIleThr	761
VL_41	SerSerAsnIleGlyAlaGlyTyrArgGlyAspAsnGlnSerHisAspGluSerLeuAsnSerLysVal	762
VL_42	GlnSerValSerSerAsnGlyAlaSerGlnGlnTyrGlySerSerProLeuThr	763
VL_43	AsnIleGlySerLysSerAspAspSerGlnLeuTrpAspGlyAlaSerAspLeuValIle	764
VL_44	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	765
VL_45	GlnSerValSerSerAsnGlyAlaSerGlnGlnTyrAsnAsnTrpProProGlnTyrThr	766
VL_46	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspTyrValVal	767
VL_47	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerLeuSerAspHisValIle	768
VL_48	AsnIleGlyThrLysSerAspAspSerGlnValTrpAspHisSerAsnAspHisValVal	769
VL_49	AsnIleGlySerLysSerAspAspSerSerAlaTrpAspSerSerLeuThrAlaValVal	770
VL_50	AsnIleGlySerLysGlyAspAspArgGlnValTrpAspThrAsnSerGlnHisValVal	771
VL_51	SerSerAsnIleGlyAsnAsnGlyTyrAspAspAlaThrTrpAspAspArgLeuLysGlyTyrVal	772
VL_52	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspGlnGlyVal	773
VL_53	GlyGlySerLeuAlaSerAsnTyrGluAspLysGlnSerTyrAspSerAlaAsnProLeuValVal	774
VL_54	AsnLeuGlyGlyTyrSerAspAspSerGlnValTrpAspSerSerSerAspLeuValVal	775
VL_55	SerGlySerIleAlaSerAsnTyrGluAspAsnGlnSerTyrAspThrSerAsnLeuValVal	776
VL_56	AsnIleGlySerLysAsnAspAspThrGlnValTrpAspArgAsnThrGlyHisValVal	777
VL_57	SerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuValVal	778
VL_58	AsnIleGlyAsnLysAsnAspAspLysGlnValTrpAspThrSerGluTyrGlnAsnArgVal	779
VL_59	SerGlySerIleAlaSerAsnTyrGluHisAsnGlnSerTyrAspAsnSerAsnProHisValVal	780
VL_60	SerSerAsnIleGlyAlaGlyTyrAspGlyAsnSerGlnSerTyrAspSerSerLeuSerGlyPheTyrVal	781
VL_61	AsnIleGlyAsnLysAsnAspAspSerGlnValTrpAspSerSerSerAspHisValVal	782
VL_62	GlnGlyIleSerSerTrpGlyAlaSerGlnGlnAlaAsnSerPheProIleThr	783
VL_63	SerGlySerIleAlaSerAsnTyrGluAspAsnGlnSerTyrAspSerSerAsnHisValVal	784
VL_64	GlnGlyValAsnSerAspGlyAlaSerGlnGlnTyrAsnAsnTrpProTrpThr	785
VL_65	LysLeuGlyAspLysTyrGluAspThrGlnAlaTrpAspThrSerAlaValVal	786
VL_66	AsnIleGlySerLysSerAspAspSerGlnLeuTrpAspAspSerSerAspHisValVal	787
VL_67	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	788
VL_68	SerLeuArgAspTyrTyrGlyLysAsnAsnSerArgAspSerSerGlyAsnHisValVal	789
VL_69	AsnIleGlyArgLysSerAspAspThrGlnLeuTyrAspSerAspSerAspAsnValVal	790
VL_70	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisProVal	791
VL_71	SerLeuArgSerTyrTyrGlyLysAsnAsnSerArgAspSerSerGlyAsnLeuGlyVal	792
VL_72	GlnAsnIleLeuThrAsnAlaAlaSerGlnGlnSerTyrSerIleProTrpThr	793
VL_73	LysLeuGlyAsnLysTyrGluAsnAsnGlnAlaTrpAspSerSerThrAlaVal	794
VL_74	GlnSerIleSerSerTyrAlaAlaSerGlnGlnSerTyrSerThrSerTrpThr	795
VL_75	AsnIleGlySerLysSerAspAspSerAlaAlaTrpAspAspSerLeuAsnGlyGlnValVal	796
VL_76	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	797
VL_77	AsnValGlyThrThrSerAspAspThrGlnValTrpAspSerSerSerAspHisValIle	798
VL_78	LysIleGlySerTyrSerAspAspSerGlnValTrpAspThrTyrGlyAspGlnValVal	799
VL_79	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisProVal	800
VL_80	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerGlySerAspPheValVal	801
VL_81	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisProVal	802
VL_82	AsnIleGlySerGlnSerAspAspSerGlnValTrpAspGlySerAsnAspHisValVal	803
VL_83	AsnIleGlyArgGluSerAspAspSerGlnValTrpAspSerSerIleAspHisValVal	804
VL_84	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	805
VL_85	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	806
VL_86	AsnIleGlySerLysGlyAspAspSerGlnValTrpAspAsnSerSerAspSerValVal	807
VL_87	GlyGlySerIleAlaSerAsnTyrLysAspAsnGlnSerTyrGlySerGlyAsnValVal	808
VL_88	SerGlySerIleAlaSerAsnTyrGluHisAsnGlnSerPheAspArgAsnAsnProLysTrpVal	809
VL_89	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisLeuValVal	810
VL_90	LysLeuGlyAspLysTyrHisAspThrGlnValTrpAspGlyThrThrAspHisPheLeu	811
VL_91	AsnIleGlySerLysSerTyrAspSerGlnValTrpAspSerValSerAspProValMet	812
VL_92	SerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrAlaGlySerAsnAsnLeuVal	813
VL_93	LysLeuGlyAspLysTyrGlnAsnAsnGlnAlaTrpAspSerSerAlaValVal	814
VL_94	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerThrSerAspHisProGluValVal	815
VL_95	AsnIleGlySerLysSerAspAspAspGlnValTrpAspSerGlySerAspHisValVal	816
VL_96	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	817
VL_97	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	818
VL_98	SerSerAsnIleGlyAsnAsnTyrGluAsnAsnGlyThrTrpAspSerSerLeuSerAlaGlyVal	819
VL_99	SerSerAsnIleGlyAlaGlyTyrAspGlyAsnSerGlnSerTyrAspSerSerLeuSerTrpVal	820
VL_100	SerSerAspValGlyGlyTyrAsnPheGlyValSerSerSerTyrArgIleArgAspSerLeuVal	821
VL_101	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	822
VL_102	GlyGlyGlyIleAlaAspAsnTyrAspAspAspGlnSerTyrAspSerAlaValProValVal	823
VL_103	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerAspAsnAspAsnSerGluValIle	824
VL_104	AsnIleGlySerLysAsnAspAspAsnGlnValTrpAspSerSerSerGluHisValVal	825
VL_105	AsnIleGlySerAsnSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	826
VL_106	IleLeuGlyHisTyrHisGlyLysAspAsnAsnSerArgAspArgSerGlyThrGlnValLeu	827
VL_107	SerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuValVal	828
VL_108	GlnSerValSerThrAsnGlyAlaSerGlnGlnTyrAsnThrTrpProProValArg	829
VL_109	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValVal	830
VL_110	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValVal	831
VL_111	LysIleGlySerLysIleHisAspSerGlnValTrpAspValAsnThrAspHisValVal	832
VL_112	SerSerAspValGlyGlyTyrAsnTyrGluValThrSerSerTyrThrSerSerSerThrPheValVal	833
VL_113	SerGlySerIleValSerAsnTyrGluAspAsnGlnSerTyrAspSerGlyAsnValVal	834
VL_114	GlnSerValSerSerSerTyrGlyAlaSerGlnGlnTyrGlySerSerProLeuThr	835
VL_115	SerGlySerIleAlaThrAsnTyrGluAspAsnGlnSerTyrAspSerSerThrGlyVal	836
VL_116	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValVal	837
VL_117	AsnIleGluSerLysSerAspAspSerGlnValTrpAspSerGlyHisGlnVal	838
VL_118	SerSerTyrIleAlaThrAsnSerSerAspSerAlaAlaTrpAspAspSerLeuAsnAlaTyrVal	839
VL_119	SerSerAspIleGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuValVal	840
VL_120	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValVal	841
VL_121	SerSerAsnIleGlyAlaGlyTyrAspGlyAsnAsnAlaThrTrpAspAspSerLeuAsnAlaProTyrVal	842
VL_122	LysLeuGlyAsnLysTyrGlnAspAspGlnAlaTrpAspSerThrTyrValVal	843
VL_123	LysLeuGlyAspLysTyrGlnAspThrGlnAlaTrpAspSerThrThrLeuVal	844
VL_124	GlyGlySerIleAlaSerAsnTyrLysAspAsnGlnSerTyrGlySerGlyAsnValVal	845
VL_125	SerSerAsnIleAlaSerAsnThrSerAsnAsnSerAlaTrpAspAspSerLeuHisThrTyrVal	846
VL_126	SerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrAlaGlySerAspThrValVal	847
VL_127	SerSerAsnIleGlyAsnAsnTyrAspAsnAspGlyThrTrpAspAsnSerLeuSerAlaValVal	848
VL_128	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerSerSerAspHisValVal	849
VL_129	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValVal	850
VL_130	SerSerAsnIleGlyAsnAsnTyrGluAsnAsnGlyThrTrpAspSerSerLeuSerAlaValVal	851
VL_131	SerSerAspValGlyGlyTyrAspTyrGluValSerSerSerTyrThrSerSerSerThrLeuValVal	852
VL_132	AsnIleGlySerLysSerAlaAspSerGlnValTrpAspSerSerPheAspValAla	853
VL_133	AsnIleGlyAspLysArgTyrAspThrGlnValTrpAspThrAspThrAsnHisAlaVal	854
VL_134	SerSerAspValGlyAlaTyrAsnTyrAspValSerSerSerTyrThrThrSerSerThrLeuVal	855
VL_135	LysLeuGlyAspLysTyrGlnAspSerGlnThrTrpAspSerSerThrValVal	856
VL_136	LysLeuGlyAspLysTyrGlnAspIleGlnAlaTrpAspArgSerSerTyrVal	857
VL_137	SerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrSerGlySerAsnAsnLeuValVal	858
VL_138	SerSerAspValGlyGlyTyrAsnTyrAspValAsnSerSerTyrThrSerSerAsnThrLeuValVal	859
VL_139	SerSerAsnIleGlyAlaGlyTyrAspGlyAsnSerGlnSerTyrAspSerSerLeuSerGlySerGlyTyrVal	860
VL_140	SerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuValVal	861
VL_141	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrLeuValVal	862
VL_142	AsnIleGlySerLysSerAspAspSerGlnValTrpAspSerGlyAsnIleHisProValVal	863
VL_143	GlyAsnAsnTyrGluAsnAsnGlyThrTrpAspSerSerLeuAsnValGlyVal	864
VL_144	LysLeuGlyAsnLysTyrGlnAspAsnGlnAlaTrpAspSerSerThrAlaVal	865
VL_145	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrAlaGlySerSerValVal	866
VL_146	SerSerAspValGlyGlyTyrAsnTyrGluValSerSerSerTyrThrSerSerSerThrLeuValVal	867
VL_147	GlySerAsnIleGlyAlaGlyTyrAspGlyAsnIleAlaAlaTrpAspAspSerLeuAsnGlyLeuTyrVal	868
VL_148	SerSerAspValGlyGlyTyrAsnTyrAspValSerSerSerTyrThrSerSerSerThrPheValVal	869
VL_149	SerSerAsnIleGlyIleAsnThrArgAsnAsnAlaAlaTrpAspAspSerLeuSerGlyTrpVal	870
VL_150	GlySerAspIleGlyAspTyrLysTyrAspValThrSerProHisThrProSerArgValIle	871
VL_151	SerSerAsnIleGlyAlaGlyTyrAspGlyAsnSerAlaAlaTrpAspAspGlyProSerGlyTyrVal	872
VL_152	LysLeuGlyAspLysTyrArgAspAsnGlnAlaTrpAspSerSerThrValVal	873
VL_153	GlnSerIleAspThrSerAlaAlaSerGlnGlnSerTyrSerThrProGlnTyrThr	874
VL_154	GlnSerIleSerSerTrpLysAlaSerGlnGlnTyrAsnThrTyrPheProThr	875

TABLE 6
DISCRETE CDR5 FOR VL SEQUENCES
	SEQ		SEQ		SEQ
	ID		ID		ID
VL_ID	NO:	VL_CDR1	NO:	VL_CDR2	NO:	VL_CDR3
VL_1	876	ThrSerAsnIleGlyAlaAsnHi	1030	ThrLysAsn	1184	AlaAlaTrpAspAspSerLeuArgGlyTrpT
		s				hr
VL_2	877	SerSerAspIleGlyGlyTyrLys	1031	AspValThr	1185	GlySerTyrSerSerSerSerSerHisTyrVal
		Tyr
VL_3	878	GlnSerIleSerSerPhe	1032	AlaAlaSer	1186	GlnGlnSerTyrSerThrProTrpThr
VL_4	879	GlnSerValSerSerAsn	1033	GlyAlaSer	1187	GlnHisTyrAsnAsnTrpProProGlnIleTh
						r
VL_5	880	GlnSerValSerSerAsn	1034	GlyAlaSer	1188	GlnGlnTyrGlyTyrSerGlnIleThr
VL_6	881	AsnIleGlySerLysSer	1035	AspAspSer	1189	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_7	882	AsnIleGlySerLysSer	1036	AspAspSer	1190	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_8	883	SerSerAsnIleGlyAlaGlyTyr	1037	SerSerAsn	1191	GlnSerPheAspProSerLeuSerAspSerT
		Asp				rpVal
VL_9	884	SerGlySerIleThrAspAspTy	1038	GluAspHis	1192	GlnSerTyrAspAlaGluSerTrpVal
		r
VL_10	885	GlnSerValSerSerAsn	1039	GlyAlaSer	1193	GlnGlnTyrGlyTyrSerGlnIleThr
VL_11	886	AsnIleGlySerLysSer	1040	AspAspSer	1194	GlnValTrpAspSerSerSerAspLeuLeuT
						yrVal
VL_12	887	GlnSerValSerSerSerTyr	1041	GlyAlaSer	1195	GlnGlnTyrGlyArgSerProPheThr
VL_13	888	GlnSerValThrSerAsnTyr	1042	GlyAlaSer	1196	GlnGlnTyrGlySerSerProThr
VL_14	889	ThrGlyAlaValThrSerGlyPh	1043	SerAlaThr	1197	LeuLeuTyrTyrGlyGlyAlaGlnProTrpVa
		eTyr				l
VL_15	890	AsnIleGlySerLysSer	1044	AspAspSer	1198	GlnLeuTrpAspGlyAlaSerAspLeuValIl
						e
VL_16	891	GlnThrIleSerSerTyr	1045	GlyAlaSer	1199	GlnGlnSerTyrSerThrProGlnThr
VL_17	892	AsnIleGlySerLysSer	1046	AspAspSer	1200	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_18	893	AsnIleGlySerLysSer	1047	AspAspSer	1201	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_19	894	GlnArgValArgSerSerTyr	1048	GlyAlaSer	1202	GlnGlnTyrGlySerSerProProArgIleIle
VL_20	895	GlnThrValSerAsnAsn	1049	AspAlaSer	1203	GlnGlnTyrGlySerSerProLeuThr
VL_21	896	AsnIleGlySerLysSer	1050	AspAspSer	1204	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_22	897	AspIleGluSerLysSer	1051	AspAspSer	1205	GlnValTrpAspGlyIleIleAsnGlnValVal
VL_23	898	GlnGlyValArgAlaSerSer	1052	AlaAlaSer	1206	GlnGlnTyrGlyArgSerProThr
VL_24	899	GlnSerIleSerSerTyr	1053	AlaAlaSer	1207	GlnGlnSerTyrSerThrProProTyrThr
VL_25	900	GlnSerValSerSerSerTyr	1054	GlyAlaSer	1208	GlnGlnTyrGlySerSerProGlnTyrThr
VL_26	901	AsnIleGlySerLysSer	1055	AspAspSer	1209	GlnValTrpGlySerSerAsnAspProValV
						al
VL_27	902	AsnIleGlySerLysSer	1056	AspAspSer	1210	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_28	903	SerSerAsnIleGlyAsnAsnTy	1057	AspAsnAsn	1211	GlyThrTrpAspSerSerLeuSerAlaValVa
		r				l
VL_29	904	AsnIleGlyAlaLysSer	1058	AspAspSer	1212	GlnValTrpAspAsnThrGlyAspHisProA
						rgValIle
VL_30	905	GlnSerLeuValTyrSerAspGl	1059	LysValSer	1213	MetGlnGlyLysHisTrpProProThr
		yAsnThrTyr
VL_31	906	SerLeuArgSerTyrTyr	1060	GlyLysAsn	1214	AsnSerArgAspSerSerGlyAsnHisTrpV
						al
VL_32	907	AsnIleGlySerLysSer	1061	AspAspSer	1215	GlnValTrpAspSerSerSerAspHisSerVa
						lVal
VL_33	908	AsnIleGlySerTyrSer	1062	AspAspSer	1216	GlnValTrpAspSerSerSerAspHisValIle
VL_34	909	AsnIleGlySerLysSer	1063	AspAspSer	1217	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_35	910	AsnLeuGlyGlyArgTyr	1064	GlnAspLeu	1218	GlnAlaTrpAspThrTyrThrValVal
VL_36	911	AsnIleGlySerLysSer	1065	AspAspSer	1219	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_37	912	SerLeuArgSerTyrTyr	1066	GlyLysAsn	1220	AsnSerArgAspSerSerGlyAsnHisValV
						al
VL_38	913	LysLeuGlyAspLysTyr	1067	GlnAspThr	1221	GlnAlaTrpAspSerSerThrAsnTyrVal
VL_39	914	GlnSerIleAsnSerAsn	1068	GlyAlaSer	1222	GlnGlnPheGluGlnTrpProLeuThr
VL_40	915	GlnArgIleSerLysTyr	1069	GlySerSer	1223	GlnGlnSerAspSerValProIleThr
VL_41	916	SerSerAsnIleGlyAlaGlyTyr	1070	GlyAspAsn	1224	GlnSerHisAspGluSerLeuAsnSerLysV
		Arg				al
VL_42	917	GlnSerValSerSerAsn	1071	GlyAlaSer	1225	GlnGlnTyrGlySerSerProLeuThr
VL_43	918	AsnIleGlySerLysSer	1072	AspAspSer	1226	GlnLeuTrpAspGlyAlaSerAspLeuValIl
						e
VL_44	919	AsnIleGlySerLysSer	1073	AspAspSer	1227	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_45	920	GlnSerValSerSerAsn	1074	GlyAlaSer	1228	GlnGlnTyrAsnAsnTrpProProGlnTyrT
						hr
VL_46	921	AsnIleGlySerLysSer	1075	AspAspSer	1229	GlnValTrpAspSerSerSerAspTyrValVa
						l
VL_47	922	AsnIleGlySerLysSer	1076	AspAspSer	1230	GlnValTrpAspSerLeuSerAspHisValIle
VL_48	923	AsnIleGlyThrLysSer	1077	AspAspSer	1231	GlnValTrpAspHisSerAsnAspHisValV
						al
VL_49	924	AsnIleGlySerLysSer	1078	AspAspSer	1232	SerAlaTrpAspSerSerLeuThrAlaValVa
						l
VL_50	925	AsnIleGlySerLysGly	1079	AspAspArg	1233	GlnValTrpAspThrAsnSerGlnHisValV
						al
VL_51	926	SerSerAsnIleGlyAsnAsnGl	1080	TyrAspAsp	1234	AlaThrTrpAspAspArgLeuLysGlyTyrV
		y				al
VL_52	927	AsnIleGlySerLysSer	1081	AspAspSer	1235	GlnValTrpAspSerSerSerAspGlnGlyV
						al
VL_53	928	GlyGlySerLeuAlaSerAsnT	1082	GluAspLys	1236	GlnSerTyrAspSerAlaAsnProLeuValV
		yr				al
VL_54	929	AsnLeuGlyGlyTyrSer	1083	AspAspSer	1237	GlnValTrpAspSerSerSerAspLeuValV
						al
VL_55	930	SerGlySerIleAlaSerAsnTyr	1084	GluAspAsn	1238	GlnSerTyrAspThrSerAsnLeuValVal
VL_56	931	AsnIleGlySerLysAsn	1085	AspAspThr	1239	GlnValTrpAspArgAsnThrGlyHisValV
						al
VL_57	932	SerSerAspValGlyGlyTyrAs	1086	GluValSer	1240	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_58	933	AsnIleGlyAsnLysAsn	1087	AspAspLys	1241	GlnValTrpAspThrSerGluTyrGlnAsnA
						rgVal
VL_59	934	SerGlySerIleAlaSerAsnTyr	1088	GluHisAsn	1242	GlnSerTyrAspAsnSerAsnProHisValV
						al
VL_60	935	SerSerAsnIleGlyAlaGlyTyr	1089	GlyAsnSer	1243	GlnSerTyrAspSerSerLeuSerGlyPheT
		Asp				yrVal
VL_61	936	AsnIleGlyAsnLysAsn	1090	AspAspSer	1244	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_62	937	GlnGlyIleSerSerTrp	1091	GlyAlaSer	1245	GlnGlnAlaAsnSerPheProIleThr
VL_63	938	SerGlySerIleAlaSerAsnTyr	1092	GluAspAsn	1246	GlnSerTyrAspSerSerAsnHisValVal
VL_64	939	GlnGlyValAsnSerAsp	1093	GlyAlaSer	1247	GlnGlnTyrAsnAsnTrpProTrpThr
VL_65	940	LysLeuGlyAspLysTyr	1094	GluAspThr	1248	GlnAlaTrpAspThrSerAlaValVal
VL_66	941	AsnIleGlySerLysSer	1095	AspAspSer	1249	GlnLeuTrpAspAspSerSerAspHisValV
						al
VL_67	942	AsnIleGlySerLysSer	1096	AspAspSer	1250	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_68	943	SerLeuArgAspTyrTyr	1097	GlyLysAsn	1251	AsnSerArgAspSerSerGlyAsnHisValV
						al
VL_69	944	AsnIleGlyArgLysSer	1098	AspAspThr	1252	GlnLeuTyrAspSerAspSerAspAsnValV
						al
VL_70	945	AsnIleGlySerLysSer	1099	AspAspSer	1253	GlnValTrpAspSerSerSerAspHisProV
						al
VL_71	946	SerLeuArgSerTyrTyr	1100	GlyLysAsn	1254	AsnSerArgAspSerSerGlyAsnLeuGlyV
						al
VL_72	947	GlnAsnIleLeuThrAsn	1101	AlaAlaSer	1255	GlnGlnSerTyrSerIleProTrpThr
VL_73	948	LysLeuGlyAsnLysTyr	1102	GluAsnAsn	1256	GlnAlaTrpAspSerSerThrAlaVal
VL_74	949	GlnSerIleSerSerTyr	1103	AlaAlaSer	1257	GlnGlnSerTyrSerThrSerTrpThr
VL_75	950	AsnIleGlySerLysSer	1104	AspAspSer	1258	AlaAlaTrpAspAspSerLeuAsnGlyGlnV
						alVal
VL_76	951	AsnIleGlySerLysSer	1105	AspAspSer	1259	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_77	952	AsnValGlyThrThrSer	1106	AspAspThr	1260	GlnValTrpAspSerSerSerAspHisValIle
VL_78	953	LysIleGlySerTyrSer	1107	AspAspSer	1261	GlnValTrpAspThrTyrGlyAspGlnValV
						al
VL_79	954	AsnIleGlySerLysSer	1108	AspAspSer	1262	GlnValTrpAspSerSerSerAspHisProV
						al
VL_80	955	AsnIleGlySerLysSer	1109	AspAspSer	1263	GlnValTrpAspSerGlySerAspPheValV
						al
VL_81	956	AsnIleGlySerLysSer	1110	AspAspSer	1264	GlnValTrpAspSerSerSerAspHisProV
						al
VL_82	957	AsnIleGlySerGlnSer	1111	AspAspSer	1265	GlnValTrpAspGlySerAsnAspHisValV
						al
VL_83	958	AsnIleGlyArgGluSer	1112	AspAspSer	1266	GlnValTrpAspSerSerIleAspHisValVal
VL_84	959	AsnIleGlySerLysSer	1113	AspAspSer	1267	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_85	960	AsnIleGlySerLysSer	1114	AspAspSer	1268	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_86	961	AsnIleGlySerLysGly	1115	AspAspSer	1269	GlnValTrpAspAsnSerSerAspSerValV
						al
VL_87	962	GlyGlySerIleAlaSerAsnTyr	1116	LysAspAsn	1270	GlnSerTyrGlySerGlyAsnValVal
VL_88	963	SerGlySerIleAlaSerAsnTyr	1117	GluHisAsn	1271	GlnSerPheAspArgAsnAsnProLysTrp
						Val
VL_89	964	AsnIleGlySerLysSer	1118	AspAspSer	1272	GlnValTrpAspSerSerSerAspHisLeuV
						alVal
VL_90	965	LysLeuGlyAspLysTyr	1119	HisAspThr	1273	GlnValTrpAspGlyThrThrAspHisPheL
						eu
VL_91	966	AsnIleGlySerLysSer	1120	TyrAspSer	1274	GlnValTrpAspSerValSerAspProValM
						et
VL_92	967	SerSerAspValGlyGlyTyrAs	1121	GluValSer	1275	SerSerTyrAlaGlySerAsnAsnLeuVal
		nTyr
VL_93	968	LysLeuGlyAspLysTyr	1122	GlnAsnAsn	1276	GlnAlaTrpAspSerSerAlaValVal
VL_94	969	AsnIleGlySerLysSer	1123	AspAspSer	1277	GlnValTrpAspSerThrSerAspHisProGl
						uValVal
VL_95	970	AsnIleGlySerLysSer	1124	AspAspAsp	1278	GlnValTrpAspSerGlySerAspHisValVa
						l
VL_96	971	AsnIleGlySerLysSer	1125	AspAspSer	1279	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_97	972	AsnIleGlySerLysSer	1126	AspAspSer	1280	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_98	973	SerSerAsnIleGlyAsnAsnTy	1127	GluAsnAsn	1281	GlyThrTrpAspSerSerLeuSerAlaGlyVa
		r				l
VL_99	974	SerSerAsnIleGlyAlaGlyTyr	1128	GlyAsnSer	1282	GlnSerTyrAspSerSerLeuSerTrpVal
		Asp
VL_100	975	SerSerAspValGlyGlyTyrAs	1129	GlyValSer	1283	SerSerTyrArgIleArgAspSerLeuVal
		nPhe
VL_101	976	AsnIleGlySerLysSer	1130	AspAspSer	1284	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_102	977	GlyGlyGlyIleAlaAspAsnTy	1131	AspAspAsp	1285	GlnSerTyrAspSerAlaValProValVal
		r
VL_103	978	AsnIleGlySerLysSer	1132	AspAspSer	1286	GlnValTrpAspSerAspAsnAspAsnSer
						GluValIle
VL_104	979	AsnIleGlySerLysAsn	1133	AspAspAsn	1287	GlnValTrpAspSerSerSerGluHisValVa
						l
VL_105	980	AsnIleGlySerAsnSer	1134	AspAspSer	1288	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_106	981	IleLeuGlyHisTyrHis	1135	GlyLysAsp	1289	AsnSerArgAspArgSerGlyThrGlnValL
				Asn		eu
VL_107	982	SerSerAspValGlyGlyTyrAs	1136	GluValSer	1290	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_108	983	GlnSerValSerThrAsn	1137	GlyAlaSer	1291	GlnGlnTyrAsnThrTrpProProValArg
VL_109	984	SerSerAspValGlyGlyTyrAs	1138	AspValSer	1292	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_110	985	SerSerAspValGlyGlyTyrAs	1139	AspValSer	1293	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_111	986	LysIleGlySerLysIle	1140	HisAspSer	1294	GlnValTrpAspValAsnThrAspHisValV
						al
VL_112	987	SerSerAspValGlyGlyTyrAs	1141	GluValThr	1295	SerSerTyrThrSerSerSerThrPheValVa
		nTyr				l
VL_113	988	SerGlySerIleValSerAsnTyr	1142	GluAspAsn	1296	GlnSerTyrAspSerGlyAsnValVal
VL_114	989	GlnSerValSerSerSerTyr	1143	GlyAlaSer	1297	GlnGlnTyrGlySerSerProLeuThr
VL_115	990	SerGlySerIleAlaThrAsnTyr	1144	GluAspAsn	1298	GlnSerTyrAspSerSerThrGlyVal
VL_116	991	SerSerAspValGlyGlyTyrAs	1145	AspValSer	1299	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_117	992	AsnIleGluSerLysSer	1146	AspAspSer	1300	GlnValTrpAspSerGlyHisGlnVal
VL_118	993	SerSerTyrIleAlaThrAsnSer	1147	SerAspSer	1301	AlaAlaTrpAspAspSerLeuAsnAlaTyrV
						al
VL_119	994	SerSerAspIleGlyGlyTyrAs	1148	GluValSer	1302	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_120	995	SerSerAspValGlyGlyTyrAs	1149	AspValSer	1303	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_121	996	SerSerAsnIleGlyAlaGlyTyr	1150	GlyAsnAsn	1304	AlaThrTrpAspAspSerLeuAsnAlaProT
		Asp				yrVal
VL_122	997	LysLeuGlyAsnLysTyr	1151	GlnAspAsp	1305	GlnAlaTrpAspSerThrTyrValVal
VL_123	998	LysLeuGlyAspLysTyr	1152	GlnAspThr	1306	GlnAlaTrpAspSerThrThrLeuVal
VL_124	999	GlyGlySerIleAlaSerAsnTyr	1153	LysAspAsn	1307	GlnSerTyrGlySerGlyAsnValVal
VL_125	1000	SerSerAsnIleAlaSerAsnTh	1154	SerAsnAsn	1308	SerAlaTrpAspAspSerLeuHisThrTyrV
		r				al
VL_126	1001	SerSerAspValGlyGlyTyrAs	1155	GluValSer	1309	SerSerTyrAlaGlySerAspThrValVal
		nTyr
VL_127	1002	SerSerAsnIleGlyAsnAsnTy	1156	AspAsnAsp	1310	GlyThrTrpAspAsnSerLeuSerAlaValV
		r				al
VL_128	1003	AsnIleGlySerLysSer	1157	AspAspSer	1311	GlnValTrpAspSerSerSerAspHisValVa
						l
VL_129	1004	SerSerAspValGlyGlyTyrAs	1158	AspValSer	1312	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_130	1005	SerSerAsnIleGlyAsnAsnTy	1159	GluAsnAsn	1313	GlyThrTrpAspSerSerLeuSerAlaValVa
		r				l
VL_131	1006	SerSerAspValGlyGlyTyrAs	1160	GluValSer	1314	SerSerTyrThrSerSerSerThrLeuValVal
		pTyr
VL_132	1007	AsnIleGlySerLysSer	1161	AlaAspSer	1315	GlnValTrpAspSerSerPheAspValAla
VL_133	1008	AsnIleGlyAspLysArg	1162	TyrAspThr	1316	GlnValTrpAspThrAspThrAsnHisAlaV
						al
VL_134	1009	SerSerAspValGlyAlaTyrAs	1163	AspValSer	1317	SerSerTyrThrThrSerSerThrLeuVal
		nTyr
VL_135	1010	LysLeuGlyAspLysTyr	1164	GlnAspSer	1318	GlnThrTrpAspSerSerThrValVal
VL_136	1011	LysLeuGlyAspLysTyr	1165	GlnAspIle	1319	GlnAlaTrpAspArgSerSerTyrVal
VL_137	1012	SerSerAspValGlyGlyTyrAs	1166	GluValSer	1320	SerSerTyrSerGlySerAsnAsnLeuValVa
		nTyr				l
VL_138	1013	SerSerAspValGlyGlyTyrAs	1167	AspValAsn	1321	SerSerTyrThrSerSerAsnThrLeuValVa
		nTyr				l
VL_139	1014	SerSerAsnIleGlyAlaGlyTyr	1168	GlyAsnSer	1322	GlnSerTyrAspSerSerLeuSerGlySerGl
		Asp				yTyrVal
VL_140	1015	SerSerAspValGlyGlyTyrAs	1169	GluValSer	1323	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_141	1016	SerSerAspValGlyGlyTyrAs	1170	AspValSer	1324	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_142	1017	AsnIleGlySerLysSer	1171	AspAspSer	1325	GlnValTrpAspSerGlyAsnIleHisProVal
						Val
VL_143	1018	GlyAsnAsnTyr	1172	GluAsnAsn	1326	GlyThrTrpAspSerSerLeuAsnValGlyV
						al
VL_144	1019	LysLeuGlyAsnLysTyr	1173	GlnAspAsn	1327	GlnAlaTrpAspSerSerThrAlaVal
VL_145	1020	SerSerAspValGlyGlyTyrAs	1174	AspValSer	1328	SerSerTyrAlaGlySerSerValVal
		nTyr
VL_146	1021	SerSerAspValGlyGlyTyrAs	1175	GluValSer	1329	SerSerTyrThrSerSerSerThrLeuValVal
		nTyr
VL_147	1022	GlySerAsnIleGlyAlaGlyTyr	1176	GlyAsnIle	1330	AlaAlaTrpAspAspSerLeuAsnGlyLeuT
		Asp				yrVal
VL_148	1023	SerSerAspValGlyGlyTyrAs	1177	AspValSer	1331	SerSerTyrThrSerSerSerThrPheValVa
		nTyr				l
VL_149	1024	SerSerAsnIleGlyIleAsnThr	1178	ArgAsnAsn	1332	AlaAlaTrpAspAspSerLeuSerGlyTrpV
						al
VL_150	1025	GlySerAspIleGlyAspTyrLy	1179	AspValThr	1333	SerProHisThrProSerArgValIle
		sTyr
VL_151	1026	SerSerAsnIleGlyAlaGlyTyr	1180	GlyAsnSer	1334	AlaAlaTrpAspAspGlyProSerGlyTyrVa
		Asp				l
VL_152	1027	LysLeuGlyAspLysTyr	1181	ArgAspAsn	1335	GlnAlaTrpAspSerSerThrValVal
VL_153	1028	GlnSerIleAspThrSer	1182	AlaAlaSer	1336	GlnGlnSerTyrSerThrProGlnTyrThr
VL_154	1029	GlnSerIleSerSerTrp	1183	LysAlaSer	1337	GlnGlnTyrAsnThrTyrPheProThr

TABLE 7
VH CDR SEQUENCES COMBINED
		SEQ ID
mAb ID	VH_CDR1/2/3	NO:
VH_1	GlyAspSerIleSerSerGlyTyrTrpIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrP	1338
	roAspTyr
VH_2	GlyAspSerValSerSerAsnSerAlaAlaIleAsnProAsnSerGlyGlyThrAlaArgGluValAlaThrIlePro	1339
	AlaHisPheAspTyr
VH_3	GlyAspSerValSerSerAsnSerAlaAlaIleSerAlaTyrAsnGlyAsnThrAlaArgAspTyrAspIleLeuThr	1340
	GlyLeuAspTyr
VH_4	GlyAspSerValSerSerAsnSerAlaAlaIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleA	1341
	snGlyTrpTyrGlyAsn
VH_5	GlyAspSerValSerSerAsnSerAlaAlaIleSerGlySerGlyGlySerThrAlaLysAspTrpAlaGlyTyrValA	1342
	snGlyTrpTyrGlyAsn
VH_6	GlyAspSerValSerSerAsnSerAlaAlaIleSerGlySerGlyGlySerThrAlaLysAspTrpGlyThrSerLeuL	1343
	euTyrGlyTyrPheAspTyr
VH_7	GlyAspSerValSerSerAsnSerAlaAlaIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrp	1344
	ThrProAspTyr
VH_8	GlyAspSerValSerSerAsnSerAlaAlaIleTyrSerGlyGlySerThrAlaArgAspPheGluGlySerGlyAla	1345
	LeuAspVal
VH_9	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrSerSerLysTrpTyrAsnAlaArgGlyGlySerSerGlu	1346
	PheTyrTyrTyrGlyMetAspVal
VH_10	GlyAspSerValSerSerAspSerAlaSerIleSerGlySerGlyGlyIleThrAlaLysAspTrpAlaGlyTyrThrA	1347
	snGlyTrpTyrGlySer
VH_11	GlyGlySerIleSerGlySerAsnTyrTyrIleSerGlySerGlyGlyIleThrAlaLysAspTrpAlaGlyTyrThrAs	1348
	nGlyTrpTyrGlySer
VH_12	GlyGlySerIleSerSerSerAsnTrpIleSerGlySerGlyGlySerThrAlaLysAspArgSerArgArgAlaProT	1349
	yrTyrPheAspTyr
VH_13	GlyGlySerIleSerSerSerAsnTrpIleSerGlySerGlyGlySerThrAlaLysValTyrArgGlyTyrAspAlaPh	1350
	eAspIle
VH_14	GlyGlySerIleSerSerSerAsnTrpIleTyrProGlyAspSerAspThrAlaArgHisAlaGlyAspGlyGlnIleA	1351
	spTyr
VH_15	GlyGlySerIleSerSerSerAsnTrpThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluGlySerGlyLeuTyr	1352
	TyrTyrTyrGlyMetAspVal
VH_16	GlyGlySerValSerSerAsnSerAlaAlaIleSerGlySerGlyGlySerThrAlaArgGlyGlySerGlyTrpTyrHi	1353
	sTyrPheAspTyr
VH_17	GlyGlyThrPheSerSerTyrAlaIleSerGlyThrGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1354
	rpTyrGlySer
VH_18	GlyGlyThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1355
	AspTyr
VH_19	GlyGlyThrPheSerSerTyrAlaIleTrpTyrAspGlySerAsnLysAlaArgLeuGlySerGlyTrpSerLeuAs	1356
	pTyr
VH_20	GlyPheThrPheAsnThrTyrAlaIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1357
	TrpPheGlyAsn
VH_21	GlyPheThrPheAsnThrTyrAlaIleSerGlySerGlyAspIleThrAlaLysAspTrpAlaGlyTyrValAsnGly	1358
	TrpTyrGlyAsn
VH_22	GlyPheThrPheAsnThrTyrAlaIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPr	1359
	oAspTyr
VH_23	GlyPheThrPheAspAspTyrAlaIleAsnAlaGlyAsnGlyAsnThrAlaArgGlyGlyTyrCysSerSerThrS	1360
	erCysTyrProAspTyrAsnTrpPheAspPro
VH_24	GlyPheThrPheAspAspTyrAlaIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGl	1361
	yTrpTyrAlaAsn
VH_25	GlyPheThrPheAspAspTyrAlaIleTyrSerGlyGlySerThrAlaArgAspArgArgGlyGlyAsnTrpTyrGl	1362
	uPheAspTyr
VH_26	GlyPheThrPheAspAspTyrAlaIleTyrSerGlyGlySerThrAlaArgGluGlyLeuAlaMetAlaGlyTyrP	1363
	heAspTyr
VH_27	GlyPheThrPheGlyAsnHisGlyIleLysHisAspGlySerGluGlnAlaArgValAlaValGlyAlaAsnLeuAla	1364
	PheAspIle
VH_28	GlyPheThrPheSerArgTyrGlyIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1365
	TrpTyrGlyAsn
VH_29	GlyPheThrPheSerAsnAlaTrpIleIleProIlePheGlyThrAlaAlaArgGlyMetAlaGlnSerProAlaPh	1366
	eAspTyr
VH_30	GlyPheThrPheSerAsnAlaTrpIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1367
	TrpTyrGlyAsn
VH_31	GlyPheThrPheSerAsnAlaTrpThrTyrTyrAsnSerLysTrpTyrAsnAlaArgGluThrGlyGlyPheAsp	1368
	Tyr
VH_32	GlyPheThrPheSerAsnTyrAlaIleAsnThrAspGlyGlyAsnThrAlaArgAspProValArgGlyAspGlyT	1369
	yrAsnPheAspTyr
VH_33	GlyPheThrPheSerAsnTyrAlaIleSerGlySerGlyAspIleThrAlaLysAspTrpAlaGlyTyrValAsnGly	1370
	TrpTyrGlyAsn
VH_34	GlyPheThrPheSerAsnTyrAlaIleSerGlySerGlyGlySerThrAlaLysAlaThrGlyTyrSerSerGlyTrp	1371
	TyrGlyAlaTyrPheAspTyr
VH_35	GlyPheThrPheSerAsnTyrAlaIleTyrHisSerGlySerThrAlaArgAspArgGlySerMetAspVal	1372
VH_36	GlyPheThrPheSerAsnTyrAlaIleTyrProGlyAspSerAspThrAlaArgLeuGlyArgThrSerHisGlnS	1373
	erTrpAspLeuGlyTyr
VH_37	GlyPheThrPheSerAsnTyrAlaIleTyrProGlyAspSerAspThrAlaSerGlyAlaSerProTyrTyrPheAs	1374
	pTyr
VH_38	GlyPheThrPheSerAsnTyrAlaIleTyrSerGlyGlySerThrAlaArgGluSerAsnThrAlaAsnThrHisPh	1375
	eAspTyr
VH_39	GlyPheThrPheSerAsnTyrAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGlyGlyValGlyAlaThrTr	1376
	pTyrTyrGlyMetAspVal
VH_40	GlyPheThrPheSerAsnTyrGlyIleSerTyrAspGlySerAsnLysAlaLysGlnGlnTrpLeuGlyThrTrpTy	1377
	rPheAspLeu
VH_41	GlyPheThrPheSerAsnTyrGlyIleSerTyrAspGlySerAsnLysAlaLysGlyLeuLeuValAlaSerIleTyr	1378
	AspAlaPheAspIle
VH_42	GlyPheThrPheSerAspTyrAlaIleSerTrpAsnSerGlySerIleAlaLysAspIleAlaAlaGlyGlyLeuAspS	1379
	er
VH_43	GlyPheThrPheSerAspTyrTyrValSerGlySerGlyThrSerThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1380
	TrpTyrGlyAsn
VH_44	GlyPheThrPheSerSerTyrAlaIleAsnProAsnSerGlyAspThrAlaArgGluGlnTrpLeuGlyProAlaH	1381
	isPheAspTyr
VH_45	GlyPheThrPheSerSerTyrAlaIleAsnProAsnSerGlyGlyThrAlaArgGluArgAsnArgAlaGlyGluP	1382
	heSerAlaPheAspIle
VH_46	GlyPheThrPheSerSerTyrAlaIleGluProGlyAsnGlyAspThrAlaArgGlyAlaSerGlyLeuAspPhe	1383
VH_47	GlyPheThrPheSerSerTyrAlaIleLysGlnAspGlySerGluLysAlaArgAspLeuHisCysGlySerSerCy	1384
	sGlyProGluAla
VH_48	GlyPheThrPheSerSerTyrAlaIleSerAlaTyrAsnGlyAsnThrAlaArgAspProValTyrSerSerSerTr	1385
	pGlyGlyTyrAlaPheAspIle
VH_49	GlyPheThrPheSerSerTyrAlaIleSerAlaTyrAsnGlyAsnThrAlaArgAspThrPheGlyGlyGlySerTy	1386
	rTyrGlyHisGlyTyr
VH_50	GlyPheThrPheSerSerTyrAlaIleSerAsnAspGlyValAsnAsnAlaArgGluAsnSerAsnAlaTrpLysV	1387
	alMetAspVal
VH_51	GlyPheThrPheSerSerTyrAlaIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1388
	TrpTyrGlyAsn
VH_52	GlyPheThrPheSerSerTyrAlaIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1389
	rpTyrGlyAsn
VH_53	GlyPheThrPheSerSerTyrAlaIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAspGlyT	1390
	rpTyrGlyAsn
VH_54	GlyPheThrPheSerSerTyrAlaIleSerGlySerGlyGlyArgThrAlaLysAspTrpGlyAlaTyrSerSerGly	1391
	TrpTyrGlyAsp
VH_55	GlyPheThrPheSerSerTyrAlaIleSerGlySerGlyGlyAsnIleAlaLysAspTrpAlaGlyTyrSerAsnGlyT	1392
	rpTyrGlySer
VH_56	GlyPheThrPheSerSerTyrAlaIleSerGlySerGlyGlyIleThrAlaLysAspTrpAlaGlyTyrSerAsnGlyT	1393
	rpPheGlySer
VH_57	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlyGlyAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1394
	AspTyr
VH_58	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnGlnAlaValGlyValGlyPheIleThrAspGly	1395
	TyrPheGlnHis
VH_59	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1396
	AspTyr
VH_60	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1397
	AspTyr
VH_61	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysAlaLysGlnGlnTrpLeuGlyThrTrpTyr	1398
	PheAspLeu
VH_62	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysAlaLysGluTrpGlyGlyGlyAspSerPro	1399
	ThrAspMetGlyLeuPheAspTyr
VH_63	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysThrArgValGlySerGlyGlyTrpThrPro	1400
	AspTyr
VH_64	GlyPheThrPheSerSerTyrAlaIleTrpTyrAspGlyAsnAsnLysAlaArgAspAsnSerGlySerTyrAsnT	1401
	rpPheAsnPro
VH_65	GlyPheThrPheSerSerTyrAlaIleTyrProGlyAspSerAspThrAlaArgSerHisGlyGlySerAsnTrpPh	1402
	eAspPro
VH_66	GlyPheThrPheSerSerTyrAlaIleTyrProGlyAspSerAspThrAlaThrSerLeuGlyAspAspAlaPheA	1403
	spIle
VH_67	GlyPheThrPheSerSerTyrAlaIleTyrProGlyAspSerGluThrAlaArgLeuGlyHisSerGlySerTrpTyr	1404
	PheAspLeu
VH_68	GlyPheThrPheSerSerTyrAlaIleTyrSerGlyGlySerThrAlaArgAspLeuSerTyrSerAspAlaPheAs	1405
	pIle
VH_69	GlyPheThrPheSerSerTyrAlaIleTyrSerGlyGlySerThrAlaArgAspMetThrThrValAspAlaPheA	1406
	spIle
VH_70	GlyPheThrPheSerSerTyrAlaIleTyrSerGlyGlySerThrAlaArgAspThrAlaSerGlyGlyMetAspVa	1407
	l
VH_71	GlyPheThrPheSerSerTyrAlaPheTyrSerGlyGlySerThrAlaArgGluProTyrProGlyGlyProPheA	1408
	spIle
VH_72	GlyPheThrPheSerSerTyrGlyIleSerAlaSerGlyGlySerThrAlaAsnLeuTyrGlyAspTyrAsnAlaTyr	1409
VH_73	GlyPheThrPheSerSerTyrGlyIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1410
	TrpTyrGlyAsn
VH_74	GlyPheThrPheSerSerTyrGlyIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1411
	rpTyrGlyAsn
VH_75	GlyPheThrPheSerSerTyrGlyIleSerGlySerGlyGlyIleThrAlaLysAspTrpAlaGlyTyrThrAsnGlyT	1412
	rpTyrGlySer
VH_76	GlyPheThrPheSerSerTyrGlyIleSerGlySerGlyGlySerThrAlaLysAspLeuValLeuGly	1413
VH_77	GlyPheThrPheSerSerTyrGlyIleSerTrpAsnSerGlySerIleAlaLysAspTrpAspSerSerGlyTyrTrp	1414
	ProLeuPheAspTyr
VH_78	GlyPheThrPheSerSerTyrGlyIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1415
	AspTyr
VH_79	GlyPheThrPheSerSerTyrGlyIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1416
	AspTyr
VH_80	GlyPheThrPheSerSerTyrGlyIleTrpTyrAspGlySerAsnLysAlaArgGluValValGlySerTyrTyrLeu	1417
	AspTyr
VH_81	GlyPheThrPheSerSerTyrProIleAsnProAsnSerGlyGlyThrAlaArgGlyGlyAspCysSerSerThrSe	1418
	rCysTyrAspProAspTyr
VH_82	GlyPheThrPheSerSerTyrProIleLysGlnAspGlySerGluLysAlaArgIleGlyArgPheGlyArgLysTyr	1419
	GlyMetAspVal
VH_83	GlyPheThrPheSerSerTyrProIleSerAlaTyrAsnGlyAsnThrAlaArgGlyLeuGlyAspSerSerSerSe	1420
	rTyr
VH_84	GlyPheThrPheSerSerTyrProIleSerGlySerGlyAspIleThrAlaLysAspTrpAlaGlyTyrValAsnGly	1421
	TrpTyrGlyAsn
VH_85	GlyPheThrPheSerSerTyrProIleSerGlySerGlyAspIleThrAlaLysAspTrpAlaGlyTyrValAsnGly	1422
	TrpTyrGlyAsn
VH_86	GlyPheThrPheSerSerTyrProIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1423
	TrpTyrGlyAsn
VH_87	GlyPheThrPheSerSerTyrProIleSerGlySerGlyGlyArgThrAlaLysAspTrpGlyAlaTyrSerSerGly	1424
	TrpTyrGlyAsp
VH_88	GlyPheThrPheSerSerTyrProIleSerGlySerGlyGlyIleThrAlaLysAspTrpAlaGlyTyrThrAsnGly	1425
	TrpTyrGlySer
VH_89	GlyPheThrPheSerSerTyrProIleSerGlyThrGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1426
	TrpTyrGlySer
VH_90	GlyPheThrPheSerSerTyrProIleSerTyrAspAlaThrAsnAsnAlaLysGluArgPheThrGlyGlyTyrT	1427
	yrThrTyrPheAspTyr
VH_91	GlyPheThrPheSerSerTyrProIleTyrHisSerGlySerThrAlaArgAlaGlyGlyLeuHisLeuAspTyr	1428
VH_92	GlyPheThrPheSerSerTyrProIleTyrProGlyAspSerAspThrAlaArgGlyAsnGlyAspGlyGlyPheA	1429
	spTyr
VH_93	GlyPheThrPheSerSerTyrSerIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1430
	rpTyrGlyAsn
VH_94	GlyPheThrPheSerSerTyrTrpIleSerGlySerGlyAspIleThrAlaLysAspTrpAlaGlyTyrValAsnGly	1431
	TrpTyrGlyAsn
VH_95	GlyPheThrPheSerSerTyrTrpIleSerTyrAspGlySerAsnLysAlaArgAspArgGlyValGluGlyAlaTy	1432
	rGlyMetAspVal
VH_96	GlyPheThrPheSerSerTyrTrpIleSerTyrAspGlySerAsnLysAlaLysGlyLeuLeuValAlaSerIleTyr	1433
	AspAlaPheAspIle
VH_97	GlyPheThrPheSerSerTyrTrpIleTyrHisSerGlySerThrAlaArgGlySerAsnIlePheAspIle	1434
VH_98	GlyPheThrPheSerThrTyrAlaIleLysSerLysAsnAspGlyGlyThrThrThrThrAlaProSerLeuMetA	1435
	spVal
VH_99	GlyPheThrPheSerThrTyrAlaIleSerAlaTyrAsnGlyAsnThrAlaArgAspLeuThrPheGlySerGlyP	1436
	roThrArgAspTyr
VH_100	GlyPheThrPheSerThrTyrAlaIleSerGlySerGlyAspIleThrAlaLysAspTrpAlaGlyTyrThrAsnGly	1437
	TrpTyrGlySer
VH_101	GlyPheThrPheSerThrTyrAlaIleSerGlySerGlyAspIleThrAlaLysAspTrpAlaGlyTyrValAsnGly	1438
	TrpTyrGlyAsn
VH_102	GlyPheThrPheSerThrTyrAlaIleSerGlySerGlyGlyArgThrAlaLysAspTrpGlyAlaTyrSerSerGly	1439
	TrpTyrGlyAsp
VH_103	GlyPheThrPheSerThrTyrAlaIleSerGlySerGlyGlySerThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1440
	rpTyrGlyAsn
VH_104	GlyPheThrPheSerThrTyrAlaIleSerGlySerGlyGlySerThrAlaLysAspTrpThrAsnGlnTrpLeuAs	1441
	pAlaTyrPheAspTyr
VH_105	GlyPheThrPheSerThrTyrAlaIleSerGlySerGlyGlySerThrAlaLysGluThrIleLeuTyrAspIleLeuT	1442
	hrGlyTyrTyrAsnGluGlyAlaPheAspIle
VH_106	GlyPheThrPheSerThrTyrAlaIleSerTyrAspGlySerAsnLysAlaLysAspTrpGlyArgPheGlyGluLe	1443
	uLeuGluGlySerProTyr
VH_107	GlyPheThrPheSerThrTyrAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluPheGlnAspSerSerS	1444
	erTrpTyrGluGlyArgAlaPheAspIle
VH_108	GlyPheThrValSerSerAsnTyrIleAsnProAsnSerGlyGlyThrAlaArgAspTrpGlyArgGlyValGlyAs	1445
	pSerGlyPheValAspTyr
VH_109	GlyPheThrValSerSerAsnTyrIleAsnProLysSerGlyGlyAlaAlaArgAspPheValGlyAlaSerLeuAs	1446
	pTyr
VH_110	GlyPheThrValSerSerAsnTyrIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGly	1447
	TrpTyrGlyAsn
VH_111	GlyPheThrValSerSerAsnTyrIleSerSerSerGlySerThrIleAlaArgGlyTyrLeuGlyAlaTrpAsnPro	1448
	AspPheTyrAspTyr
VH_112	GlyPheThrValSerSerAsnTyrIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1449
	AspTyr
VH_113	GlyPheThrValSerSerAsnTyrIleThrGlySerGlyGlyThrAlaLysAspTrpAlaGlyTyrIleAsnGlyTrpP	1450
	heGlySer
VH_114	GlyPheThrValSerSerAsnTyrIleTyrProGlyAspSerAspThrAlaArgLeuGlyAspGlySerAsnPheA	1451
	spTyr
VH_115	GlyPheThrValSerSerAsnTyrThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluLysIleAlaValAlaGly	1452
	TyrTyrTyrGlyMetAspVal
VH_116	GlyPheThrValSerSerAsnTyrThrTyrTyrAsnArgLysTrpIleAsnAlaArgAspGlyGlyTrpSerGlySe	1453
	rAlaLeuAspVal
VH_117	GlyTyrArgPheThrSerTyrTrpIleTyrSerGlyGlySerThrAlaArgAspLeuHisSerAlaAlaGlyPheAsp	1454
	Tyr
VH_118	GlyTyrSerPheThrArgTyrTrpIleLysSerLysAsnAspGlyGlyThrThrThrThrAlaProSerLeuMetAs	1455
	pVal
VH_119	GlyTyrSerPheThrSerTyrTrpIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1456
	rpTyrGlyAsn
VH_120	GlyTyrSerPheThrSerTyrTrpIleSerGlySerGlyAspArgThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1457
	rpTyrGlyAsn
VH_121	GlyTyrSerPheThrSerTyrTrpIleSerTyrAspGlySerAsnLysAlaLysGlySerSerProTyrTyrTyrTyrG	1458
	lyMetAspVal
VH_122	GlyTyrSerPheThrSerTyrTrpIleTyrHisSerGlySerThrAlaArgAspGlyGlySerGlyTrpTyrAspTyr	1459
VH_123	GlyTyrSerPheThrSerTyrTrpIleTyrSerGlyGlySerThrAlaArgAspThrAlaSerGlyGlyMetAspVal	1460
VH_124	GlyTyrSerPheThrSerTyrTrpThrTyrTyrArgSerLysTrpTyrAsnAlaArgGlyValThrValProTyrTyr	1461
	TyrTyrGlyMetAspVal
VH_125	GlyTyrSerPheThrSerTyrTrpThrTyrTyrArgSerLysTrpTyrAsnAlaArgSerSerGlySerTyrGlyTyr	1462
	PheGlnHis
VH_126	GlyTyrThrPheThrArgAsnAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluGlyThrAspIleTyrTy	1463
	rTyrTyrGlyMetAspVal
VH_127	GlyTyrThrPheThrGlyTyrTyrIleAspTyrSerGlySerThrAlaArgAspGlyTrpIleArgLysGluAlaPhe	1464
	AspPro
VH_128	GlyTyrThrPheThrGlyTyrTyrIleLysSerLysAsnAspGlyGlyThrThrThrThrAlaProSerLeuMetAs	1465
	pVal
VH_129	GlyTyrThrPheThrGlyTyrTyrIleSerAlaTyrAsnGlyAsnThrAlaArgAspProGlyGlyTyrTyrTyrTyr	1466
	TyrGlyMetAspVal
VH_130	GlyTyrThrPheThrGlyTyrTyrIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1467
	AspTyr
VH_131	GlyTyrThrPheThrGlyTyrTyrIleSerTyrAspGlySerAsnLysAlaLysLeuGlyGlySerTyrSerIleTyrT	1468
	yrGlyMetAspVal
VH_132	GlyTyrThrPheThrGlyTyrTyrIleTyrProGlyAspSerGluThrAlaArgAspGlyGlyAsnTyrGlnPheAs	1469
	pTyr
VH_133	GlyTyrThrPheThrSerTyrAlaIleIleProIlePheGlyThrAlaAlaArgThrGlyArgSerGlySerTyrTyrSe	1470
	rAspAlaPheAspIle
VH_134	GlyTyrThrPheThrSerTyrGlyIleAsnProSerGlyGlySerThrAlaArgGluAspHisAspTyrSerAsnGl	1471
	nGlyGlyPheAspTyr
VH_135	GlyTyrThrPheThrSerTyrGlyIleIleProIlePheGlyThrAlaAlaAlaArgAlaProGlyGlySerSerTyrTy	1472
	rTyrTyrGlyMetAspVal
VH_136	GlyTyrThrPheThrSerTyrGlyIleSerAlaTyrAsnGlyAsnThrAlaArgAspProGlyTyrAspPheTrpSe	1473
	rGlyTyrSerAspVal
VH_137	GlyTyrThrPheThrSerTyrGlyIleSerGlySerGlyGlyArgThrAlaLysAspTrpAlaGlyTyrIleAsnGlyT	1474
	rpTyrGlyAsn
VH_138	GlyTyrThrPheThrSerTyrGlyIleSerTrpAsnSerGlySerIleAlaLysAspMetTrpGlySerLeuSerIleV	1475
	alGlyAlaThrArgAlaPheAspTyr
VH_139	GlyTyrThrPheThrSerTyrGlyIleThrGlySerGlyGlyThrAlaLysAspTrpAlaGlyTyrIleAsnGlyTrpP	1476
	heGlySer
VH_140	GlyTyrThrPheThrSerTyrGlyIleTyrHisSerGlySerThrAlaArgGlyProLeuLeuIleAlaAlaAlaGlyT	1477
	hrAspTyrTyrTyrGlyMetAspVal
VH_141	GlyTyrThrPheThrSerTyrTyrIleSerGlySerGlyGlySerThrAlaSerSerTyrGlyGlyAsnProLeuAsp	1478
	AlaPheAspIle
VH_142	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluLysIleAlaVal	1479
	AlaGlyTyrTyrTyrGlyMetAspVal
VH_143	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGluPheGlnAspS	1480
	erSerSerTrpTyrGluGlyArgAlaPheAspIle
VH_144	GlyAspSerValSerSerAsnSerAlaAlaThrTyrTyrArgSerLysTrpTyrAsnAlaArgGlyGlyValGlyAla	1481
	ThrTrpTyrTyrGlyMetAspVal
VH_145	GlyPheThrPheAspAspTyrAlaIleSerTrpAsnSerGlySerIleAlaLysAspIleAlaAlaGlyGlyLeuAsp	1482
	Ser
VH_146	GlyPheThrPheSerAsnAlaTrpIleLysSerLysAsnAspGlyGlyThrThrThrThrAlaProSerLeuMetA	1483
	spVal
VH_147	GlyPheThrPheSerAsnAlaTrpIleLysSerLysAsnAspGlyGlyThrThrThrThrAlaProSerLeuMetA	1484
	spVal
VH_148	GlyPheThrPheSerSerTyrAlaIleSerTyrAspGlySerAsnLysAlaArgAspArgGlyValGluGlyAlaTyr	1485
	GlyMetAspVal
VH_149	GlyPheThrPheSerSerTyrGlyIleSerGlySerGlyGlySerThrAlaLysAlaThrGlyTyrSerSerGlyTrpT	1486
	yrGlyAlaTyrPheAspTyr
VH_150	GlyPheThrPheSerSerTyrGlyIleSerTyrAspGlySerAsnLysAlaLysGlySerSerProTyrTyrTyrTyr	1487
	GlyMetAspVal
VH_151	GlyPheThrPheSerSerTyrGlyIleTrpTyrAspGlyAsnAsnLysAlaArgAspAsnSerGlySerTyrAsnT	1488
	rpPheAsnPro
VH_152	GlyPheThrPheSerSerTyrGlyIleTrpTyrAspGlySerAsnLysAlaArgGluValValGlySerTyrTyrLeu	1489
	AspTyr
VH_153	GlyPheThrPheSerSerTyrProIleSerTyrAspGlyGlyAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1490
	AspTyr
VH_154	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1491
	AspTyr
VH_155	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1492
	AspTyr
VH_156	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1493
	AspTyr
VH_157	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysAlaArgValGlySerGlyGlyTrpThrPro	1494
	AspTyr
VH_158	GlyPheThrPheSerSerTyrProIleSerTyrAspGlySerAsnLysThrArgValGlySerGlyGlyTrpThrPr	1495
	oAspTyr
VH_159	GlyPheThrPheSerSerTyrSerIleTrpTyrAspGlySerAsnLysAlaArgLeuGlySerGlyTrpSerLeuAs	1496
	pTyr
VH_160	GlyPheThrPheSerSerTyrTrpIleLysGlnAspGlySerGluLysAlaArgAspLeuHisCysGlySerSerCy	1497
	sGlyProGluAla
VH_161	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspLeuHisSerAlaAlaGlyPheAsp	1498
	Tyr
VH_162	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspLeuSerTyrSerAspAlaPheAs	1499
	pIle
VH_163	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspPheGluGlySerGlyAlaLeuAs	1500
	pVal
VH_164	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspThrAlaSerGlyGlyMetAspVa	1501
	l
VH_165	GlyPheThrValSerSerAsnTyrIleTyrSerGlyGlySerThrAlaArgAspThrAlaSerGlyGlyMetAspVa	1502
	l
VH_166	GlyTyrSerPheThrSerTyrTrpIleTyrProGlyAspSerAspThrAlaSerGlyAlaSerProTyrTyrPheAs	1503
	pTyr
VH_167	GlyTyrThrPheThrGlyTyrTyrIleAsnProAsnSerGlyGlyThrAlaArgGlyGlyAspCysSerSerThrSe	1504
	rCysTyrAspProAspTyr
VH_168	GlyTyrThrPheThrSerTyrGlyIleSerAlaTyrAsnGlyAsnThrAlaArgAspProValTyrSerSerSerTrp	1505
	GlyGlyTyrAlaPheAspIle
VH_169	GlyTyrThrPheThrSerTyrGlyIleSerAlaTyrAsnGlyAsnThrAlaArgGlyLeuGlyAspSerSerSerSer	1506
	Tyr
VH_170	GlyTyrThrPheThrSerTyrTyrIleAsnProSerGlyGlySerThrAlaArgGluAspHisAspTyrSerAsnGl	1507
	nGlyGlyPheAspTyr

LGALS3BP Detection Assay and Kit

In one embodiment of the present invention is a kit. This Human uG3BP ELISA kit is used for the non-radioactive quantification of human G3BP (galectin-3-binding protein, LGALS3BP, lectin galactoside-binding soluble 3 binding protein, M2BP; Mac-2 BP; 90K/Mac-2-binding protein) in urine samples. One kit is sufficient to measure 38 unknown samples in duplicate.

PRINCIPLES OF ASSAY

This assay is a Sandwich ELISA based, sequentially, on: 1) capture of human G3BP molecules from samples to the wells of a microtiter plate coated with an anti-human G3BP monoclonal antibody, 2) washing of unbound materials from samples, 3) binding of a second biotinylated anti-human G3BP monoclonal antibody to the captured molecules, 4) washing of unbound materials from samples, 5) binding of streptavidin-horseradish peroxidase (HRP) conjugate to the immobilized biotinylated antibodies, 6) washing of excess free enzyme conjugates, and 7) quantification of immobilized antibody-enzyme conjugates by monitoring horseradish peroxidase activities in the presence of the substrate 3,3′,5,5′-tetramethylbenzidine (TMB). The enzyme activity is measured spectrophotometrically by the increased absorbance at 450 nm-590 nm after acidification of formed products. Since the increase in absorbance is directly proportional to the amount of captured human G3BP in the unknown sample, the latter can be derived by interpolation from a reference curve generated in the same assay with reference standards of known concentrations of human G3BP. It will be appreciated to one of skill in the art that the anti-human G3BP monoclonal antibodies described by SEQ ID Nos: 2-31 may be incorporated into the instant assay.

REAGENTS SUPPLIED

Each kit is sufficient to run one 96-well plate and contains the following reagents: (store all reagents at 2-8° C.).

	Reagents Supplied	Volume	Quantity
	Microtiter Plate with 2 plate sealers	—	1 plate
			2 sealers
	Human G3BP Standard	lyophilized	2 vials
	Human G3BP Quality Controls 1 and 2	lyophilized	2 vials
	Assay Buffer	40 mL	1 bottle
	10X Wash Buffer	50 mL	2 bottles
	Human G3BP Detection Antibody	12 mL	1 bottle
	Enzyme Solution	12 mL	1 bottle
	Substrate Solution	12 mL	1 bottle
	Stop Solution	12 mL	1 bottle

STORAGE AND STABILITY

All components are shipped and stored at 2-8° C. Reconstituted standards and controls can be frozen for future use but repeated freeze/thaw cycles should be avoided. Refer to expiration dates on all reagents prior to use. Do not mix reagents from different kits unless they have the same lot numbers.

MATERIALS REQUIRED BUT NOT PROVIDED

• • 1. Multi-channel Pipettes and pipette tips: 5-50 μL and 50-300 μL
  • 2. Pipettes and pipette tips: 10 μL-20 μL or 20 μL-100 μL
  • 3. Reagent Reservoirs
  • 4. Polypropylene Microfuge Tubes
  • 5. Vortex Mixer
  • 6. De-ionized water
  • 7. Microtiter Plate Reader capable of reading absorbency at 450 nm and 590 nm
  • 8. Orbital Microtiter Plate Shaker
  • 9. Absorbent Paper or Cloth
  • 10.

SAMPLE COLLECTION AND STORAGE

Preparation of Urine Samples:

• • Centrifuge the sample at 4° C. to remove debris and assay immediately or aliquot and store samples at ≤−20° C.
  • Avoid repeated freeze/thaw cycles.
  • Urine samples may require a 1:10 dilution with assay buffer prior to assay.

Note:

• • A maximum of 100 μL per well of diluted or neat urine sample can be used.
  • All samples must be stored in polypropylene tubes. DO NOT STORE SAMPLES IN GLASS.

REAGENT PREPARATION

Human G3BP Standard Preparation

• • 1. Using a pipette, reconstitute the Human G3BP Standard with 500 μL distilled or de-ionized water. Invert and mix gently, let sit for 5 minutes then mix well.
  • 2. Label seven polypropylene microfuge tubes as 1, 2, 3, 4, 5, 6 and 7. Add 200 μL of Assay Buffer to tubes 1, 2, 3, 4, 5 and 6. Prepare serial dilutions by adding 500 μL of the reconstituted standard to the Tube 7, mix well and transfer 100 μL of Tube 7 to Tube 6, mix well and transfer 100 μL of Tube 6 to Tube 5, mix well and transfer 100 μL of Tube 5 to Tube 4, mix well and transfer 100 μL of the Tube 4 to Tube 3, mix well and transfer 100 μL of Tube 3 to Tube 2, mix well and transfer 100 μL of Tube 2 to Tube 1, mix well. The 0 ng/mL standard (Background) will be Assay Buffer.
  •  Note: Change tip for every dilution. Wet tip with standard before dispensing. Unused portions of reconstituted standard should be stored in small aliquots at ≤−20° C. Avoid multiple freeze/thaw cycles.

		Volume of	Volume of	Standard
		Deionized	Standard	Stock
	Tube #	Water to Add	to Add	Concentration
	Reconstituted	500 μL	0	200 ng/mL
	standard

	Volume	Volume of	Standard
	of Assay	Standard to	Concentration
Tube #	Buffer to Add	Add	(ng/mL)
Tube 7	0	500 μL of reconstituted	200
		standard
Tube 6	200 μL	100 μL of Tube 7	66.67
Tube 5	200 μL	100 μL of Tube 6	22.22
Tube 4	200 μL	100 μL of Tube 5	7.41
Tube 3	200 μL	100 μL of Tube 4	2.47
Tube 2	200 μL	100 μL of Tube 3	0.82
Tube 1	200 μL	100 μL of Tube 2	0.27

REAGENT PREPARATION (CONTINUED)

B. Human G3BP Quality Control 1 and 2 Preparation

• • Reconstitute each Human G3BP Quality Control 1 and Quality Control 2 with 500 μL distilled or de-ionized water and gently invert to ensure complete hydration (mix gently, let sit for 5 minutes then mix well). Unused portions of the reconstituted Quality Controls should be stored in small aliquots at ≤−20° C. Avoid further freeze/thaw cycles.

C. Preparation of Wash Buffer

• • Bring the 10× Wash Buffer to room temperature and mix to bring all salts into solution. Dilute 50 mL of 10× Wash Buffer with 450 mL deionized water. Store unused portion at 2-8° C. for up to one month.

HUMAN uG3BP ELISA ASSAY PROCEDURE

Warm All Reagents to Room Temperature before Setting Up the Assay.

• • 1. Remove the required number of strips from the Microtiter Assay Plate. Unused strips should be resealed in the foil pouch and stored at 2-8° C. Assemble the strips in an empty plate holder. Add 300 μL diluted Wash Buffer to each well of the plate. Decant Wash Buffer and remove the residual volume by inverting the plate and tapping it smartly onto absorbent towels several times. Repeat wash procedure two additional times. Do not let wells dry before proceeding to the next step. If an automated machine is used for the assay, follow the manufacturer's instructions for all washing steps described in this protocol.
  • 2. Add 50 uL Assay Buffer to all wells.
  • 3. Add 50 μL Assay Buffer to each of the Blank wells.
  • 4. Add 50 μL of Standards and Quality Controls to the appropriate wells (refer to Microtiter Plate Arrangement section for suggested sample order placement).
  • 5. Add 50 μL of diluted urine sample to the appropriate wells.
  • 6. Cover the plate with plate sealer and incubate at room temperature for 2 hours on an orbital microtiter plate shaker set to rotate at moderate speed, about 400 to 500 rpm.
  • 7. Remove plate sealer and decant reagents from the plate. Tap as before to remove residual volume in well. Wash wells 3 times with diluted Wash Buffer, 300 μL per well per wash. Decant and tap after each wash to remove residual buffer. (add an agitating/soaking step is recommended between each wash if using the automatic plate washer.)
  • 8. Add 100 μL Detection Antibody to each well. Re-cover plate with sealer and incubate at room temperature for 1 hour on an orbital microtiter plate shaker set to rotate at moderate speed, approximately 400-500 rpm.
  • 9. Remove plate sealer and decant reagents from the plate. Tap as before to remove residual volume in well. Wash wells 3 times with diluted Wash Buffer, 300 μL per well per wash. Decant and tap after each wash to remove residual buffer.
  • 10. Add 100 μL Enzyme Solution to each well. Cover plate with sealer and incubate with moderate shaking at room temperature for 30 minutes on the microtiter plate shaker.
  • 11. Remove sealer, decant reagents from the plate and tap plate to remove the residual volume. Wash wells 4 times with diluted Wash Buffer, 300 μL per well per wash. Decant and tap after each wash to remove residual buffer.
  • 12. Add 100 μL of Substrate Solution to each well, cover plate with sealer and shake on the plate shaker for approximately 5-20 minutes. Blue color should be formed in wells of the Human G3BP standards with intensity proportional to increasing concentrations of Human G3BP.
  •  Note: The color may develop more quickly or more slowly than the recommended incubation time depending on the localized room temperature. Please visually monitor the color development to optimize the incubation time.
  • 13. Remove sealer and add 100 μL Stop Solution and gently shake plate by hand to ensure complete mixing of solution in all wells. The blue color should turn to yellow after acidification. Wipe the bottom of the microtiter plate to remove any residue prior to reading on plate reader. Read absorbance at 450 nm (signal) and 590 nm (background) in a plate reader within 5 minutes and ensure that there are no air bubbles in any well. Record the difference of absorbance units. The absorbance of the highest Human G3BP standard should be approximately 2.5-3.5, or not to exceed the capability of the plate reader used.
  •  Note: If urine samples are diluted 1:10, final results, ng/mL concentrations of G3BP in samples, should be multiplied by a dilution factor of 10.

ASSAY CHARACTERISTICS

A. Sensitivity

• • The Minimum Detectable Concentration (MinDC) of Human G3BP is 0.08 ng/mL. It is calculated by using MILLIPLEX® Analyst 5.1. It measures the true limits of detection for an assay by mathematically determining what the empirical MinDC would be if an infinite number of standard concentrations were run for the assay under the same conditions. This reported value is the mean plus 2 standard deviations of the MinDC of multiple assays (n=8).

B. Specificity

• • The antibody pair used in this assay is specific to human G3BP.

C. Precision

• • Intra-Assay Variation

	Mean	Intra-Assay
	Levels (ng/mL)	% CV
1	219	5.9
2	636	5.6

• • Inter-Assay Variation

	Mean Levels	Inter-Assay
	(ng/mL)	% CV
1	380	8.3
2	607	8.1

• • The assay variations of this uG3BP ELISA kit was studied on urine samples at two levels on the uG3BP standard curve. The mean intra-assay variation was calculated from results of eight determinations of the indicated samples. The mean inter-assay variations of each sample were calculated from results of 8 separate assays with duplicate samples in each assay. (The urine samples were diluted with assay buffer prior to assay.)

D. Spike Recovery of G3BP in Assay Samples

• • The average recovery of human G3BP in eight urine samples is 103%. Three concentrations of human G3BP were added to individual urine samples (n=8) and the resulting G3BP content of each sample was assayed by Human uG3BP ELISA. The recovery =[(observed G3BP/(spiked G3BP concentration+basal G3BP]×100%. (The urine samples were diluted with assay buffer prior to assay.)

E. Linearity of Sample Dilution

• • The average % of expected linearity in eight urine samples is 96%. Required amounts of Assay Buffer were added for resulting dilution factors of 1, 2, 4 and 8 assayed, respectively. % expected=(observed/expected)×100%. (The urine samples were diluted with assay buffer prior to assay.)

EXPERIMENTAL EXAMPLES

The following examples are intended for illustration only and should not be construed to limit the scope of the claimed invention.

Example 1: LGALS3BP Expression is Increased in PBMCs From LN Patients and Correlates with their Interferon Status

In order to find predictive markers of disease activity in LN patients, the mRNA profiles of PBMCs isolated from LN patients were assessed and compared these profiles to those of healthy controls (HC). PBMCs were isolated from whole blood of HC (n=4) and LN donors (n=9) by Ficoll gradient. Gene expression profiling was performed by RNA-seq. FPKM values are shown. LN patients were grouped into Low interferon (IFN) or High IFN based on the median average z-score of four IFN-inducible genes, IFI44L, RSAD2, MX1, and OAS2 (Hagberg N and Rönnblom L, Scand J Immunol 2015 September; 82(3):199-20). LGALS3BP mRNA levels were significantly higher in the LN (High IFN) group vs the LN (Low IFN) group (p=0.044) and the HC group (p=0.028). From the profiling described above it was found that LGALS3BP mRNA expression was one of the best genes whose levels could be used to distinguish between LN and HC PBMCs (FIG. 1). It was also observed there was significant variability in the levels of LGALS3BP among the LN patients. LN patients are often grouped based on their type I interferon levels as measured by the levels of interferon-inducible genes (Scand J Immunol. 2015 September; 82(3):199-20). A subsequent evaluation determined if the interferon levels between the LN samples could explain the large variability observed in LGALS3BP. In the lupus nephritis patients, a bimodal distribution in the type I interferon-inducible genes was found indicating that some patients had a high interferon signature while others had a low interferon signature. In order to further sort the lupus nephritis patients into these two groups, the expression levels of four known interferon-inducible genes, IFI44L, RSAD2, OAS2, and MX1 were combined by taking the average z-score of the four genes across all the samples. Samples with interferon signature scores equal to or below the median levels were assigned to the low interferon group. Those samples with interferon scores above the median were assigned to the high interferon group. After classifying the donors into these two groups, it was found that LGALS3BP levels were 5-fold higher in the low interferon group as compared to healthy controls, and 30-fold higher in the high interferon group compared to healthy controls (p=0.028; FIG. 1). Additionally, LGALS3BP levels were 6-fold higher in the high interferon group as compared to the low interferon group (p=0.044). These data demonstrate that LGALS3BP expression is increased in LN patients and that LGALS3BP expression is likely regulated by type I interferon.

Example 2: LGALS3BP Expression can be Induced by IFNα and Other Inflammatory Stimuli

LGALS3BP has an IRF7 binding site consistent with regulation by type I interferons. In order to discover which pathways can induce LGALS3BP expression, primary human monocytes were differentiated into macrophages in vitro and were subsequently stimulated with IFNα, IFNγ, TLR4 agonist (LPS), TLR7/8 agonist (resiquimod) and TLR9 agonist (CpG). IFNα, IFNγ, and LPS induced LGALS3BP mRNA expression (FIG. 2a) and increased secretion of the protein (FIG. 2b). All stimuli induced secretion of IL-6. These data indicated that not only type I interferons can drive LGALS3BP expression but also IFNγ and other innate triggers. Based on location of histone acetylation sites, LGALS3BP expression is likely regulated by factors binding to four different regions in the LGALS3BP gene: at the promoter start site, in an upstream enhancer (region 5 K upstream), in an intronic site, or in the 3′ UTR. Motif scanning by three different methods identified immune-relevant transcriptional regulators. IRFs, AP-1, and STATs as well as other important factors such as NF-KB were found in and around the LGALS3BP gene locus. Prediction of transcription factor binding indicates that LGALS3BP expression is regulated by interferons through interferon regulatory factors (IRFs) as well as other immune stimuli that activate STATs, NF-kB, and AP-1.

Example 3: LGALS3BP Protein is Increased in Urine From LN Patients but not in Plasma

To determine if increased mRNA levels in PBMCs led to increased levels of LGALS3BP protein in patient blood, LGALS3BP was measured by ELISA in plasma from LN patients, SLE patients and healthy control (HC) donors. No significant difference in plasma LGALS3BP levels between these three groups were found despite the upregulated mRNA in PBMCs (FIG. 3). It has been demonstrated that PBMCs only contributed minor amounts of total plasma LGALS3BP. Nonetheless, significantly higher LGALS3BP levels were found in urine from LN patients compared to SLE patients and healthy controls.

Example 4: LGALS3BP Expression is Elevated in LN Patient Kidneys

LN is characterized by kidney inflammation. Current tests to monitor disease activity measure kidney function in blood and urine but not causal inflammation. LGALS3BP is induced by inflammatory stimuli and its elevated presence in urine could reflect kidney inflammation. In order to determine if increased urinary LGALS3BP is relevant as a urinary protein measurement to monitor inflammation in lupus nephritis, LGALS3BP's mRNA expression profile was examined in kidney biopsies. GEO dataset (GSE32592) that contained a total of 46 kidney biopsy samples (n=14 HC and 32 LN) that were collected from the European Renal cDNA Bank was used. The glomeruli and tubulointerstitium were isolated by microdissection and expression profiling was performed using Affymetrix GeneChip arrays. After initial quality control assessments and normalization, the expression level of LGALS3BP was found to be significantly higher in both the glomeruli (1.5-fold, p=9.2e-12) and tubulointerstitium (2.2-fold, p=1.5e-4) of LN patients compared to healthy controls (FIG. 4a). The expression profile of two additional genes, CCL2 (MCP-1) and TNFSF12 (TWEAK), both of which have been proposed as potential urinary biomarkers (Schwartz et al. Ann N Y Acad Sci. 2007 August; 1109:265-74) was then evaluated. In that dataset, CCL2 (MCP-1) (FIG. 4b) expression levels were found to be equivalent between LN and HC samples in both the glomeruli (1.3-fold, p=0.392) and tubulointerstitium (0.7-fold, p=0.33). Expression levels of TNFSF12 (FIG. 4C) was significantly higher in the glomeruli of LN samples (1.2-fold, p=9.1e-5), but significantly lower in the tubulointerstitium of LN samples (0.85-fold, p=0.017). These data suggest that LGALS3BP may be a more suitable urinary predictive marker than CCL2 (MCP-1) and TNFSF12 to distinguish between HC and LN samples.

Global differential expression was also evaluated in order to elucidate all the genes that were significantly modulated in LN patients. Using the R package limma, a model was constructed to perform the differential expression calculations while controlling for tissue differences. This allowed for the utilization of data from both the glomeruli and tubulointerstitium together. Of the 12,030 total genes included in the analysis, only 166 genes had a p-value less than 0 01 and a fold change of at least 2. The genes significantly upregulated in LN numbered 137 while 29 genes were downregulated in LN. In this analysis, LGALS3BP had a p-value of 2.11e-8 and was in the top 3% of genes with the lowest p-values. These data confirm that LGALS3BP is one of the few genes significantly upregulated in both the glomeruli and tubulointerstitium of LN kidney biopsies and, thereby, is a good predictive marker.

Staining of LN kidney biopsies with anti-LGALS3BP antibodies showed increased levels and punctate patterns in certain areas, specifically around tubules in patients with and without tubolointerstitial nephritis (FIG. 4d). LGALS3BP signal in a healthy control sample was less intense, more diffuse and mostly due to background staining of the secondary antibody (FITC anti-rabbit). Samples from diabetes mellitus (DM) and IgA nephropathy (IgAN) patients showed some but weaker LGALS3BP staining than LN.

Example 5: LGALS3BP Expression is Increased in a Mouse Model of LN Only when Kidney Damage is Detected

To further investigate if increased LGALS3BP kidney expression is induced by local inflammation its expression in BXSB-Yaa lupus mice was measured. These mice spontaneously develop systemic symptoms of SLE and LN-like inflammation and damage of the kidneys. The model is based on a duplication of the Yaa locus, which encompasses the TLR7 gene and results in increased TLR7 expression and type I interferon inflammation. Measuring the murine homolog of LGALS3BP elevated levels in mice were found with disease only when kidney damage and inflammation were detected by histology evaluating glomerular crescents, protein casts, interstitial inflammation, and vasculitis (FIG. 5). These results further indicate that LGALS3BP is expressed locally during an inflammatory process in the kidney.

Example 6: LGALS3BP Protein is Elevated in LN Patient Urine

The following experiment was designed to determine if increased LGALS3BP expression in patient kidneys translated into a measurable difference in urine protein levels, which could distinguish between LN patients, SLE patients, and healthy control donors. LGALS3BP protein was measured by ELISA in urine from LN patients, SLE patients and healthy controls. After normalizing the data to urine creatinine levels, it was found that LGALS3BP (FIG. 3A) was significantly higher in LN patients than SLE (6.8-fold, p<0.001) and HC donors (17.7-fold, p<0.001). There was also a trend for higher levels of LGALS3BP found in SLE patients versus HC donors, but this trend was not statistically significant (2.6-fold, p=0.59).

How the urine protein levels of LGALS3BP compared to other common urinalysis readouts, such as total protein levels or albumin levels was next considered. After normalizing all values to urine creatinine levels, total protein levels or albumin levels were found to perform as well to distinguish LN patients from SLE and HC donors. Both total protein levels (FIG. 6B) and albumin (FIG. 6C) levels were significantly higher in LN patients than SLE or HC donors (p<0.001 for both).

In order to apply these data to the construction of a diagnostic test, values associated with renal inflammation needed to be defined. In order to arrive at these values, the maximum value from the healthy control samples was set as the cutoff, meaning that any sample with a value higher than the maximum healthy control sample would likely have kidney inflammation. The rationale for this is based upon the assumption that healthy control donors should not have any inflammation and therefore, the values found in healthy controls should represent the normal range. For LGALS3BP/creatinine ratios, protein/creatinine ratios, and albumin/creatinine ratios, the cutoff values were 3.133, 0.166, and 0.457, respectively. Using these values, it was found that for LGALS3BP, 50 LN and 12 SLE samples were above the cutoff (FIG. 6A). For total protein, 53 LN and 18 SLE samples were above the cutoff (FIG. 6B). For albumin, 56 LN and 9 SLE samples were above the cutoff (FIG. 6C). These data suggest that LGALS3BP is more conservative in the identification of samples that are likely to have inflammation in the kidneys. For the SLE samples with LGALS3BP levels above the cutoff, these may be patients most at risk of developing lupus nephritis or SLE patients with undiagnosed LN.

Example 7: LGALS3BP Urine Levels are not a Reflection of Kidney Function and Filtering Capacity

To validate LGALS3BP as a predictive marker for LN, we further examined detected LGALS3BP in terms of total protein or albumin levels. To determine this, the Pearson correlation coefficients were assessed comparing these three measurements to one another after normalizing to urine creatinine levels. Through this empirical inquiry a very strong correlation between total protein and albumin levels was found (R=0.95; FIG. 7A). We also found positive correlations between LGALS3BP and total protein (R=0.513; FIG. 7B) and LGALS3BP and albumin levels (R=0.507; FIG. 7C). Based on these correlation coefficients, these data demonstrate that measured LGALS3BP provides a differential read-out as compared to measured total protein or albumin More specifically, in patient samples which had high levels of LGALS3BP and low levels of total protein this expression profile is consistent with patients having high levels of inflammation in their kidneys, but relatively low levels of kidney damage; consistent with a pathophysiology in LN of early stage LN. In patient samples presenting low levels of LGALS3BP and high total protein levels that expression profile is consistent with patients having low levels of kidney inflammation but a high level of kidney damage; consistent with a pathophysiology in LN of class V late-stage kidney disease with risk of kidney failure. These data demonstrate that, urinary measurements of LGALS3BP provide different and more nuanced diagnostic information concerning the severity and progression of LN as compared to measuring total protein or albumin levels in the urine.

Example 8: Urine LGALS3BP Levels Fluctuate over Time

LN patients have higher levels of total protein, albumin and LGALS3BP as compared to SLE and HC donors. In most sample donors these values remained fairly constant, especially in the HC and SLE groups over the course of time. In some LN patients, however, spikes were observed in the total protein (FIG. 5A) and albumin (FIG. 5B) and LGALS3BP (FIG. 5C). These metrics are not only in and of themselves (i.e., monitoring renal inflammation in LN patients) but are also useful in evaluating the effectiveness of certain immunosuppressive treatments in LN patients.

For all purposes in the United States of America, each and every publication and patent document cited herein is incorporated by reference for all purposes as if each such publication or document was specifically and individually indicated to be incorporated, herein, by reference.

While the invention has been described with reference to the specific embodiments, changes can be made and equivalents can be substituted to adapt to a particular context or intended use, thereby achieving benefits of the invention without departing from the scope of the claims that follow.

Example 9: Urinary LGALS3BP/Creatinine Ratios in Different Kidney Disease Groups

As show in FIG. 25, increased levels of urinary LGALS3BP preferentially in LN when active (flaring). This shows a disease-specific pattern in urinary LGALS3BP expression and a trend that is mainly driven by active inflammation in the context of LN. Diabetic Nephropathy (DM), IgAN and ANCA show low urinary LGALS3BP levels. Considering that ANCA, DM are characterized by chronic low-grade inflammation, the data show that urinary LGALS3BP levels are disease specific and are not increased by non-LN-specific kidney inflammatory states.

Active LN vs. remitting LN shows striking differences. This is significant in view of the advantages of the urinary LGALS3BP assay described in the instant application: to differentiate between active vs. chronic disease. As shown in FIGS. 26A and 26B, urine LGALS3BP data were normalized to creatinine concentration, natural log transformed and outliers were excluded for data analysis. Also, JMP pro v12 were used including ANOVA and Wilcoxon non parametric multiple comparison showing average LGALS3BP/creatinine ratios and standard error mean. Dotted line indicates average+2 standard deviations for healthy control (132.95).

Example 10: Urinary LGALS3BP/Creatinine and Urinary Protein/Creatinine Ratios do not Correlate in LN

As show in FIGS. 27A, 27B and 27C, patient urine samples were compared for LGALS3BP/Creatinine and urinary total protein/Creatinine (UPCR) levels. These data demonstrate that LGALS3BP/creatinine reports on something else (i.e., inflammation) rather than UPCR (i.e. damage) in active LN kidney disease. The fact that LGALS3BP/Cr is elevated without UPCR being up in active LN demonstrates that this metric reports on active inflammation. The same is true for more samples having elevated UPCR but low LGALS3BP/Cr in remission indicating that inflammation has resolved but kidney damage persists. Patients in remission who, nonetheless, present elevated LGALS3BP/Cr but low UPCR are at risk for a flare of LN. In the aforementioned figures, R² are Pearson correlation coefficients.

Example 11: Fluctuation of Urinary LGAL3BP/Creatinine Levels in LN Patients

As shown in FIG. 29, there is a fluctuation, over time, of urinary LGALS3BP/creatinine levels in LN patients. More specifically, LN patient urine was monitored monthly. These data indicate that urinary LGALS3BP levels change over time correlate as an early indicator of inflammation.

It is understood that in light of the teachings of this invention to one of ordinary skill in the art that certain changes and modifications may be made thereto without departing from the spirit and scope of the invention.

Claims

1. A method for generating data dispositive in diagnosing and non-invasively monitoring renal pathology using samples obtained from a mammalian subject, comprising: (i) obtaining a dataset associated with the samples, wherein the dataset comprises protein expression levels for at least two markers selected from the group consisting of: urinary LGALS3BP, urinary creatinine and proteinuria expressed as a ratio of urine protein:creatine (uPCR); and(ii) inputting the dataset into an analytical process that uses the data to generate a result useful in diagnosing and monitoring the renal pathology.

2. The method of claim 2, wherein the renal pathology comprises one or more of: glomerular diseases; systemic lupus erythematosus (SLE) disease; interstitial inflammation in lupus nephritis (LN); interstitial fibrosis in lupus nephritis (LN); renal-interstitial inflammation (INF); crescentic glomerulonephritis; membranous glomerulopathy and glomerular basement membrane abnormalities.

3. An in vitro method for prediction and/or diagnosis of lupus nephritis in a subject affected or potentially affected by systemic lupus erythematosus comprising the following steps: a) providing a sample of urine from said subject: b) measuring the levels of LGALS3BP, creatinine and total protein in said urine; c) expressing the measured levels of LGALS3BP and creatinine (c), as measured in step b), as the ratio: LGALS3BP/c and d) comparing said LGALS3BP/c ratio to said total protein with a control value, wherein an increase of the ratio of LGALS3BP/c to total protein with respect to said control value indicates a development of lupus nephritis.

4. The method according to claim 3, wherein the measurement of said LGALS3BP and creatinine levels is carried out by ELISA or Western-Blot.

5. An in vitro method for monitoring progression of lupus nephritis in a patient affected by systemic lupus erythematosus comprising the following steps: a) providing a sample of urine from said subject: b) measuring the levels of galectin 3 binding protein, creatinine and total protein in said urine; c) expressing the measured levels of LGALS3BP and creatinine (c), as measured in step b), as the ratio: LGALS3BP/c to said total protein in at least a first and at least a second urine sample of said subject, wherein said at least a first and a second urine samples obtained at different times; and d) comparing said measured LGALS3BP/c ratio to said total protein concentration obtained for said first and second urine samples.

6. The method according to claim 5, wherein said at least a first and second sample are respectively obtained before starting a therapy and during and/or after said therapy.

7. The method according to claim 6, wherein said therapy comprises treatment with steroid drugs, immunosuppressant, Rituximab, or inhibitors of angiotensin converting enzyme.

8. An in vitro method for diagnosis of systemic lupus erythematosus and lupus nephritis in a subject and discriminating them from other rheumatologic conditions and primary glomerular nephritis, said method comprising: a) providing a sample of urine from said subject: b) measuring the levels of LGALS3BP, creatinine and total protein in said urine; c) expressing the measured levels LGALS3BP and creatinine (c), as measured in step b), as the ratio: LGALS3BP/c and d) comparing said LGALS3BP/c ratio to said total protein with a control value, wherein an increase of the ratio of LGALS3BP/c to total protein with respect to said control value indicates development of lupus nephritis.